If you’ve been reading this series from the beginning, something has probably been building in the back of your mind.

The cholesterol article mentioned insulin resistance. The insulin resistance article mentioned blood pressure. The blood pressure article mentioned the kidney. The diabetes article referenced the liver. The obesity article ran through almost everything. The hormones article connected to the thyroid, which connected to sleep, which connected to depression, which connected back to inflammation, which connects to all of it.

You may have started to notice that these are not separate problems happening independently in different organs. They are the same problem expressing itself in different places at different stages of the same progression.

Medicine named them separately because it studies and treats them through specialty silos: cardiology, nephrology, endocrinology, rheumatology, psychiatry. Each specialty has its guidelines, its medications, its monitoring protocols. This is not wrong. The specialization has produced genuinely good clinical science. But it has also created a gap at the center, a space where the connections between conditions live, where the earlier stages of a long progression quietly build, where the person sitting in front of the doctor is the only one seeing the whole picture.

In October 2023, the American Heart Association did something that hadn’t been done before. They formally named that gap. They published a Presidential Advisory in Circulation introducing the concept of Cardiovascular-Kidney-Metabolic syndrome, or CKM syndrome, a unified framework that describes the interplay between obesity, metabolic dysfunction, chronic kidney disease, and cardiovascular disease as a single, staged, progressive system rather than a collection of separate conditions [1].

This is the capstone of this series. Not because it’s the most dramatic diagnosis we’ve covered, but because it’s the frame that makes all the others make sense. If you have two or more of the conditions covered in this series, or if you’ve been told you’re “borderline” on several things without anyone connecting the dots, this article is for you.

Part 1: What CKM Syndrome Actually Is

The System Behind the Diagnoses

CKM syndrome is defined as a health disorder arising from the interconnections among excess and dysfunctional adipose tissue, metabolic dysfunction, chronic kidney disease, and cardiovascular disease [1]. Those four things don’t just happen to co-occur in the same people. They drive each other, each one worsening the others through shared biological mechanisms.

Here is the essential biology in plain language.

Dysfunctional fat tissue, particularly visceral fat stored around abdominal organs, is not passive. It is metabolically active and inflammatory. It releases hormones and inflammatory signals that cause insulin resistance. Insulin resistance forces the pancreas to produce more insulin, which drives more fat storage, raises blood pressure, damages blood vessel walls, impairs kidney filtration, and promotes liver fat accumulation. The liver, under this metabolic pressure, begins to store fat itself (MASLD), which amplifies the inflammatory signals further. The kidneys, filtering blood under chronic metabolic and inflammatory stress, begin to lose efficiency, first showing as tiny amounts of protein in the urine (albuminuria), years before kidney function measurably declines. The heart and blood vessels, exposed to years of elevated blood pressure, insulin resistance, dyslipidemia, and inflammation, develop atherosclerosis, the buildup of plaque that eventually causes heart attack and stroke.

This is not a chain of bad luck. It is one biological cascade with multiple exit points, and every exit point has a window of intervention before it becomes a clinical event.

The CKM framework formalizes this into five stages that describe where someone is in the progression and what the appropriate response is at each stage [1]:

Stage 0 describes no metabolic risk factors, no kidney disease, no cardiovascular disease. This is where we want everyone. The goal here is preservation: healthy diet, regular movement, adequate sleep, blood pressure in range, and screening every 3 to 5 years.

Stage 1 means excess or dysfunctional adiposity is present, but no metabolic risk factors yet. Weight has shifted, waist circumference is elevated, but glucose, kidney function, and cardiovascular markers are still normal. This is the earliest intervention window and the one most often missed because there is no diagnosis yet to treat. Lifestyle is the primary and most effective intervention here.

Stage 2 is where metabolic risk factors are present: prediabetes or diabetes, hypertension, dyslipidemia, and/or early kidney changes such as mildly elevated albumin in the urine or reduced eGFR. Population-based studies reveal that Stage 2 represents the most prevalent category, affecting nearly half of adults in Western cohorts [4]. It is also the stage where most people in this series will recognize themselves. Lifestyle remains essential; targeted medications become appropriate.

Stage 3 means subclinical cardiovascular disease is present: early atherosclerosis detectable on imaging, early heart function changes, or high predicted cardiovascular risk including advanced kidney disease. No heart attack yet. No stroke yet. But the biology is progressing toward one without intervention.

Stage 4 describes established, symptomatic cardiovascular disease: heart attack, stroke, heart failure, peripheral arterial disease, or kidney failure. This is the stage medicine is best at treating, and the one that all the earlier stages, if addressed, are trying to prevent.

The profound clinical implication of this framework is this: by the time most people receive any of the diagnoses in this series, they are already in Stage 2. The question is whether anyone is looking at the full picture, or treating each component of Stage 2 in a separate specialist’s office without ever naming the system underneath.

Why This Framework Changes Everything

Before CKM syndrome was formally named, a patient with high blood pressure, prediabetes, elevated triglycerides, and slightly reduced kidney function would likely see four different specialists, receive four separate treatments, and never be told that these four things are one condition at a particular stage of progression.

The AHA’s framework does not just add a new diagnostic label. It proposes a fundamentally different model of care: one that starts earlier, screens more comprehensively, addresses root causes rather than individual markers, and deploys the medications that protect multiple organ systems simultaneously rather than treating each organ in sequence [1].

It also introduces a new risk calculator that starts at age 30, rather than the previous standard of age 40, and accounts for kidney function, blood sugar, and social determinants of health alongside traditional cardiovascular risk factors. This matters because CKM syndrome disproportionately affects populations that have historically been underscreened: people of color, people with lower socioeconomic access to preventive care, and people whose risk accumulates earlier and progresses faster than the old risk models predicted [1].

Part 2: Seeing Yourself in the Stages

The Connective Thread Through This Series

Even if you haven’t read the full series, what follows maps conditions you may already be managing onto a single framework. You don’t need the prior articles to find yourself here.

The conditions covered across this series connect to the CKM framework in a direct and specific way. Here is where each one fits.

High cholesterol (Article 1), particularly the pattern of elevated triglycerides, low HDL, and small dense LDL particles, is a direct marker of metabolic dysfunction and a core component of Stage 2 CKM. It is driven by insulin resistance and visceral adiposity, not primarily by dietary fat intake.

High blood pressure (Article 2) is both a driver of CKM progression and a consequence of it. The kidney-blood pressure relationship is bidirectional: elevated blood pressure damages kidney filtering capacity, and declining kidney function raises blood pressure further. Managing blood pressure in the CKM context means managing the whole system, not just the number.

Insulin resistance (Article 3) is the metabolic engine of CKM syndrome. It sits at the center of the cascade. Visceral fat drives it, and it drives everything else: blood sugar dysregulation, blood pressure, dyslipidemia, kidney stress, liver fat, cardiovascular inflammation.

Hormonal imbalance (Article 4) both reflects and accelerates metabolic dysfunction. Declining estrogen increases insulin resistance, redistributes fat to the visceral compartment, and raises cardiovascular risk. Low testosterone in men drives the same metabolic shifts. Hormonal health is not separate from metabolic health. It is part of the same system.

MASLD (Article 5) is the hepatic manifestation of CKM. Researchers have recently proposed expanding the CKM acronym to include the liver explicitly, calling it CRHM syndrome, because MASLD is so consistently present in the metabolic cascade that excluding it from the framework is increasingly clinically indefensible [3]. The liver’s health tracks directly with the health of the rest of the system.

Obesity (Article 6), specifically excess visceral adiposity, is Stage 1 of the CKM framework. It is the upstream driver that, if addressed early, can prevent the transition to Stage 2. This is why obesity medicine has moved from lifestyle advice to clinical disease management with appropriate pharmacotherapy.

Type 2 diabetes (Article 7) is Stage 2 CKM. The diabetes article made the point that this diagnosis was building for years before the threshold was crossed. The CKM framework shows where it fits in a continuum that started with adiposity and progressed through insulin resistance.

Thyroid disorders (Article 8) amplify every metabolic parameter in the CKM cascade. Thyroid dysfunction is not peripheral to metabolic health. It is part of the same integrated system.

Sleep disorders (Article 9) and depression and anxiety (Article 10) are specifically identified in the AHA’s CKM advisory as risk factors for CKM progression [1]. Chronic sleep disruption drives insulin resistance, elevates cortisol, raises blood pressure, and worsens every metabolic marker. Depression and metabolic dysfunction are bidirectionally linked. These are not lifestyle adjuncts. They are clinical components of the same system.

Sjögren’s disease (Article 11) and endometriosis (Article 12) are chronic inflammatory autoimmune conditions that both drive and are driven by systemic inflammation, the same inflammatory environment that accelerates CKM progression. Hypertension, dyslipidemia, and metabolic dysfunction are documented comorbidities in both conditions. The inflammatory burden of autoimmune disease is a CKM risk amplifier.

This is why the series was structured the way it was. Not as a collection of independent diagnoses, but as a progressive map of one biological system expressing itself in different places, across different life stages, in different bodies.

Part 3: This Is Not Your Fault, But It Is Your Opportunity

What the Framework Means for You

Medicine has been very good at naming what has already happened: diagnosing the heart attack, treating the kidney failure, managing the established diabetes. It has been considerably less good at identifying the decade of biology that preceded those events and acting on it while action is still most effective.

The CKM framework is medicine’s formal acknowledgment of this failure and its formal commitment to doing better. The staging system is not just academic taxonomy. It is a clinical call to action: find people in Stage 1 and Stage 2, before Stage 3 and Stage 4 become the story.

Population-based studies reveal that Stage 2 represents the most prevalent category, affecting nearly half of adults in Western cohorts. Progression occurs in 34% of Stage 1 individuals, with each stage transition conferring incrementally higher cardiovascular mortality risk [4].

Half of adults. Nearly half of the people reading this series are likely already in Stage 2 of a progression that most of them don’t know they’re in.

That is not a reason for alarm. It is the exact reason this series exists. Because Stage 2 is where lifestyle intervention is most powerful, where the right medications produce the most meaningful long-term protection, and where knowing what you’re dealing with gives you the most leverage over what happens next.

Part 4: What Good Assessment Looks Like

Reading Your Body as a System

A CKM-aware clinical assessment doesn’t require new tests. It requires looking at the tests you’ve probably already had, together, as a system, rather than in separate specialist offices.

Here is what we look at to stage someone in the CKM framework and understand where the most important levers are.

Adiposity assessment uses waist circumference and body composition rather than just BMI. Visceral fat is the upstream driver. Waist above 94cm in men and 80cm in women (ethnicity-adjusted) places Stage 1 on the table regardless of what the scale says.

Fasting glucose and A1c establish where someone sits on the glucose continuum: normal, impaired fasting glucose, prediabetes, or diabetes. The staging matters because it determines the urgency and the appropriate intervention.

Fasting insulin and HOMA-IR capture the metabolic driver that A1c alone doesn’t show. Elevated fasting insulin with normal glucose is Stage 1 metabolic dysfunction, and it’s where the window for reversal is widest.

Full lipid panel including triglycerides reveals the pattern that matters most: high triglycerides, low HDL, small dense LDL. This metabolic dyslipidemia pattern is a Stage 2 CKM marker and a stronger cardiovascular risk signal than elevated LDL alone.

Blood pressure should be assessed as a pattern across multiple measurements, not a single reading. The target in the CKM framework is below 130/80 mmHg [1].

eGFR and urine albumin-to-creatinine ratio (UACR) together tell the kidney’s story. eGFR measures filtration rate. UACR measures whether protein is leaking into the urine, the earliest sign of kidney stress, appearing years before eGFR declines. Albuminuria is a powerful biomarker for both kidney and cardiovascular outcomes, but it is significantly underutilized even in patients with established kidney disease. If your UACR has never been checked, ask for it by name.

High-sensitivity CRP measures systemic inflammation. Elevated hs-CRP in the context of metabolic risk factors indicates that the inflammatory cascade is active, accelerating progression and independently raising cardiovascular risk.

Liver enzymes and FIB-4 address liver involvement in the CKM cascade. As covered in the MASLD article, elevated liver enzymes in the context of metabolic risk factors warrant formal staging, not watchful waiting.

Coronary artery calcium (CAC) score provides direct evidence of subclinical atherosclerosis for patients in Stage 2 or 3 where cardiovascular risk assessment is guiding statin decisions. The AHA CKM framework supports its use for risk stratification in this context [1].

We also track fasting insulin (the upstream driver that standard panels miss), hs-CRP (the inflammatory status of the system), vitamin D, and full hormonal panels, because the hormonal dimension of CKM, though not part of the formal staging criteria, is clinically inseparable from metabolic health in both men and women.

Part 5: What Actually Moves the Needle

The Foundation at Every Stage

The integrative foundation of CKM management is the same at every stage, because these interventions address the root biological drivers, not just individual markers. More is possible here than most patients are told.

Dietary quality. The Mediterranean and DASH dietary patterns consistently show benefit across every component of CKM syndrome: blood pressure, triglycerides, glucose regulation, kidney protection, cardiovascular risk, and liver fat. Not because of any single nutrient, but because the overall pattern reduces dietary inflammatory burden, supports gut microbiome diversity, improves insulin sensitivity, and provides the nutrients required for vascular and metabolic health. This is the dietary pattern with the broadest evidence base across the widest range of conditions, and it is the one we return to with almost every patient in this series.

Resistance training specifically. Muscle is metabolically active tissue. Every kilogram of lean muscle mass improves insulin sensitivity, increases glucose disposal, reduces visceral fat, supports kidney function through better metabolic regulation, and independently reduces cardiovascular risk. Resistance training is not optional in CKM management. It is a primary intervention.

Sleep. As established in the sleep article, chronic sleep disruption drives every metabolic component of CKM syndrome. Below 7 hours nightly produces measurable worsening of insulin sensitivity, blood pressure, inflammatory markers, and hormonal balance. Sleep is not a lifestyle supplement to the clinical protocol. It is part of the clinical protocol.

Stress and cortisol regulation. Chronic activation of the stress response drives visceral fat accumulation, insulin resistance, blood pressure elevation, and immune dysregulation. The mechanisms are enzymatic and hormonal, not metaphorical. Managing stress through whatever combination of approaches a given person can sustain, whether breathwork, nature exposure, boundary-setting, therapy, or reduced overcommitment, is metabolic medicine.

The Medications That Protect the Whole System

This is the part of CKM management that has transformed most dramatically in the last five years, and the part that most patients, even those already diagnosed, are not being fully told about.

Two drug classes have emerged as the closest thing medicine currently has to CKM-wide protective agents. Both were developed for diabetes management, and both have demonstrated benefits so far beyond blood sugar control that they have been formally integrated into CKM guidelines.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) cause the kidneys to excrete glucose directly into the urine. Their metabolic effects include modest weight loss, blood pressure reduction, and reduced cardiac preload and afterload. Their organ-protective effects are the most clinically significant: substantially reduced risk of hospitalization for heart failure, meaningful slowing of kidney disease progression, and cardiovascular mortality reduction in high-risk patients, effects that appear to operate independently of their glucose-lowering action [1, 2]. For patients with diabetes and chronic kidney disease, SGLT2 inhibitors should be prioritized given their favorable impact on kidney function decline and the risks of heart failure and cardiovascular mortality.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce substantial weight loss, improve insulin sensitivity, reduce blood pressure, lower triglycerides, reduce liver fat, and have demonstrated significant reductions in major adverse cardiovascular events in high-risk patients [1, 2]. The FLOW trial specifically demonstrated kidney-protective effects of semaglutide in people with type 2 diabetes and chronic kidney disease, reducing the risk of major kidney outcomes and cardiovascular death by 24% compared to placebo [5]. That finding cements GLP-1 agents as cardiorenal medicines, not just weight loss tools.

The AHA CKM framework specifically supports considering both classes for patients in Stage 2 and above, because their multi-organ protective effects align directly with the multi-system nature of the syndrome [1]. A patient in Stage 2 or 3 CKM being managed on a blood pressure medication alone, without these classes being discussed, is not receiving the full breadth of what the current evidence supports.

Part 6: The Monitoring Framework

Screening That Matches the Stage

Adults at Stage 0 should be screened for components of metabolic syndrome every 3 to 5 years. At Stage 1, every 2 to 3 years. At Stage 2 or higher, annually.

Annual screening at Stage 2 and above should include fasting glucose and A1c, fasting lipid panel with triglycerides, urine albumin-to-creatinine ratio, eGFR, blood pressure, waist circumference, and liver enzymes. These numbers together tell the story of whether the system is improving, stable, or progressing.

At Heal Integrative Wellness, we also track fasting insulin, hs-CRP, vitamin D, and full hormonal panels, because the hormonal dimension of CKM is clinically inseparable from metabolic health in both men and women, even if it sits outside the formal staging criteria.

The question we are always asking is whether the overall trajectory of the system is improving. Individual markers can fluctuate. What matters is the direction of travel over 6 months and a year. Are triglycerides coming down? Is fasting insulin improving? Is the UACR stable or falling? Is blood pressure better managed? That trajectory, more than any single number, tells you whether the intervention is working.

Where This Series Has Been Going

Twelve articles. Twelve conditions. One system.

Cholesterol, blood pressure, insulin resistance, hormones, liver, obesity, diabetes, thyroid, sleep, mental health, autoimmune disease: these are not separate stories. They are chapters in the same one. The story of a metabolic and inflammatory system that, under enough pressure, over enough time, expresses itself in whichever tissue is most vulnerable for that particular person.

What we hope you’ve taken from this series is not a checklist of things to worry about. It’s a way of understanding your body as a connected whole, where treating one part without looking at the others is like fixing one leak in a pipe while five others are dripping. And where catching the system early, understanding its direction, and addressing its root drivers is the difference between managing disease and genuinely preventing it.

The appointment has never been long enough to give you all of this. That’s why this series exists.

If you’ve recognized yourself anywhere in these pages, if your picture is more complex than any single diagnosis captures, that’s exactly the kind of complexity we’re built to work with at Heal Integrative Wellness.

This is what integrative medicine is for. Not alternatives. Not wellness shortcuts. The whole picture, grounded in the best available evidence, held by someone with time to look at all of it.

We’re glad you’re here.

Book a Consultation with Heal Integrative Wellness

Subscribe now

Sources

1. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606–1635. doi:10.1161/CIR.0000000000001184

2. Gajjar A, Raju AK, Gajjar A, et al. SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular-kidney-metabolic syndrome. Biomedicines. 2025;13(8):1924. doi:10.3390/biomedicines13081924

3. Theodorakis N, Nikolaou M. From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework. Biomolecules. 2025;15(2):213. doi:10.3390/biom15020213

4. Laffin LJ, Bakris GL. Cardiovascular-kidney-metabolic syndrome: prevalence, risks, disease trajectories, and early-stage management. American Journal of Physiology: Cell Physiology. 2025. doi:10.1152/ajpcell.00499.2025

5. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine. 2024;391(2):109–121. doi:10.1056/NEJMoa2403347

This article is written and reviewed by the clinical team at Heal Integrative Wellness. It is for educational purposes and does not replace individualized medical advice. Please consult your healthcare provider before making changes to your treatment plan.

© Heal Integrative Wellness — Series 3: The First Diagnosis

One of the patients I think about most came to our clinic at 34, already a decade into a journey that should have taken one year.

She was 16 the first time she missed school because of her period.

By 22, she had been to the emergency room twice with pain so severe she couldn’t stand. Both times she was given painkillers and sent home. By 26, she had been told by three different doctors that some women just have difficult periods. By 28, she was struggling with infertility and nobody had yet considered that the pain and the fertility problem might have the same cause.

She was finally diagnosed with endometriosis at 29. Stage III. After thirteen years of symptoms.

Her story is not an outlier. Studies report diagnostic delays ranging from five to over ten years, and that gap has not meaningfully improved despite growing awareness [1]. In some countries the delay stretches beyond a decade. The disease progresses during those years. The pain worsens. Fertility becomes more complicated. The psychological toll of not being believed compounds into something that takes years of its own to recover from.

One detail that surprises many people, including those already managing a gynecological diagnosis: endometriosis is found in approximately 30 to 50% of women with infertility. If you have been trying to conceive without success and nobody has mentioned endometriosis, that is a conversation worth having with your doctor.

In November 2024, the National Institute for Health and Care Excellence updated its endometriosis guideline with a significant shift in emphasis: diagnosis should be based on symptom history even when imaging is inconclusive, and treatment should begin based on symptoms rather than waiting for definitive surgical confirmation [4]. That change represents a formal acknowledgment that the current diagnostic pathway is failing people.

This article is about what endometriosis actually is, why it takes so long to diagnose, what a proper assessment looks like, and what treatment can genuinely achieve, including the integrative approaches that make a real difference to daily life.

Part 1: Recognizing the Pattern

What Endometriosis Actually Is

Endometriosis is a chronic inflammatory disease in which tissue similar to the lining of the uterus grows outside the uterus, on the ovaries, fallopian tubes, the lining of the pelvis, the bowel, the bladder, and in severe cases on distant organs. This tissue responds to the hormonal cycle the same way the uterine lining does, thickening, breaking down, and bleeding with each cycle. But unlike the uterine lining, it has nowhere to go. The result is inflammation, scar tissue, adhesions that bind organs together, and cysts called endometriomas on the ovaries.

The inflammatory environment endometriosis creates is not localized. It is systemic. It drives immune dysregulation, central sensitization of the nervous system (where the pain-processing system becomes amplified and hyperresponsive), gut inflammation, and hormonal disruption. This is why endometriosis produces a symptom profile that extends well beyond the pelvis, and why it is so frequently misattributed to other conditions.

Endometriosis affects approximately 190 million women worldwide, an estimated 1 in 10 women of reproductive age. Despite this, research funding remains disproportionately low relative to its prevalence and impact.

The Patterns Worth Knowing

Pelvic pain is the hallmark, but not all pelvic pain looks the same in endometriosis. It may be cyclical (worst around menstruation), or it may become chronic and persistent as the disease progresses. The pain is often disproportionate to what a clinician might expect, which historically led to it being attributed to “low pain tolerance” rather than to the disease itself. Central sensitization explains why pain can persist even after treatment removes visible disease: the nervous system has been recalibrated toward amplified pain responses.

Dysmenorrhea (painful periods) — severe period pain that interferes with daily activities is not normal, even though it is common. The distinction matters enormously and is still not being communicated clearly enough. Pain that requires strong analgesia, causes vomiting, or causes missed work or school is a symptom that warrants investigation, not normalization.

Dyspareunia (pain with sex), particularly deep dyspareunia, meaning pain felt deep in the pelvis during penetration, is a highly specific feature of endometriosis and is strongly associated with deep infiltrating disease involving the uterosacral ligaments, rectovaginal septum, or bowel.

Bowel and bladder symptoms including cyclical diarrhea, constipation, bloating, painful bowel movements around menstruation, and cyclical urinary frequency or pain are among the most frequently missed features of endometriosis. When these symptoms are cyclical, they strongly suggest endometriosis involving the bowel or bladder. They are also the symptoms most frequently attributed to irritable bowel syndrome, delaying the correct diagnosis for years.

Fatigue in endometriosis is significant and persistent, yet poorly recognized in clinical practice. The systemic inflammation, hormonal disruption, chronic pain, and sleep disruption from pain together create a fatigue burden that is real and often severe.

Infertility is found in approximately 30 to 50% of women with endometriosis. The mechanisms are multiple: distorted pelvic anatomy from adhesions and endometriomas, impaired egg quality from ovarian inflammation, altered tubal function, and an inflammatory uterine environment that may impair implantation.

The Conditions Endometriosis Gets Mistaken For

This is the list that costs years. Because endometriosis produces bowel symptoms, it gets diagnosed as IBS. Because it produces fatigue and mood changes, it gets attributed to depression or anxiety. Because pelvic pain is considered “normal for women,” it gets normalized rather than investigated. And because the only definitive diagnostic test has historically required surgery, many clinicians wait for certainty before taking the patient’s symptoms seriously.

The 2024 NICE guideline update specifically addresses this: a positive symptom history, particularly cyclical pelvic pain, painful periods, and pain with sex, is now sufficient to initiate investigation and treatment without waiting for imaging confirmation [4]. A normal ultrasound does not rule out endometriosis, because superficial peritoneal disease and many forms of deep infiltrating disease are not visible on standard pelvic ultrasound.

Part 2: This Is Not in Your Head, and the Guidelines Now Say So

The Cost of Not Being Believed

The endometriosis diagnostic delay is not primarily a technological failure. We don’t lack the imaging capability or the surgical ability to identify this disease. The delay is primarily a cultural and systemic failure to take women’s pain seriously.

Studies consistently show that women in pain are less likely to receive adequate analgesia, more likely to have their pain attributed to psychological causes, and more likely to wait longer for diagnostic evaluation than men with equivalent pain levels. These are not abstract statistics. They are what happened to the woman in the opening story. They are what happens to patients who describe being told for years that they need to manage their stress better.

The 2024 NICE guideline represents something genuinely important in this context. By formally stating that treatment can and should begin based on symptoms alone, it repositions the patient’s account of their own experience as clinically authoritative. That is the shift this disease has needed for a long time [4].

What this means in practice: if you have cyclical pelvic pain that disrupts your life, painful periods that go beyond ordinary discomfort, pain with sex, or cyclical bowel symptoms, you have grounds to ask for investigation and treatment now. Not after imaging confirms something. Not after surgery. Now.

Part 3: What Good Testing and Assessment Actually Looks Like

This section gets more clinical. If you’ve just been diagnosed and your head is still spinning, bookmark this and bring it to your next appointment. It’s written to help you know what questions to ask and what to expect, not to overwhelm you.

The Diagnostic Pathway

There is no blood test that diagnoses endometriosis. CA-125, a tumour marker sometimes used in other contexts, is specifically not recommended for endometriosis diagnosis by NICE because it lacks both sensitivity and specificity [4]. The diagnosis is clinical and imaging-based, with definitive confirmation by laparoscopy if needed.

Clinical history is the starting point and, per the updated 2024 guidelines, the most important one [4]. A detailed symptom history covers menstrual pattern and cycle-related symptoms, the character and severity of pelvic pain (cyclical versus constant, location, whether it is worsening over time), pain with sex, bowel and bladder symptoms particularly around menstruation, and history of fertility difficulty. Family history of endometriosis in a first-degree relative meaningfully increases diagnostic likelihood.

Transvaginal ultrasound (TVUS) is now recommended by the 2024 NICE guideline for all women with suspected endometriosis [4]. Performed by an experienced sonographer, it can identify ovarian endometriomas and deep infiltrating disease. Its limitation is that it does not reliably detect superficial peritoneal disease, the most common form. A normal ultrasound does not rule out endometriosis and should not be used to dismiss symptoms.

Pelvic MRI is recommended when deep infiltrating endometriosis is suspected, particularly when bowel, bladder, or ureteral involvement is possible [4]. It is more sensitive than ultrasound for mapping deep disease and essential for surgical planning.

Diagnostic laparoscopy remains the gold standard for definitive diagnosis, allowing direct visualization and histological confirmation of endometriotic lesions. The 2024 NICE guideline supports offering laparoscopy to patients with symptoms strongly suggestive of endometriosis who have not responded to medical management, or where deep disease is suspected [4]. A normal laparoscopy does not absolutely exclude very early disease.

What we add from an integrative perspective: Given the systemic inflammatory nature of endometriosis and its hormonal drivers, our workup also includes a full hormonal panel to assess estrogen dominance patterns and progesterone status, fasting insulin and inflammatory markers given the insulin-endometriosis relationship, vitamin D levels, a full iron panel (heavy menstrual bleeding causes iron deficiency in a significant proportion of patients), and a thyroid panel. These don’t diagnose endometriosis, but they shape the full management picture.

Part 4: What Actually Moves the Needle

Medical Management First

The 2024 NICE guideline explicitly recommends initiating treatment based on symptoms before waiting for surgical confirmation [4]. The first-line medical options are:

NSAIDs for acute pain management. A short trial of NSAIDs is reasonable as first-line analgesia, with the understanding that this is symptomatic relief, not treatment of the underlying disease.

Combined oral contraceptive pill suppresses the cyclical hormonal fluctuations that drive endometriotic tissue activity, reducing pain in many patients. Continuous use without the pill-free week is more effective for pain control than cyclic use.

Progestogens including norethisterone, medroxyprogesterone acetate, and the levonorgestrel-releasing IUD (Mirena) all suppress endometriotic activity through progestogenic effects. The Mirena coil has strong evidence for pain reduction and is particularly useful for patients who want long-term hormonal management with minimal systemic exposure.

GnRH analogues induce a temporary menopause state, dramatically reducing estrogen and suppressing endometriotic activity. They are highly effective for pain but not suitable for long-term use without add-back hormonal therapy due to bone density loss. Generally used in specialist settings.

The Integrative Approach

This is where we spend significant time with endometriosis patients, because the medical management addresses hormonal activity but doesn’t address the full systemic inflammatory picture. The integrative approach is not a replacement for medical or surgical management. It is what makes the difference between managing the disease and genuinely living well with it.

Anti-inflammatory dietary pattern. Endometriosis is fundamentally an inflammatory disease, and dietary inflammation is a modifiable driver. Multiple studies demonstrate that women with higher dietary omega-6 to omega-3 ratios have higher endometriosis risk and worse symptom severity [3]. The Mediterranean dietary pattern, with its high omega-3 content, polyphenol richness, and low refined carbohydrate and trans-fat content, consistently reduces inflammatory burden in inflammatory conditions. Specifically: reduce red meat (associated with increased endometriosis risk in epidemiological studies), increase fatty fish, reduce trans fats and ultra-processed food, increase cruciferous vegetables (which support estrogen metabolism through glucosinolate pathways), and prioritize fiber-rich foods that support healthy estrogen clearance through the gut.

Omega-3 supplementation. EPA and DHA directly reduce prostaglandin-mediated inflammation, which is a primary driver of endometriosis-associated pain. High-quality omega-3 supplementation at 2 to 3g EPA and DHA combined is one of the most clinically defensible adjunct interventions in endometriosis management [3].

Magnesium. Magnesium glycinate at 300 to 400mg daily has evidence for reducing dysmenorrhea through relaxation of uterine smooth muscle and reduction of prostaglandin production [5]. It is one of the most accessible and well-tolerated additions to a pain management protocol.

N-acetylcysteine (NAC). NAC is an antioxidant with growing evidence in endometriosis. Observational and prospective studies have shown reductions in endometrioma size and pain scores with NAC supplementation in women with ovarian endometriomas, a meaningful finding given how limited non-surgical options are for established ovarian disease [6]. I recommend NAC at 600mg three times daily in a cyclical protocol (three days on, three days off) for patients with ovarian endometriomas and significant oxidative stress markers.

Vitamin D. Vitamin D deficiency is consistently more prevalent in women with endometriosis, and lower levels correlate with higher disease severity [7]. Standard lab ranges define sufficiency at 30 ng/mL, but many integrative clinicians recommend targeting 50 to 70 ng/mL for patients with inflammatory conditions. I recommend targeting levels above 60 ng/mL, though optimal thresholds haven’t been established in randomized trials, so this is worth discussing with your provider.

Gut health. The gut microbiome influences estrogen metabolism through a collection of bacteria sometimes called the estrobolome. Dysbiosis, an imbalance in gut bacteria, can impair estrogen clearance, increasing circulating estrogen levels and potentially worsening endometriosis. Supporting gut health through dietary fiber diversity, fermented foods, and addressing underlying gut inflammation is a relevant part of the hormonal picture.

Pain neuroscience education and nervous system regulation. For patients with central sensitization, where pain persists beyond obvious disease activity, is amplified by stress, and is present outside the pelvis, specific approaches including breathwork, vagal toning, and mindfulness-based pain management have evidence for reducing pain by addressing the neural amplification component. To be clear: this is not a suggestion that the pain is psychological. Years of real inflammatory disease physically recalibrate the nervous system toward amplified pain responses. These tools work by recalibrating it in the other direction. They are a complement to, not a replacement for, physical treatment.

The Surgical Conversation

Laparoscopic excision of endometriotic tissue by a skilled surgeon remains the most effective treatment for established symptomatic endometriosis, particularly deep infiltrating disease and endometriomas [4]. Excision (cutting out lesions) is superior to ablation (burning them) for long-term symptom control. Referral to a specialist endometriosis center is appropriate for complex or deep disease.

Surgery is not a cure and endometriosis can recur. But for many patients with significant disease burden, skilled surgery followed by suppressive medical management and the integrative approaches above produces the most meaningful improvement in quality of life.

Part 5: Retesting and What to Watch

The Ongoing Management Framework

Endometriosis is a chronic condition requiring long-term management, not a single intervention and discharge.

Every 6 months initially: symptom assessment using a pain diary (which the 2024 NICE guideline specifically recommends) [4], hormonal panel review, inflammatory markers, and iron studies if menstrual blood loss is significant. Is the management working? Is breakthrough pain occurring? Does fertility planning affect medication choices?

Annually: ultrasound review for any patient with known endometriomas to monitor for growth, full panel assessment, and a dedicated conversation about whether the current management approach still fits the patient’s current life stage and priorities.

Fertility monitoring: for patients with known endometriosis who are planning or attempting to conceive, earlier and proactive referral to a reproductive medicine specialist is appropriate rather than waiting for a defined period of failed attempts. The 2024 NICE guideline specifically supports this [4].

Track at home: pain diary (symptom type, severity, cycle day, what helped), bowel and bladder symptoms, energy levels, mood, and the impact of symptoms on daily activities. This data is your most powerful tool in consultations. It transforms a subjective account into a documented pattern that is difficult to dismiss.

Return sooner if you notice a sudden change in pain character or severity, new symptoms especially urinary or bowel symptoms not previously present, suspected ovarian cyst torsion (sudden severe unilateral pain requiring emergency evaluation), or if you are trying to conceive without success after six months with known endometriosis.

Where to Go From Here

Endometriosis is a disease that has too often been met with dismissal, normalization, and delay. The diagnostic gap of five to ten years is not acceptable, and the updated 2024 NICE guideline says so by shifting the standard toward action based on what patients are experiencing rather than waiting for technology to prove it [1, 4].

If you have recognized yourself in this article, the pain, the fatigue, the bowel symptoms that come and go with your cycle, the infertility, the years of being told it’s normal, you have grounds to ask for more. A proper assessment. A referral to a specialist if initial management doesn’t help. Treatment based on your symptoms, not on a normal ultrasound.

Your pain has a name. And it has a treatment.

If you want to understand what your full picture looks like from an integrative perspective, what’s driving the inflammation, what can be optimized beyond hormonal management, and how to support your body through this, that’s the conversation we’re here to have.

Book a Consultation with Heal Integrative Wellness

Subscribe now

Sources

1. De Corte P, Klinghardt M, von Stockum S, Heinemann K. Time to diagnose endometriosis: current status, challenges and regional characteristics — a systematic literature review. BJOG. 2025;132(2):118–130. doi:10.1111/1471-0528.17973

2. Fryer J, Mason-Jones AJ, Woodward A. Understanding diagnostic delay for endometriosis: a scoping review using the social-ecological framework. Health Care Women Int. 2025;46(3):335–351. doi:10.1080/07399332.2024.2413056

3. Missmer SA, Chavarro JE, Malspeis S, et al. A prospective study of dietary fat consumption and endometriosis risk. Human Reproduction. 2010;25(6):1528–1535. doi:10.1093/humrep/deq044

4. National Institute for Health and Care Excellence. Endometriosis: diagnosis and management. NICE guideline NG73. Updated November 2024. Available at: https://www.nice.org.uk/guidance/ng73

5. Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception. 2010;81(3):185–196. doi:10.1016/j.contraception.2009.09.014

6. Anastasi E, Scaramuzzino S, Viscardi MF, et al. Efficacy of N-acetylcysteine on endometriosis-related pain, size reduction of ovarian endometriomas, and fertility outcomes. International Journal of Environmental Research and Public Health. 2023;20(6):4686. doi:10.3390/ijerph20064686

7. Mariani M, Viganò P, Gentilini D, et al. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Human Reproduction. 2012;27(7):2010–2019. doi:10.1093/humrep/des136

This article is written and reviewed by the clinical team at Heal Integrative Wellness. It is for educational purposes and does not replace individualized medical advice. Please consult your healthcare provider before making changes to your treatment plan.

© Heal Integrative Wellness — Series 3: The First Diagnosis

You’ve probably been told it’s stress. Or perimenopause. Or just getting older.

But if you wake up at night reaching for water, spend your mornings with eyes that feel like sandpaper, and carry a fatigue that no amount of sleep seems to fix, those symptoms aren’t separate problems. They are one condition. And most doctors aren’t connecting them.

It’s called Sjögren’s disease, and it is the second most common autoimmune rheumatic disease in the world. Over 90% of those diagnosed are women [1]. Most of them waited years to get a name for what they were experiencing, because each symptom was routed to a different specialist and nobody looked at the whole picture.

One detail that surprises many people: up to 22% of Sjögren’s patients have co-existing thyroid disease [1]. If you’ve been managing a thyroid condition, whether Hashimoto’s or another thyroid diagnosis, and you still don’t feel right despite treatment, there may be a reason your doctors haven’t found yet. Sjögren’s is frequently the missing piece.

The diagnostic delay is significant. Patients routinely wait years, sometimes more than a decade, between their first symptoms and a formal diagnosis [2]. In that time they collect referrals: to ophthalmology for dry eyes, to dentistry for cavities that keep returning, to rheumatology for joint pain that doesn’t fit a pattern, to psychiatry for fatigue and depression. Each specialist treats their piece. Nobody looks at the whole picture.

This article is about what that picture actually looks like, and what to do when you recognize yourself in it.

Part 1: Recognizing the Pattern

Why Sjögren’s Is So Easy to Miss

In 2024, the British Society for Rheumatology published a comprehensive updated management guideline that formally shifted the terminology from “Sjögren’s syndrome” to “Sjögren’s disease.” The name change is deliberate and important [1]. Syndrome implies a loose collection of symptoms. Disease acknowledges what this actually is: a defined, chronic autoimmune condition with systemic consequences. That distinction matters for how seriously it is taken, by clinicians and by patients alike.

Sjögren’s disease occurs when the immune system attacks the glands that produce moisture throughout the body, primarily the tear glands and salivary glands, but not only those. It’s an inflammatory process driven by immune cells infiltrating glandular tissue and disrupting its ability to function. Because those glands are present throughout the body, including the eyes, mouth, nose, throat, airways, skin, and vagina, the symptoms can appear in a bewildering range of places that don’t obviously point to a single cause.

This is exactly why it gets missed. Each symptom gets routed to the specialist for that body part. The ophthalmologist treats the dry eyes as dry eye disease. The dentist treats the decay from reduced saliva. The rheumatologist may or may not consider autoimmune disease. The GP sees fatigue, orders a basic panel that comes back unremarkable, and moves on. Nobody says: wait, these belong together.

The Full Symptom Picture

Most people know Sjögren’s as the dry eyes and dry mouth disease. But the symptom profile is considerably broader than that, and the symptoms most likely to be dismissed — fatigue, brain fog, joint pain — are the ones most likely to delay diagnosis.

Sicca symptoms refer to dryness of the eyes (grittiness, burning, light sensitivity, blurred vision), dryness of the mouth (difficulty chewing dry foods, altered taste, needing water to swallow, waking at night to drink), and dryness of the nose, throat, airways, and skin. These are the hallmark features. But many patients with established Sjögren’s have mild or atypical dryness, symptoms so gradual they’ve been normalized over years.

Fatigue in Sjögren’s is not ordinary tiredness. It is one of the most debilitating features of the disease and one of the most frequently dismissed. Clinical medicine has few tools to assess or treat fatigue well, and this symptom has driven more Sjögren’s patients into misdiagnosis as depression, fibromyalgia, or functional disorder than almost any other feature [2]. If your fatigue has been attributed to everything except an autoimmune process, Sjögren’s belongs in the differential.

Cognitive symptoms, what patients often describe as brain fog, include difficulty concentrating, word-finding problems, memory lapses, and a mental slowness that wasn’t there before. These are documented features of Sjögren’s disease with real neurological underpinnings. They are also among the symptoms most likely to be attributed to anxiety, depression, or middle age.

Joint pain and stiffness tend to affect the small joints of the hands and wrists. The pain is often migratory, moving between joints, and intermittent. It is not typically the destructive joint disease seen in rheumatoid arthritis, but it is real, recurrent, and impactful.

Peripheral neuropathy, meaning tingling, numbness, or burning sensations in the hands or feet, is an underrecognized feature of Sjögren’s that frequently leads to neurology referrals and inconclusive workups before the autoimmune root is identified.

Recurrent dental decay is another common early sign. Reduced saliva dramatically increases cavity risk. Patients with Sjögren’s often describe a sudden change in their dental health — previously well-maintained teeth deteriorating rapidly — which is sometimes the first signal that something systemic has shifted.

The overlap picture matters too. Sjögren’s disease occurs both as a standalone condition (primary Sjögren’s) and alongside other autoimmune conditions including rheumatoid arthritis, lupus, and systemic sclerosis. It also overlaps significantly with thyroid disease: in population-based registries, up to 22% of Sjögren’s patients have co-existing thyroid disease [1]. If you have Hashimoto’s and your symptoms feel broader than thyroid dysfunction alone, Sjögren’s is worth investigating.

Who Is Most at Risk

Sjögren’s disease is diagnosed most commonly in women between the ages of 40 and 60, but it can present at any age including in young adults and adolescents. The 2024 BSR guideline covers management across all ages for the first time, acknowledging this broader range [1]. Family history of autoimmune disease increases risk. Hormonal transitions, particularly perimenopause, appear to be a triggering or worsening factor in some patients, though the mechanisms are still being studied.

Part 2: This Is Not in Your Head

The Years That Get Lost

In patient surveys and clinical studies, a significant proportion of Sjögren’s patients report a delay of five years or more between symptom onset and diagnosis [2]. Five years of dry eyes being treated as environmental. Five years of fatigue being attributed to stress or perimenopause. Five years of dental decay with no explanation. Five years of brain fog that nobody could account for.

Sjögren’s patients report being told for years that they have functional disorders, fibromyalgia, depression, or difficult menopause. These conditions may co-occur with Sjögren’s, and they are frequently blamed for symptoms that are primarily caused by the disease itself.

I want to name what happens to a person during those years. Not just the physical progression of the disease, though untreated Sjögren’s does progress and the consequences of delayed diagnosis include increased risk of dental damage, corneal damage, and systemic complications. I mean what happens to the person’s relationship with their own body. The gradual erosion of confidence that comes from describing symptoms accurately and being sent home repeatedly without answers. The self-blame. The wondering whether it’s all in your head.

It isn’t. The fact that a 2024 major society guideline now formally emphasizes early recognition and interdisciplinary diagnosis as priorities, not exceptions, tells you that medicine is beginning to reckon with the cost of getting this wrong [1].

Part 3: What Good Testing Actually Looks Like

This section gets more clinical. You don’t need to absorb all of it today. If you’ve just been diagnosed and your head is still spinning, bookmark this and bring it to your next appointment. It’s written to help you know what questions to ask and what to expect, not to overwhelm you.

The Diagnostic Workup

Diagnosing Sjögren’s disease requires putting several pieces together. No single test confirms it. The 2016 ACR/EULAR classification criteria, now widely used in clinical diagnosis, incorporate blood tests, eye assessment, and tissue biopsy into a scoring system [1]. Here’s what a thorough evaluation includes.

Anti-SSA/Ro antibodies are the most clinically useful blood test in Sjögren’s. They are present in approximately 60 to 70% of people with primary Sjögren’s disease. Their presence alongside sicca symptoms and fatigue is a strong signal. Their absence does not rule out the diagnosis. A meaningful proportion of patients are seronegative and still have confirmed disease [1].

Anti-SSB/La antibodies are less sensitive than anti-SSA but add specificity when positive. They are usually ordered at the same time.

ANA (antinuclear antibody) is a general autoimmune screen. It is positive in the majority of Sjögren’s patients but nonspecific on its own. A positive ANA alongside sicca symptoms and fatigue should prompt more targeted antibody testing.

Full blood count, ESR, and CRP are systemic inflammation markers. ESR is more commonly elevated in Sjögren’s than CRP. Anemia, low white cell count, and low platelets can all occur and reflect systemic disease involvement.

Serum immunoglobulins — elevated IgG is a common finding in Sjögren’s, reflecting chronic immune activation, and is used to monitor disease over time.

Rheumatoid factor is positive in approximately 40% of Sjögren’s patients. Its presence alongside sicca symptoms should prompt consideration of Sjögren’s even without the classic dry eye and dry mouth presentation.

Ocular surface assessment by an ophthalmologist or optometrist experienced in dry eye disease should include Schirmer’s test to measure tear production, and ocular staining with fluorescein and lissamine green to assess corneal and conjunctival damage. These findings are scored components of the ACR/EULAR diagnostic criteria [1].

Minor salivary gland biopsy involves a small tissue sample taken from the inner lower lip, assessed for the characteristic lymphocytic infiltration that is the hallmark of Sjögren’s disease. This is the most specific diagnostic test available and is recommended when antibody testing is negative but clinical suspicion remains high [1]. It is a minor outpatient procedure.

Salivary flow assessment measures unstimulated whole saliva production. Very low flow rates in the context of other features contribute to the diagnostic score.

Thyroid panel including TPO antibodies is part of our standard workup given the high rate of co-existing thyroid disease in Sjögren’s patients.

Part 4: What Actually Moves the Needle

Managing Sjögren’s: The Whole Picture

There is currently no cure for Sjögren’s disease and no disease-modifying treatment with the same evidence base as exists for rheumatoid arthritis. But “no cure” is not the same as “nothing helps.” The 2024 BSR guideline frames management around empowering individuals to manage their condition through conserving and replacing secretions, preventing damage, and where needed suppressing systemic disease activity [1]. That is a practical and genuinely useful framework.

Moisture management comes first. Preservative-free artificial tears used frequently throughout the day, not just when uncomfortable, are the foundation of eye management. Cyclosporine eye drops (Restasis) and lifitegrast (Xiidra) target the inflammatory component of Sjögren’s dry eye and have meaningful evidence for reducing symptoms and protecting the ocular surface. Punctal plugs are tiny inserts that block the drainage canals in the eyelids, reducing tear loss. They are simple, reversible, and effective for many patients.

For the mouth: regular sips of water, sugar-free gum and lozenges to stimulate saliva, saliva substitutes at night, and meticulous dental hygiene with fluoride toothpaste and regular professional care. The connection between Sjögren’s and accelerated dental decay is not widely communicated to patients, and it should be. Prevention is far more effective than repair.

The Integrative Approach: What the Evidence Actually Shows

Omega-3 fatty acids, specifically EPA and DHA, have been studied for Sjögren’s-associated dry eye disease, and the biological rationale is sound. Omega-3 fatty acids modulate the inflammatory cascade that damages lacrimal gland function and the ocular surface. It’s worth understanding both what the evidence supports and where it’s less certain, because the picture is more nuanced than it is sometimes presented.

Earlier trials, including a well-designed multicenter study by Epitropoulos et al., found that oral re-esterified omega-3 supplementation significantly improved tear osmolarity, tear break-up time, and inflammatory markers in patients with dry eye and meibomian gland dysfunction [3]. That study, along with several others, shaped early enthusiasm for omega-3 as a dry eye intervention.

The DREAM trial, a larger and more rigorous double-masked randomized controlled trial published in the New England Journal of Medicine in 2018, found that omega-3 supplementation was not significantly better than an olive oil placebo for dry eye disease outcomes [4]. This was an important finding that tempered the field’s earlier confidence. It is worth noting that the DREAM trial enrolled patients with general dry eye disease rather than specifically Sjögren’s-associated dry eye, and some researchers have raised questions about whether the olive oil placebo was truly inert given its own anti-inflammatory properties.

Clinically, omega-3 supplementation carries an excellent safety profile, supports cardiovascular and general anti-inflammatory health, and remains a reasonable adjunct for Sjögren’s patients, particularly those with concurrent meibomian gland dysfunction. We discuss it with patients as a low-risk option with plausible benefit and mixed direct evidence, rather than a proven first-line treatment. The anti-inflammatory dietary rationale remains solid even if the isolated supplement evidence is contested.

Vitamin D deficiency is consistently more prevalent in Sjögren’s patients than in matched controls, and lower vitamin D levels have been associated with higher disease activity in several studies [5, 6]. A 2023 systematic review and meta-analysis pooling data from nine clinical studies found a significantly higher prevalence of vitamin D insufficiency in Sjögren’s disease patients compared to healthy controls [5]. The proposed mechanism involves vitamin D’s role as an immune modulator: it promotes tolerance and dampens the kind of autoreactive immune activity that drives Sjögren’s pathology.

In clinical practice, we aim to optimize vitamin D levels rather than simply correct frank deficiency. My recommended target level is in the 50 to 70 ng/mL range. This is an area where clinical opinion varies and the optimal threshold for autoimmune benefit has not been established in randomized trials, so it’s worth an honest conversation with your provider about what target makes sense for you.

An anti-inflammatory dietary pattern is another cornerstone. The Mediterranean pattern reduces systemic inflammatory burden, supports gut microbiome diversity, and provides the polyphenols that modulate immune function. There is no randomized trial specifically in Sjögren’s disease, but the anti-inflammatory dietary evidence in autoimmune disease more broadly is consistent. Reducing ultra-processed food, refined sugar, and pro-inflammatory oils while increasing olive oil, fish, legumes, and vegetables is a defensible and low-risk step for every patient with an inflammatory autoimmune condition.

Hydroxychloroquine (Plaquenil) is the most commonly prescribed systemic medication for Sjögren’s disease, and it’s worth being honest about both what it does and what it doesn’t do. It is an antimalarial used in autoimmune disease for decades and is generally well tolerated [1]. The 2024 BSR guideline recommends it particularly for systemic features including joint pain (arthralgia), skin vasculitis (purpura), and elevated inflammatory markers [1]. These are the indications where clinical experience is most consistent.

However, the JOQUER trial, a double-blind randomized controlled trial specifically designed to evaluate hydroxychloroquine for the primary symptoms of Sjögren’s disease, found no significant benefit over placebo for dryness, fatigue, or pain at 24 weeks [7]. This doesn’t mean hydroxychloroquine has no role, and the 2024 BSR guideline continues to support its use for systemic features. But it does mean that if you are taking it primarily hoping to improve dryness or fatigue, it may not be delivering what you expect. This is a conversation worth having directly with your rheumatologist about what specifically it is being prescribed to address in your case.

Pilocarpine and cevimeline are medications that stimulate secretion from functioning glandular tissue, increasing both saliva and tear production in patients with residual glandular function. Pilocarpine has good evidence for both dry mouth and dry eye in Sjögren’s [1]. Side effects including flushing, sweating, and increased urination can limit use for some patients, but they are worth discussing if moisture symptoms are significantly affecting your daily life.

Fatigue management is formally acknowledged in the 2024 BSR guideline as a priority target, not a side issue [1]. The approach is multimodal: identify and treat contributing factors such as thyroid disease, anemia, sleep disruption, depression, and pain; consider hydroxychloroquine if not already prescribed; and address sleep quality directly. Structured activity pacing, a technique developed in chronic fatigue management, can help patients avoid the boom-and-bust cycle of overexertion followed by crash.

Neuropathy management requires early recognition. For patients with peripheral neuropathy, referral to a neurologist with experience in autoimmune neuropathy is important. Immunoglobulin therapy has evidence for the most severe forms. For milder sensory symptoms, optimizing vitamin B12, vitamin D, and omega-3 status is a reasonable starting point.

Emerging therapies. For the first time, there is genuine momentum toward a targeted treatment for Sjögren's disease. Ianalumab, a monoclonal antibody in development by Novartis, works through a dual mechanism: depleting overactive B cells and blocking the BAFF receptor, a key driver of the immune dysfunction underlying the disease. Both Phase III trials met their primary endpoint in 2025, and regulatory submission is expected to follow. It is not yet approved, but for patients with moderate to severe systemic disease, it is worth asking your rheumatologist about as the landscape develops.

A note on lymphoma risk. This is a conversation patients deserve to have and often don’t. Sjögren’s disease carries an elevated lifetime risk of B-cell lymphoma compared to the general population. Multiple studies estimate approximately 5% lifetime risk in primary Sjögren’s, reflecting a roughly 10-fold relative increase [1]. This is not a reason to panic. The large majority of patients with Sjögren’s never develop lymphoma. But it is a reason for regular monitoring, and it is why persistent enlarged lymph nodes, unexplained fevers, or night sweats in a Sjögren’s patient warrant prompt investigation rather than watchful waiting.

Part 5: Retesting and What to Watch

The 6-Month and Annual Framework

At diagnosis baseline, a thorough workup includes the full antibody panel (anti-SSA, anti-SSB, ANA, rheumatoid factor), full blood count, ESR, CRP, immunoglobulins, complete metabolic panel, full thyroid panel including TPO antibodies, vitamin D, B12, and iron studies.

At 6 months, repeat inflammatory markers (ESR, CRP) and full blood count, and assess symptom response to any initiated treatments. If hydroxychloroquine was started, an eye examination establishes baseline retinal status before long-term use. Rare retinal toxicity with prolonged high-dose hydroxychloroquine is monitored with annual eye exams once treatment is established.

Annually, a full panel review, ophthalmology assessment for ocular surface status, dental review with awareness of Sjögren’s-associated decay risk, and clinical assessment for any new systemic features including lymph node changes, unexplained weight loss, and new neuropathy symptoms.

At home, tracking dry eye symptoms (severity, frequency, and impact on activities), mouth dryness and dental health, fatigue levels, joint symptoms, and any cognitive changes gives both you and your clinical team a clearer picture over time. A symptom diary is specifically recommended in the 2024 BSR guideline as a tool for monitoring treatment response [1].

Return sooner than scheduled if you notice new lymph node enlargement that doesn’t resolve within a few weeks, unexplained fever, night sweats, significant unexplained weight loss, a sudden worsening of any established symptom, or new neurological symptoms such as significant weakness, loss of coordination, or vision changes beyond typical Sjögren’s dry eye.

What to Ask For

If you’ve been managing dry eyes, dry mouth, fatigue, and joint pain in separate specialist silos, ask directly: has anyone checked anti-SSA and anti-SSB antibodies? Has anyone considered whether these symptoms might represent a single autoimmune process? These are not specialist-only questions. They can and should be raised with your GP or primary care provider.

If antibody testing comes back negative but your symptoms are strong, ask about a minor salivary gland biopsy. A negative antibody test does not rule out Sjögren’s disease, and the biopsy is the most specific diagnostic tool available [1].

Where to Go From Here

Sjögren’s disease is not a diagnosis that means a lifetime of progressive decline without recourse. It is a chronic condition that responds meaningfully to the right management: moisture protection, anti-inflammatory interventions, systemic treatment where indicated, and careful monitoring.

What patients with Sjögren’s need most, and receive least, is a clinician who understands that the symptom picture belongs together. The dry eyes, the dry mouth, the fatigue, the brain fog, the joint pain, and the dental changes are not separate problems that happen to exist in the same person. They are one disease expressing itself across multiple systems.

You deserve to have someone look at the whole picture. If you’ve been managing the pieces separately and the pieces don’t fully explain how you feel, that’s the conversation worth having.

Book a Consultation with Heal Integrative Wellness

Subscribe now

Sources

1. Price EJ, Benjamin S, Bombardieri M, et al. British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease. Rheumatology (Oxford). 2025;64(2):409–439. doi:10.1093/rheumatology/keae152 (Published online April 2024; print issue February 2025.)

2. Meinecke A, Kreis K, Olson P, et al. Impact of time to diagnosis in patients with primary Sjögren’s syndrome: a cross-sectional study. Clinical and Experimental Rheumatology. 2024;42(12):2444–2452. doi:10.55563/clinexprheumatol/karr2a

3. Epitropoulos AT, Donnenfeld ED, Shah ZA, et al. Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes. Cornea. 2016;35(9):1185–1191. doi:10.1097/ICO.0000000000000940

4. Asbell PA, Maguire MG, Pistilli M, et al.; Dry Eye Assessment and Management Study Research Group. n-3 fatty acid supplementation for the treatment of dry eye disease. New England Journal of Medicine. 2018;378(18):1681–1690. doi:10.1056/NEJMoa1709691

5. Gergianaki I, Fanouriakis A, Repa A, et al. Vitamin D and Sjögren’s disease: revealing the connections — a systematic review and meta-analysis. Nutrients. 2023;15(3):497. doi:10.3390/nu15030497

6. Agmon-Levin N, Kivity S, Tzioufas AG, et al. Low levels of vitamin D are associated with neuropathy and lymphoma among patients with Sjögren’s syndrome. Journal of Autoimmunity. 2012;39(3):234–239. doi:10.1016/j.jaut.2012.05.018

This article is written and reviewed by the clinical team at Heal Integrative Wellness. It is for educational purposes and does not replace individualized medical advice. Please consult your healthcare provider before making changes to your treatment plan.

© Heal Integrative Wellness — Series 3: The First Diagnosis

If you’ve done the work. If you’ve been in therapy, tried the medication, made the lifestyle changes — and you’re still not where you expected to be. If after all of it you still have mornings that feel impossible, a fatigue that doesn’t respond to rest, a fog that makes you feel less like yourself than you used to be.

You’re not imagining it. And you may not have been given the full picture.

A meaningful proportion of people with depression and anxiety have biological contributors that are actively working against their recovery — inflammation, nutritional deficiencies, thyroid dysfunction, insulin resistance, undiagnosed sleep disorders, gut dysbiosis — that standard psychiatric workups simply don’t look for. When those contributors go unaddressed, even skilled, thoughtful psychiatric care is fighting upstream against a biological current it can’t see.

This isn’t an argument against medication or therapy. Those interventions genuinely help people and sometimes they’re the most important thing. It’s an argument for asking one question that rarely gets asked: is there a body-level story underneath the mind-level diagnosis?

I think about one patient in particular when I write this. He had been on two antidepressants. They helped — partially, incompletely. Enough to function. Not enough to feel like himself.

His psychiatrist was thoughtful and his therapist was skilled. The work was real and it mattered. But after three years he still had mornings where getting out of bed felt like climbing out of quicksand. Still had a kind of fatigue that no amount of sleep touched. Still had a cognitive fog that made his work slower, harder, and less satisfying than it had ever been.

He came to see me because his wife had read something about the gut-brain connection and thought it was worth exploring. He was skeptical. But he came.

His labs told a story nobody had connected before. His high-sensitivity CRP: the most sensitive inflammatory marker on a standard panel was 4.8 mg/L. His fasting insulin was elevated. His vitamin D was 19 ng/mL. His ferritin was 14, borderline depleted. His comprehensive stool analysis showed significant gut dysbiosis.

None of these were part of his psychiatric workup. None had been checked.

We didn’t replace his psychiatrist or his therapist. We didn’t take him off his medication. We addressed the biology underneath. Six months later he described himself as feeling, for the first time in years, genuinely well, not managed, not functional, but well.

I want to be clear about what this story is and isn’t. It is not an argument that depression and anxiety are never truly psychiatric conditions, or that medication and therapy are the wrong approach. They are often exactly the right approach. The research on cognitive behavioral therapy is among the strongest in medicine. Antidepressants help a significant proportion of the people who take them.

But here is what I know from clinical practice: a meaningful proportion of people with depression and anxiety have unaddressed biological contributors: inflammation, nutritional deficiencies, thyroid dysfunction, insulin resistance, undiagnosed sleep disorders, gut dysbiosis, that are actively working against recovery. When those contributors go unidentified and untreated, even the most skilled psychiatric care is fighting upstream against a biological current.

This masterclass is about that question and what it looks like when someone actually takes the time to answer it.

Part 1: Recognizing the Pattern

Why the Biology of Depression Is More Complex Than the Model Suggests

The model most people carry for depression ,that it is caused by low serotonin and corrected by medications that raise it was always more of a working hypothesis than settled science. It served a purpose: it destigmatized depression as a biological brain condition rather than a character weakness. But the simplification has cost us.

A 2023 umbrella review published in Molecular Psychiatry — one of the most discussed papers in psychiatry in recent years — found no consistent evidence across multiple research areas that depression is associated with lowered serotonin concentration or activity [1]. This doesn’t mean SSRIs don’t help people, they clearly do. But it does mean the mechanism is more complex than a simple deficit, and that focusing exclusively on the serotonin pathway while ignoring other biological contributors leaves real opportunities unaddressed.

What the last decade of research has been moving toward is a more heterogeneous model: one that recognizes multiple distinct biological subtypes of depression with different drivers and, potentially, different optimal treatments.

The Inflammatory Subtype

The most compelling emerging framework is what researchers call immuno-metabolic or inflammatory depression. The concept: for a meaningful subset of people with major depressive disorder, estimates in the research range from 25–40%. Depression is driven primarily by systemic inflammation rather than neurotransmitter imbalance [2].

The mechanisms are documented. Pro-inflammatory cytokines: the chemical messengers of immune activation cross the blood-brain barrier and directly alter brain function. They impair the production of serotonin, dopamine, and other neurotransmitters. They increase glutamate activity, creating a neurotoxic environment. They activate the HPA axis, chronically elevating cortisol. They disrupt the prefrontal cortex and hippocampus, regions directly involved in mood regulation, stress response, and memory [2].

What triggers this inflammatory state? The same drivers of systemic inflammation more broadly: metabolic dysfunction, visceral adiposity, insulin resistance, poor sleep, gut dysbiosis, chronic stress, nutritional deficiencies. Which means these are the same conditions this series has been tracking. This is the link that makes integrative medicine not an add-on but a central part of the picture.

Clinically, inflammatory depression tends to present with specific features: prominent fatigue and low energy more than classic sadness, psychomotor slowing, cognitive impairment, and atypical features like increased sleep and increased appetite. Elevated high-sensitivity CRP in someone with depression is a meaningful clinical signal that inflammation is part of the story [2].

The Gut-Brain Axis

The relationship between gut health and mental health has moved from fringe to firmly peer-reviewed territory. The evidence base is now substantial enough that it has been reviewed in major journals including Molecular Psychiatry and Clinical Psychology Review [3].

The biology: the gut microbiome communicates with the brain through multiple channels simultaneously: the vagus nerve (a direct neural highway), the immune system (roughly 70% of immune cells reside in the gut), and through the production of neurotransmitter precursors and metabolites. Approximately 90% of the body’s serotonin is produced in the gut, not the brain [5]. Short-chain fatty acids produced by gut bacteria regulate inflammation and directly influence brain function. The microbiome modulates the HPA axis and affects tryptophan metabolism: the pathway that produces serotonin and, under inflammatory conditions, neurotoxic compounds instead [3].

Consistent findings in the research: people with depression and anxiety have measurably different gut microbiome composition than matched controls. Specifically, lower abundance of the anti-inflammatory, butyrate-producing bacteria (Faecalibacterium, Coprococcus) and increased pathobionts associated with inflammation [3].

This doesn’t mean gut health is the whole story of depression. It means it is part of the story for a meaningful proportion of people and one that is not evaluated in any standard psychiatric workup.

The Nutritional Gaps

Several nutritional deficiencies have direct, documented relationships with depression and anxiety. These are not speculative associations:

Vitamin D deficiency is associated with depression across multiple large population studies. Vitamin D receptors are present throughout the brain, including in regions directly involved in mood regulation. Supplementation trials in people with documented deficiency show meaningful improvement in depressive symptoms [6].

Iron deficiency — even without frank anemia — impairs dopamine synthesis, disrupts sleep architecture, causes cognitive slowing, and produces fatigue patterns that are indistinguishable from depression. Ferritin below 30 ng/mL is functionally significant even when hemoglobin looks normal. (Note: this threshold is above many standard lab reference ranges but is consistent with functional medicine practice and supported by neurological research.)

Magnesium deficiency reduces GABA receptor sensitivity. GABA is the brain’s primary calming neurotransmitter: Magnesium deficiency elevates cortisol, and impairs sleep. It is likely the most common nutritional deficiency that most people have never been tested for.

Omega-3 fatty acids (EPA specifically) have anti-inflammatory and neurological effects that are clinically meaningful in depression. Multiple meta-analyses support EPA supplementation as an adjunct in depression, particularly for inflammatory presentations [7].

B12 and folate are both essential for methylation: the biochemical process underlying neurotransmitter synthesis. B12 deficiency is common in people on metformin, older adults, and those following plant-based diets. It produces mood, cognitive, and neurological symptoms that are consistently mistaken for primary psychiatric illness.

Part 2: This Is Also In Your Body

The Conversation That Rarely Happens in Psychiatry

I want to be careful here, because this section is not a critique of psychiatric care. Clinicians working in mental health are doing important work under significant systemic constraints, and psychiatric medication genuinely saves lives.

But the standard psychiatric workup for depression and anxiety — even a thorough one — does not typically include inflammatory markers, metabolic panels, nutritional assessments, sleep studies, thyroid antibodies, or gut health evaluation. Not because these aren’t relevant, but because the system wasn’t designed to integrate them. The model of mental health care was built largely separately from the model of physical health care, and the two have been slow to converge.

The result is that a person with inflammatory depression, vitamin D deficiency, undiagnosed sleep apnea, and subclinical hypothyroidism may spend years cycling through antidepressants while the biological substrate driving their symptoms goes entirely unaddressed.

The immunometabolic depression research by Milaneschi, Lamers, Berk, and Penninx laid out clearly how biological dysregulations, particularly inflammatory and metabolic, map consistently to specific depressive symptom patterns, and how these biological subtypes may respond differently to different treatments [2]. The implication is not that we should abandon antidepressants. It’s that we should stop treating all depression as if it has the same biological cause.

The brain is an organ. It responds to what’s happening in the body it lives in. Addressing that body is part of treating the brain.

✦ Subscribe to Continue Reading

The rest of this masterclass — including the complete biological workup I run for patients presenting with depression or anxiety, the interventions with the strongest evidence for the inflammatory subtype, the dietary and supplement protocol, the gut health approach, and how to bring this conversation to your existing providers — is available to paid subscribers.

Every piece in this series is written by our clinical team, grounded in peer-reviewed evidence, and built for people who feel like something is being missed in their care.

Already a subscriber? Continue below.

Book a Consultation

Part 3: What Good Testing Actually Looks Like

The Biological Workup That’s Missing

A comprehensive integrative evaluation for depression and anxiety starts where standard psychiatry often ends. Here’s what I include:

High-sensitivity CRP (hs-CRP) — the most accessible inflammatory marker in a standard panel. Below 1 mg/L is low risk; 1–3 mg/L is moderate; above 3 mg/L suggests meaningful systemic inflammation. People with depression and elevated CRP are less likely to respond to SSRIs and more likely to benefit from anti-inflammatory interventions [2]. This single number helps me understand which direction the conversation needs to go.

Full thyroid panel — TSH, free T3, free T4, TPO antibodies. As covered in the previous masterclass, TSH alone is insufficient. Hypothyroidism and Hashimoto’s are among the most commonly missed biological drivers of depression, fatigue, and brain fog. An elevated TPO antibody alongside depressive symptoms is a clinically significant finding.

Full iron panel — ferritin, serum iron, transferrin saturation, and TIBC. Ferritin below 30 ng/mL is functionally relevant to mood and cognition even when hemoglobin is normal. This threshold is above many standard lab reference ranges but is consistent with the neurological research on iron and brain function. This is routinely missed because standard “anemia screens” look only at hemoglobin.

25-hydroxyvitamin D — I’m not looking for the lab’s lower limit of “normal” (often 20 ng/mL). I’m looking for levels above 50–60 ng/mL in patients with mood symptoms. The clinical difference between 25 ng/mL and 60 ng/mL is not trivial.

Fasting glucose, fasting insulin, HOMA-IR — insulin resistance is independently associated with depression, and the relationship is bidirectional. HOMA-IR (calculated from fasting glucose and insulin) above 1.9–2.0 suggests early insulin resistance; above 2.9 is consistent with meaningful resistance. Addressing insulin resistance often improves mood, energy, and cognitive function even without direct psychiatric intervention.

Homocysteine — elevated homocysteine reflects impaired methylation, often due to B12, folate, or B6 deficiency. It is neurotoxic and associated with depression and cognitive decline. It’s easily treated when identified and easy to miss when not tested.

Omega-3 index — measures EPA and DHA as a percentage of red blood cell membranes, reflecting long-term status. Below 4% is associated with increased depression risk; the therapeutic range is generally above 8%. This is a more meaningful measure than a food recall.

Comprehensive metabolic panel and liver enzymes — liver function affects drug metabolism, hormone processing, and toxin clearance. Impaired liver function can undermine psychiatric medication efficacy and overall metabolic resilience.

Sleep evaluation — as covered in the previous masterclass, comorbid sleep apnea in depression is common, frequently missed, and when treated often produces dramatic improvements in mood. If fatigue and non-restorative sleep are prominent features, a sleep study is not optional.

Gut health assessment — comprehensive stool analysis can assess microbial diversity, inflammatory markers in the gut, and intestinal permeability markers. I use these selectively, in patients where gut symptoms coexist with mood symptoms, rather than universally. The evidence for clinical actionability is growing and the testing is still evolving — I’m honest with patients about where that line is.

Part 4: What Actually Moves the Needle

The Anti-Inflammatory Foundation

For patients where inflammation appears to be a primary driver, the anti-inflammatory intervention is the therapeutic anchor.

Dietary pattern — the Mediterranean dietary pattern has the most robust evidence for mental health benefit. The SMILES trial( a randomized controlled trial published in BMC Medicine) demonstrated that dietary intervention targeting the Mediterranean pattern produced significant improvement in depression scores compared to a social support control condition, with 32% of dietary intervention participants achieving remission [4]. This was a clinical trial showing that food functions as medicine for depression. The mechanisms are multiple: reduced inflammatory dietary burden, improved omega-3 to omega-6 ratio, better gut microbiome diversity, improved insulin sensitivity, and better provision of the nutrients required for neurotransmitter synthesis.

Omega-3 supplementation (EPA specifically) at 1–2g EPA daily has shown consistent benefit as an adjunct in depression across multiple meta-analyses, with the strongest effects in inflammatory presentations [7]. This is not a subtle supplement effect. In the right patient it is a clinically meaningful one.

Exercise — the antidepressant effect of exercise is now one of the most consistently replicated findings in psychiatric research. A 2024 network meta-analysis published in the BMJ found that exercise interventions were significantly more effective than active controls for depression, anxiety, and psychological distress [8]. The mechanisms are multiple: neurogenesis, BDNF upregulation, HPA axis regulation, reduction of inflammatory markers, and improvement in sleep architecture. 30–45 minutes of moderate-to-vigorous aerobic exercise three or more times weekly produces effects that are clinically comparable to antidepressants for mild-to-moderate depression. This is not a lifestyle suggestion. It is a clinical intervention.

Gut microbiome support — the intervention with the most consistent evidence is dietary: increased fiber diversity, fermented foods (yogurt, kefir, kimchi, sauerkraut), polyphenol-rich foods (berries, olive oil, legumes), and reduced ultra-processed food. The dietary pattern that supports the microbiome and the dietary pattern that reduces inflammation are essentially the same pattern, which is one reason the Mediterranean approach keeps appearing.

Probiotic supplementation has a growing evidence base specifically for depression and anxiety. Multi-strain formulations appear more effective than single-strain products. The evidence is promising. I recommend probiotic support selectively for patients with clear gut symptoms alongside mood symptoms, not universally.

The Nutritional Protocol

Vitamin D — for patients with levels below 40 ng/mL and mood symptoms, I supplement to achieve levels above 60 ng/mL. This typically requires 3,000–5,000 IU daily with monitoring at 3 months [6].

Magnesium glycinate — 200–400mg at night. Glycinate form for better absorption; timing to support sleep alongside mood. This is one of the most consistently helpful interventions I see in practice for the anxious, poorly sleeping patient with muscle tension and nighttime racing thoughts.

B12 and methylfolate — for anyone with elevated homocysteine, documented B12 deficiency, or who is on metformin (which depletes B12 through gut absorption impairment). Methylcobalamin rather than cyanocobalamin for better neurological utilization; methylfolate rather than folic acid for those with MTHFR variants that impair conversion.

EPA-rich omega-3 — 1–2g EPA daily as an adjunct to existing treatment, particularly in inflammatory presentations [7].

Iron — for anyone with ferritin below 30 ng/mL and mood or cognitive symptoms. Pair with vitamin C for absorption. Retest at 3 months. The target ferritin for neurological function optimization is above 50 ng/mL, which is above many standard lab reference ranges but consistent with functional and neurological medicine research.

Ashwagandha (KSM-66) — for anxiety with prominent HPA axis activation — the “tired but wired” pattern, anxiety worse in the evening, difficulty settling. The evidence for cortisol reduction and anxiety symptom improvement is among the most consistent in the adaptogen category [9]. One important note: ashwagandha is contraindicated in pregnancy and should be used with caution in people with thyroid conditions or those on thyroid medication, as it can influence thyroid hormone levels. Given the thyroid issues this patient population often carries, discuss this with your provider before starting.

When Medication Is the Right Answer

For moderate-to-severe depression, suicidal ideation, panic disorder, OCD, and conditions where the evidence for psychiatric medication is strong medication is appropriate and often necessary. Full stop. The biological contributors I’ve described in this masterclass are not an alternative to psychiatric care for serious mental illness. They are an upstream intervention, a way to optimize the biology on which that care operates.

What I push back on is the use of psychiatric medication as the first and only response, without investigating whether there is a modifiable biological contributor that — if addressed — could meaningfully change the treatment picture. That investigation is not alternative medicine. It is integrative medicine: looking at the whole system before assuming which single lever will fix it.

My approach for a patient presenting with depression or anxiety: comprehensive biological workup as above. Identify and address modifiable contributors sometimes alongside existing psychiatric medication, sometimes first. Refer to or collaborate with psychiatry when symptoms are severe, when suicidality is present, or when biological intervention alone is clearly insufficient. The goal is not to choose between the medical model and the integrative model. It is to use both, thoughtfully.

Part 5: Retesting and What to Watch

The 90-Day and 6-Month Framework

At 90 days: recheck hs-CRP (should be trending down if anti-inflammatory interventions are working), vitamin D (to confirm dose is achieving target levels), ferritin (to confirm iron repletion), and homocysteine if elevated at baseline.

For mood tracking, I use validated scales — PHQ-9 for depression, GAD-7 for anxiety — at baseline and at 90 days. These give objective data to compare with subjective experience, which often diverges in interesting ways. Some patients feel meaningfully better before their scores reflect it; others score better while not yet feeling it subjectively. Both directions tell me something useful.

At 6 months: reassess the full metabolic picture. Has insulin resistance improved? Are inflammatory markers stable or continuing to improve? Is sleep better? Has gut symptomatology changed? These are the systems-level outcomes that tell me whether the biological terrain is genuinely shifting.

Track between labs: morning mood before the day’s demands have had a chance to influence it, sleep quality, energy at mid-morning, appetite, social motivation, cognitive sharpness, and physical symptoms — gut comfort, headaches, muscle tension. The pattern across these gives a fuller picture than any single question about how you’re feeling.

Return sooner if: suicidal ideation develops or intensifies, depressive symptoms significantly worsen despite intervention, or new physical symptoms appear. The biological contributors I’ve described are real — but they are not the whole story for everyone, and escalating psychiatric care when it’s needed is always the right call.

Bringing This to Your Existing Providers

If you’re already working with a psychiatrist or therapist, this information doesn’t have to create tension in that relationship. Most thoughtful clinicians are genuinely interested in whether there are biological contributors to their patient’s symptoms — they simply may not have the time or specialty knowledge to investigate them systematically. Asking your psychiatrist to check hs-CRP, vitamin D, thyroid antibodies, and ferritin is a reasonable clinical request. Sharing that you’re working with an integrative medicine practitioner to address these alongside your psychiatric care is a collaborative frame, not a challenging one.

Where to Go From Here

The brain is a biological organ. It is affected by what you eat, how you sleep, what’s happening in your gut, how your immune system is functioning, what your hormones are doing, and whether your cells are receiving adequate nutrients. None of this makes depression “your fault.” All of it makes it more responsive to intervention than the standard model suggests.

I see people regularly who have been told their symptoms are a fixed feature of their brain chemistry. People who have learned to manage rather than expect resolution, people who stopped looking for a cause because they were told there wasn’t one. Sometimes that’s right. But often the current system allows us to discover there is something biological underneath that hasn’t been looked at.

That’s what this series is here to help you find.

If you’re ready to look at the whole picture, we’re here for that conversation.

Book a Consultation with Heal Integrative Wellness

Sources

1. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Molecular Psychiatry. 2023;28(8):3243–3256. doi:10.1038/s41380-022-01661-0

2. Milaneschi Y, Lamers F, Berk M, Penninx BWJH. Depression heterogeneity and its biological underpinnings: toward immunometabolic depression. Biological Psychiatry. 2020;88(5):369–380. doi:10.1016/j.biopsych.2020.01.014

3. Simpson CA, Diaz-Arteche C, Eliby D, Schwartz OS, Simmons JG, Cowan CSM. The gut microbiota in anxiety and depression — a systematic review. Clinical Psychology Review. 2021;83:101943. doi:10.1016/j.cpr.2020.101943

4. Jacka FN, O’Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial). BMC Medicine. 2017;15(1):23. doi:10.1186/s12916-017-0791-y

5. Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264–276. doi:10.1016/j.cell.2015.02.047

6. Shaffer JA, Edmondson D, Wasson LT, et al. Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials. Psychosomatic Medicine. 2014;76(3):190–196. doi:10.1097/PSY.0000000000000044

7. Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Translational Psychiatry. 2019;9(1):190. doi:10.1038/s41398-019-0515-5

8. Noetel M, Sanders T, Gallardo-Gómez D, et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2024;384:e075847. doi:10.1136/bmj-2023-075847

9. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine. 2012;34(3):255–262. doi:10.4103/0253-7176.106022

This masterclass is written and reviewed by the clinical team at Heal Integrative Wellness. It is for educational purposes and does not replace individualized medical advice. If you are experiencing thoughts of self-harm or suicide, please contact the 988 Suicide and Crisis Lifeline by calling or texting 988.

© Heal Integrative Wellness — Series 3: The First Diagnosis

There might be.

Sleep disorders are among the most under-evaluated contributors to everything we cover in this series: mood, weight, blood pressure, hormonal imbalance, insulin resistance. Two conditions in particular are being missed at a scale that should concern everyone: obstructive sleep apnea and chronic insomnia. They’re different problems with different biology. They frequently coexist. And both are doing considerably more damage than most people realize, not just to sleep quality, but to the cardiovascular system, metabolism, hormones, and mental health.

I want to tell you about a patient who changed the way I think about this.

Her cardiologist referred her for antidepressants.

Her primary care doctor had already tried two. She’d seen a therapist for six months working on sleep hygiene and anxiety. She was eating well, exercising, not drinking. She was doing everything right and still waking up every morning feeling like she hadn’t slept, exhausted, foggy, irritable, with a headache that started before she got out of bed.

She came to see me for what she described as “treatment-resistant depression.”

I asked if she snored. She said she didn’t think so. Her husband hadn’t mentioned it. I asked about waking up at night, morning headaches, feeling unrested even after eight hours in bed.

She had all of it.

A home sleep study came back with 22 apnea events per hour. Moderate obstructive sleep apnea. She had never been tested because she didn’t fit the profile. She wasn’t overweight, wasn’t a heavy snorer, wasn’t a middle-aged man. She was a 44-year-old woman in perimenopause whose sleep apnea looked like depression, and for three years it had been treated as exactly that.

Two months on CPAP, and the person sitting across from me was different. Not cured of everything, but present. Clear. Sleeping. Functioning.

I share this story not to be dramatic about it but because it is not unusual. Variations of it walk through my door regularly. And the gap it represents between what was happening and what was being treated is not a failure of individual care. It is a systemic failure to recognize that sleep disorders, particularly in women, often don’t look like what the textbooks describe.

This story is not unusual. Variations of it walk through my door regularly. The gap it represents (between what was happening and what was being treated) is not a failure of individual care. It’s what happens when the right question never gets asked.

This masterclass is about asking it.

Part 1: Recognizing the Pattern

Two Very Different Problems That Often Travel Together

Obstructive sleep apnea (OSA) happens when the muscles of the upper airway relax during sleep, causing partial or complete airway blockage. The brain registers the oxygen drop and triggers a brief arousal to restore breathing often so quick the sleeper never consciously wakes. This can happen dozens or hundreds of times per night. Each event fragments sleep, drops oxygen, and activates the stress response. The person wakes convinced they slept fine because they have no memory of it. Their partner may report snoring, gasping, or pauses in breathing or they may sleep alone and have no witness at all.

Chronic insomnia has a different mechanism entirely. It is not a breathing disorder. It is a disorder of hyperarousal. The nervous system stays in a state of heightened activation that prevents the transition into sleep or causes early awakening. It can be triggered by stress, trauma, hormonal shifts, or a period of disrupted sleep that becomes self-reinforcing through anxiety about sleep itself. Insomnia often has an identifiable origin story that the patient can name. Over time it evolves into a pattern where the bed itself becomes associated with wakefulness, and the harder someone tries to sleep, the more activated the nervous system becomes.

These two conditions travel together frequently, and recognizing this matters. Someone with untreated sleep apnea often develops insomnia as a secondary consequence of fragmented, nonrestorative nights. And someone with chronic insomnia disrupting their sleep architecture may have apnea events that would otherwise be captured in a sleep study but are being obscured by baseline disruption. Treating one while missing the other produces partial results at best.

The Patterns Worth Knowing

OSA in men presents more classically: loud snoring, witnessed breathing pauses, excessive daytime sleepiness, waking with a dry mouth or sore throat, morning headaches. This is the presentation most screening tools and most clinicians are looking for, because most of the research and most of the screening tools were built on male populations.

OSA in women is different — and this is where the diagnostic gap lives. Women with sleep apnea are significantly more likely to present with insomnia, fatigue, morning headaches, mood disturbance, anxiety, and depression rather than obvious snoring and daytime sleepiness [1]. These are the symptoms that send women to psychiatry, not to a sleep lab. Research consistently shows that women are diagnosed with OSA at later stages, have significantly worse quality of life at the time of diagnosis, and are frequently misdiagnosed with depression, anxiety, or hypothyroidism for years before anyone looks at their sleep [1].

The perimenopause transition substantially increases OSA risk in women. Estrogen and progesterone both appear to have a protective effect on upper airway muscle tone. As these hormones decline, OSA risk rises and the symptoms that result overlap so completely with perimenopausal sleep disruption that neither condition gets properly evaluated [1].

Chronic insomnia presents as difficulty falling asleep, difficulty staying asleep, early morning awakening with inability to return to sleep, or waking that feels nonrestorative — on at least three nights per week, for at least three months. The defining feature is daytime impairment: fatigue, cognitive difficulty, mood changes, reduced work performance or relationship functioning. If daytime function is not meaningfully impaired, it isn’t clinical insomnia by the diagnostic definition it’s a sleep preference mismatch, which is a different problem.

What Sleep Deprivation Is Actually Doing

This matters for every topic in this series, because poor sleep is not a standalone quality-of-life issue. It is a metabolic disease driver.

Insufficient sleep defined as less than 7 hours for most adults produces consistent, measurable hormonal changes. Ghrelin (hunger hormone) rises, leptin (satiety hormone) falls, cortisol dysregulates, insulin sensitivity deteriorates, inflammatory markers elevate, and testosterone declines in men. These are not subtle effects. They happen reliably with sleep restriction and they work directly against every other health intervention.

Untreated OSA specifically drives cardiovascular risk through repeated overnight oxygen drops, sustained sympathetic nervous system activation, and inflammatory cascades. The associations between OSA and hypertension, atrial fibrillation, coronary artery disease, and stroke are well-established and mechanistically understood [2]. OSA is not a comfort problem. It is a cardiovascular disease risk factor that happens to cause discomfort along the way.

Part 2: This Is Not in Your Head

The Missed Diagnosis That Costs Years

The woman in my opening story is representative of a pattern. The reason it keeps happening is structural. The most widely used primary care screening tool for OSA, the STOP-BANG questionnaire. It was developed predominantly from studies of male patients and includes snoring, tiredness, observed apnea, high blood pressure, BMI over 35, age over 50, neck circumference over 40cm, and male sex. A woman in perimenopause who is fatigued, has normal BMI, doesn’t obviously snore, and sleeps alone scores low. The questionnaire says she’s low risk, but she has moderate OSA.

The 2025 AASM guidelines on OSA in hospitalized patients mark a meaningful shift toward proactive, pathway-based screening rather than reactive diagnosis [2]. The broader clinical trend is toward recognizing that OSA is underdiagnosed specifically in the populations where it presents atypically. The consequence of missed diagnosis is years of inappropriate treatment alongside progressive cardiovascular, metabolic, and cognitive harm.

For insomnia, the harm is different in kind but equally real. Chronic sleep deprivation accelerates every condition we’ve covered in this series. Someone doing everything right and not sleeping well is working against a significant biological headwind every single day.

✦ Subscribe to Continue Reading

The rest of this masterclass — including exactly how to access sleep testing, what the different tests measure and when each is appropriate, the treatment options for OSA beyond CPAP, the behavioral approaches for insomnia that outperform medication in the long run, where supplements actually fit, and the monitoring framework, is available to paid subscribers.

Every piece in this series is written by our clinical team, grounded in peer-reviewed evidence, and built around the questions we hear most often from people who have been treated for everything except what’s actually going on.

Already a subscriber? Continue below.

Book A consultation

Subscribe now

Part 3: What Good Testing Actually Looks Like

Diagnosing OSA: Home Testing vs. the Sleep Lab

If OSA is suspected the diagnostic pathway is clear, even if it’s not being offered proactively.

Home sleep apnea testing (HSAT) is the first-line diagnostic approach for most adults with uncomplicated presentations. A small device worn overnight measures airflow, oxygen saturation, respiratory effort, and heart rate. It can be done at home and is interpreted by a sleep specialist. The AASM guidelines support HSAT for adults with a high clinical probability of moderate-to-severe OSA [2]. The limitation is that it records device time, not total sleep time, so it can slightly underestimate severity. For most people it’s an accessible and accurate starting point.

In-laboratory polysomnography (PSG) is the gold standard diagnostic test. It captures everything the home test does plus sleep staging, brain activity, leg movements, and full cardiac monitoring. It is recommended when HSAT results are inconclusive or when other sleep disorders are suspected alongside OSA, parasomnias, narcolepsy, periodic limb movement disorder, or conditions involving significant cardiovascular or respiratory complexity.

For women specifically, I have a lower threshold for recommending in-lab testing rather than home testing. Women with OSA tend to have more REM-predominant disease with breathing events concentrated in REM sleep and lower overall AHI (apnea-hypopnea index) scores despite significant symptoms [1]. A home test that records a shorter total window may miss the period when events are most frequent. This is one of the mechanisms through which women remain underdiagnosed even when testing does happen.

Diagnosing Insomnia: This Is Clinical, Not a Lab Test

Insomnia is diagnosed through clinical evaluation, a sleep study won’t diagnose it and isn’t necessary. What’s needed is a thorough history: onset, pattern, what triggered it, what maintains it, sleep environment and habits, and assessment of daytime impairment.

What I also evaluate in anyone presenting with insomnia:

Medical contributors — thyroid dysfunction, pain conditions, restless legs syndrome, GERD, and respiratory conditions all disrupt sleep. Treating insomnia without addressing these is managing a symptom while the cause continues.

Medication effects — stimulants, certain antidepressants, beta-blockers, corticosteroids, and thyroid medication taken too late in the day are all documented sleep disruptors. A medication review often reveals a fixable contributor that nobody connected to the sleep problem.

Comorbid OSA — up to 50% of people with chronic insomnia also have sleep apnea. Someone who reports lying awake for hours at night may actually be experiencing frequent arousals from apnea events that they’re interpreting as an inability to fall asleep. If there is any clinical suggestion of this, a sleep study belongs in the insomnia evaluation.

Circadian evaluation — delayed sleep phase (unable to fall asleep until the early hours, unable to wake at a conventional time) and advanced sleep phase (falling asleep early and waking at 3–4am) are distinct conditions from classical insomnia with different management approaches.

Part 4: What Actually Moves the Needle

For OSA: There’s More Than One Option

CPAP — continuous positive airway pressure — remains the most effective treatment for moderate to severe OSA. It delivers a constant airstream through a mask that keeps the upper airway open during sleep. When tolerated and used consistently, the improvements in sleep quality, daytime function, blood pressure, blood sugar, cardiovascular risk markers, and mood are real and meaningful [2].

Tolerance is the genuine challenge. Many people find the mask uncomfortable or disruptive, and CPAP adherence is a real clinical problem, not a patient motivation problem.

Oral mandibular advancement devices (MADs) — custom-fitted by a dentist with sleep medicine training, these devices move the lower jaw slightly forward during sleep to widen the upper airway. They are less effective than CPAP for severe OSA, but for mild-to-moderate disease they produce clinically meaningful AHI reduction and substantially better real-world adherence. For many patients, a device they’ll actually use is more effective than a device that stays on the nightstand.

Positional therapy — a significant proportion of OSA events are position-dependent, concentrated in the supine (back-sleeping) position. Wearable positional devices, specialty pillows, or even a simple tennis ball stitched into the back of a sleep shirt can reduce AHI substantially for these patients. It’s underused and often highly effective.

Weight loss — for OSA associated with excess weight, meaningful weight loss produces real AHI reduction. A 10% body weight reduction correlates with approximately a 26% reduction in AHI in some studies. GLP-1 medications producing substantial weight loss are therefore directly relevant to OSA management. The 2025 Canadian obesity pharmacotherapy guidelines explicitly identify OSA as a comorbidity where GLP-1 therapy has specific documented benefit [3].

Hypoglossal nerve stimulation (Inspire therapy) — a small implanted device that stimulates the nerve controlling tongue position during sleep, preventing airway collapse. It has become a meaningful option for people with moderate-to-severe OSA who cannot tolerate CPAP. Patient satisfaction is high in well-selected candidates.

Modifiable contributors — alcohol meaningfully worsens OSA by relaxing upper airway muscle tone. Even moderate alcohol before bed increases apnea events measurably. Nasal congestion from allergies or anatomical factors is a fixable contributor. Hypothyroidism, covered in the previous masterclass, independently worsens OSA and should be addressed in any combined picture.

For Insomnia: Start With CBT-I

Cognitive Behavioral Therapy for Insomnia (CBT-I) is the most effective long-term treatment for chronic insomnia. Not just compared to placebo, compared to sleeping medication. This is the first-line recommendation from every major sleep medicine organization globally, backed by robust clinical trial evidence [2].

CBT-I addresses the behavioral and cognitive drivers of insomnia rather than suppressing symptoms temporarily. Its core components: sleep restriction (counterintuitive but powerfully effective), stimulus control (rebuilding the association between bed and sleep rather than wakefulness), sleep hygiene optimization, and cognitive restructuring of the anxious thoughts about sleep that maintain the problem. The effects are durable unlike medication, which stops working when stopped, CBT-I changes the brain’s arousal patterns in ways that persist.

CBT-I can be delivered by a trained therapist, through structured digital programs, or via self-guided workbooks. If you have chronic insomnia and haven’t tried CBT-I, this is the first step — not a sleeping pill.

Sleep restriction — the most counterintuitive component and the most powerful. By initially limiting time in bed to match actual sleep time, it builds sleep pressure that makes falling and staying asleep genuinely easier. The first week or two are uncomfortable. The durability of the results is worth it.

Morning light exposure — bright light within the first hour of waking anchors the circadian clock, promotes earlier melatonin onset in the evening, and improves sleep onset at night. This is not optional self-care. It is a circadian intervention with documented biological effect. Ideally natural sunlight; a bright light therapy lamp works when that isn’t possible.

Where supplements fit in:

Magnesium glycinate — magnesium is required for GABA receptor function (GABA is the brain’s primary calming neurotransmitter), cortisol regulation, and sleep architecture. Deficiency is genuinely common and often contributes to difficulty staying asleep and nighttime awakening. Glycinate form is better absorbed and better tolerated than the oxide form that dominates retail. This is one of the most consistently useful supplements I recommend for sleep.

Melatonin — widely misunderstood and misused. Melatonin is a circadian timing signal, not a sedative. Low doses (0.5–1mg) taken 1–2 hours before the desired sleep time help shift the circadian clock earlier. The high doses on retail shelves (5–10mg) are pharmacologically supraphysiological and can dysregulate circadian rhythms over time. For jet lag and circadian phase issues, melatonin is evidence-based and appropriate. For chronic insomnia, it is not the solution.

Ashwagandha (KSM-66 extract) — has the most consistent clinical evidence among adaptogenic herbs for both sleep quality and anxiety reduction. Several randomized trials in healthy adults and in people with insomnia have shown meaningful improvements in sleep onset, duration, and perceived quality [4]. It’s a reasonable adjunct for anxiety-driven insomnia, not a primary intervention.

Phosphatidylserine — helps reduce evening cortisol in people with HPA axis overactivation, the physiological pattern that produces the “tired but wired” experience, exhausted through the day but unable to settle at bedtime. Evidence is modest but consistent for this specific presentation.

The Honest Conversation About Sleep Medication

Benzodiazepines and Z-drugs (zolpidem, eszopiclone) suppress sleep symptoms without addressing their cause, produce tolerance and dependence with regular use, impair sleep architecture, and carry significant fall and cognitive risks especially in older adults. They have a role in acute insomnia management. They are not appropriate as long-term primary treatment for chronic insomnia.

Low-dose doxepin and orexin receptor antagonists (suvorexant, lemborexant) have better-fitting mechanisms and safety profiles for specific insomnia presentations. These are worth knowing about if medication is needed.

My approach: CBT-I first. Evaluate and address contributing factors: thyroid, sleep apnea, anxiety, cortisol patterns. Optimize nutritional and circadian factors. Use medication judiciously for the acute phase or as a bridge while behavioral work takes hold, not as the long-term solution.

Part 5: Retesting and What to Watch

The 4-Week and 3-Month Check-In

For OSA on CPAP: most modern machines generate compliance data: hours of use, residual AHI on therapy, mask leak rates. A 4-week review of this data tells you whether the pressure settings are adequate and whether there are mask or interface issues to address. Adequately treated OSA should produce a residual AHI below 5, good overnight oxygen saturation. Usually within 2–6 weeks, there should be meaningful improvement in daytime energy and cognitive clarity. If you’re using it consistently and not improving, the settings or the delivery interface likely need adjustment.

For insomnia on CBT-I: a sleep diary for the first 4–6 weeks is essential. Record time to bed, estimated time to fall asleep, number of awakenings, wake time, and estimated total sleep. This data guides the sleep restriction component and allows objective tracking in a domain where subjective experience often lags behind objective improvement. Most people see meaningful change by 6–8 weeks.

Blood markers worth reviewing alongside sleep treatment: inflammatory markers (CRP), blood pressure, fasting glucose, and cortisol. Treated OSA produces measurable improvements in all of these. If metabolic markers aren’t improving alongside sleep, there may be additional contributors to investigate.

Track at home: energy on waking before caffeine, headache frequency, mood consistency, cognitive sharpness mid-morning, and exercise tolerance. If you have a wearable device, heart rate variability during sleep is a useful proxy for how well the nervous system is recovering overnight.

Return sooner than scheduled if: OSA symptoms return after a period of stable treatment (mask seal may have degraded, pressure may need adjustment), new cardiac symptoms develop, insomnia significantly worsens, or sleep disruption appears following a medication change.

Where to Go From Here

Sleep is not passive time. It is the period during which your immune system builds its defenses, your brain clears metabolic waste, your hormones reset, your cardiovascular system recovers, and your insulin sensitivity restores. Nothing else you do for your health operates independently of how well you sleep.

If you’ve been tired for years and been told it’s anxiety, stress, depression, or just how you are, consider whether anyone has actually looked at your sleep. Not asked about it…actually looked at it, with data.

The woman in my opening story is sleeping now. Her treatment-resistant depression resolved when we treated the sleep apnea that was causing it. That’s not a remarkable outcome. That’s what happens when the right diagnosis finally gets made.

If any of this resonated and you want to understand what’s actually going on with your sleep, that’s a conversation we’re glad to have.

Book a Consultation with Heal Integrative Wellness

Sources

1. Seda G, Han TS. Effect of obstructive sleep apnea on neurocognitive performance, fatigue, and sex differences. Sleep Medicine Clinics. 2020;15(1):77–85. doi:10.1016/j.jsmc.2019.11.005; see also: Theorell-Haglöw J, Lindberg E. Sex differences in obstructive sleep apnea. Current Sleep Medicine Reports. 2016;2(2):71–78. doi:10.1007/s40675-016-0041-9

2. American Academy of Sleep Medicine. Evaluation and management of obstructive sleep apnea in adults hospitalized for medical care: an AASM systematic review, meta-analysis, and GRADE assessment. Journal of Clinical Sleep Medicine. 2025. doi:10.5664/jcsm.11866

3. Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M, et al. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ. 2025;197(27):E797–E809. doi:10.1503/cmaj.250502

4. Cheah KL, Norhayati MN, Husniati Yaacob L, Abdul Razak AR. Effect of ashwagandha (Withania somnifera) extract on sleep: a systematic review and meta-analysis. PLOS ONE. 2021;16(9):e0257843. doi:10.1371/journal.pone.0257843

This masterclass is written and reviewed by the clinical team at Heal Integrative Wellness. It is for educational purposes and does not replace individualized medical advice. Please consult your healthcare provider before making changes to your treatment plan.

© Heal Integrative Wellness — Series 3: The First Diagnosis

Because “normal” and “fine” are not the same thing. And nowhere is that gap more consequential than in thyroid medicine.

The thyroid is one of the most routinely checked organs in medicine and one of the most poorly evaluated. That’s not a contradiction, it’s the problem. Most standard thyroid panels check one number: TSH. And TSH alone can look completely normal while the thyroid system underneath it is struggling. It’s like checking the thermostat on the wall and declaring the heating system fine. The thermostat reads normal. The furnace is barely functioning.

I see this pattern constantly. One patient I think about often had been to three doctors in two years. Fatigue so heavy it felt like moving through water. Hair coming out in the shower in amounts that alarmed her. Weight climbing even though she was eating less than ever. Cold when no one around her was. A brain fog so thick she’d started writing herself notes for conversations she’d already had. Each time, she was told her labs were fine. Her TSH was in range.

She came to me and I ran a full panel: TSH, free T3, free T4, and thyroid antibodies. Within a week we had the answer: Hashimoto’s thyroiditis with subclinical hypothyroidism. Her TSH was technically in the normal range. But her free T3, the active form of thyroid hormone that actually gets into your cells, was at the very bottom of it. And her antibodies were significantly elevated, meaning her immune system had been quietly attacking her thyroid for years.

Two years. Three doctors. One blood test that should have been ordered from the start.

I’m not telling you this to criticize those clinicians, they were following standard protocol exactly as they should. I’m telling you because the standard protocol has a gap, and that gap is failing a lot of people. This masterclass is about what a proper thyroid evaluation actually looks like, what Hashimoto’s really means for your health, and what it takes to feel genuinely well… not just “in range.”

Part 1: Recognizing the Pattern

Why Thyroid Problems Are So Easy to Miss

Your thyroid is a small butterfly-shaped gland at the base of your throat that runs your metabolism in the most literal sense. It produces hormones primarily T4 and T3, that tell every cell in your body how to use energy. Not just your metabolic rate. Every cell. Your heart rate, body temperature, digestion, mood, memory, skin, hair, fertility, and cholesterol metabolism. When thyroid function slows down, all of these systems slow together.

This is exactly why thyroid problems are so easy to miss. People come in describing fatigue, weight gain, cold intolerance, constipation, dry skin, hair thinning, brain fog, low mood, elevated cholesterol, and irregular periods. Because no single symptom points clearly to the thyroid, each one gets addressed in isolation while the underlying cause goes untreated. You end up with five separate problems when there was really only one all along.

The Patterns Worth Knowing

Classic hypothyroidism looks like fatigue that doesn’t improve with rest, unexplained weight gain, feeling cold when others are comfortable, dry skin, hair thinning or loss, particularly the outer third of the eyebrows, which is a specific and telling sign. Constipation, slowed heart rate, and a persistent low mood that doesn’t respond to lifestyle changes. This is the presentation most clinicians recognize and look for.

Hashimoto’s thyroiditis is the most common cause of hypothyroidism in iodine-sufficient countries, and it is fundamentally different from simple thyroid underperformance. Hashimoto’s is an autoimmune condition: the immune system produces antibodies that gradually destroy thyroid tissue. What makes it clinically distinct is that it can cause fluctuating symptoms: periods of feeling relatively normal alternating with flares of fatigue, brain fog, and mood disturbance, as the inflammatory process waxes and wanes. Some people with Hashimoto’s also experience transient spells that feel more like hyperthyroidism: anxiety, palpitations, insomnia, as damaged tissue releases stored hormone. These episodes get misattributed to stress constantly [1].

Subclinical hypothyroidism is where the most clinical disagreement lives, and where the most patients fall through the cracks. It is defined as elevated TSH with normal free T4 and T3. By conventional guidelines, many patients in this category are not offered treatment unless TSH rises above 10 mIU/L [2]. But “subclinical” does not mean asymptomatic. Research consistently shows that people in this category experience real reductions in quality of life, cardiovascular changes, lipid dysregulation, and cognitive symptoms, especially when TSH is consistently above 4–5 mIU/L [3]. The decision to treat should incorporate symptoms and the full clinical picture, not a TSH number alone.

Thyroid dysfunction in perimenopause deserves specific attention because it is one of the most commonly missed overlaps in women’s health. Declining estrogen directly affects thyroid hormone binding and metabolism. Women who were well-compensated before their 40s can develop symptomatic thyroid dysfunction during the perimenopause transition, and the symptoms overlap so completely with perimenopause itself: fatigue, mood changes, weight shifts, sleep disruption, that neither gets properly evaluated. If you’re in your 40s and your symptoms fit both patterns, both genuinely need to be investigated.

Part 2: This Is Not in Your Head

Why “Normal” Doesn’t Always Mean Fine

I want to explain something that I think every patient deserves to understand.

TSH stands for thyroid-stimulating hormone. It’s produced by the pituitary gland and tells the thyroid to make more hormone. When thyroid output falls, the pituitary raises TSH sending a louder signal. So elevated TSH is indeed a marker that the thyroid is underperforming.

Here’s the problem. The “normal” TSH range used in most labs (roughly 0.4 to 4.5 mIU/L) was established from population studies that included people with undiagnosed thyroid disease. The upper end of “normal” includes people who were already symptomatic and simply hadn’t been diagnosed. Many endocrinologist working in this space believe that for a symptomatic patient, a TSH consistently above 2.5 mIU/L warrants further investigation, meaning a full free hormone panel and antibody testing, not a “we’ll repeat it in a year” [2, 3].

The second problem is that TSH tells you nothing about what’s happening downstream. T4 is the main hormone the thyroid produces, but it’s largely inactive on its own, it has to be converted to T3, the active form, in the liver, kidneys, and other tissues. Some people convert T4 to T3 poorly, particularly under chronic stress, with certain nutritional deficiencies, or in the presence of inflammation. Their TSH and T4 can look perfectly normal while their T3 is low at the cellular level. Standard panels miss this entirely.

This is why people can have every symptom of hypothyroidism while being told their results are normal. The test being ordered is not asking the right question.

I’ve had patients come to me on levothyroxine,the standard T4 medication, for years, still exhausted, still gaining weight, still foggy. Their TSH was controlled. They were not feeling controlled. When we checked their free T3, it was at the floor. That’s a different problem requiring a different conversation.

✦ Subscribe to Continue Reading

The rest of this masterclass including what every marker in a complete thyroid panel actually tells you, the full Hashimoto’s workup, the supplement interventions with the strongest evidence, what the research actually says about T4/T3 combination therapy, and the monitoring framework is available to paid subscribers.

Every piece in this series is written by our clinical team, grounded in peer-reviewed evidence, and built around the questions we hear most often from patients who’ve been told their results are fine and still don’t feel fine.

Already a subscriber? Continue below.

Book a Consultation

Subscribe now

Part 3: What Good Testing Actually Looks Like

The Full Panel — What Each Number Is Telling You

A complete thyroid evaluation is not a TSH. Here’s what it actually includes:

TSH is the starting point, not the conclusion. An elevated TSH signals the pituitary is working harder to drive the thyroid. But a normal TSH does not mean a normal thyroid system. It means the pituitary’s feedback loop is currently compensated.

Free T4 (fT4) is the main hormone the thyroid produces. “Free” means unbound the portion that’s actually available to be used by your body. If fT4 is low, the thyroid isn’t producing adequately. If it’s normal but symptoms are present, we need to look at what’s happening to it downstream.

Free T3 (fT3) is the active form that gets into cells and actually runs metabolic function. This is the number most often absent from standard panels and most often explaining why symptomatic people have been told everything is fine. Low fT3 with normal TSH and fT4 points to a conversion problem: a downstream failure that is just as clinically impactful as a production failure.

Reverse T3 (rT3) is an inactive form of T3 that competes with active T3 at the same cellular receptor. Under chronic stress, significant illness, or prolonged caloric restriction, the body shifts toward producing more rT3 as a metabolic brake. Elevated rT3 can produce every symptom of hypothyroidism even when other markers look fine. I request this in patients with persistent symptoms despite reasonable-looking panels.

TPO antibodies (anti-thyroid peroxidase) are the primary marker for Hashimoto’s. Elevated TPO antibodies indicate an autoimmune attack on the thyroid — even before thyroid function has measurably changed. Catching this early matters: it identifies people at risk for progressive thyroid decline, explains the fluctuating symptoms, and opens a completely different treatment conversation around the immune process itself [1].

Thyroglobulin antibodies (anti-Tg) are a secondary autoimmune marker. Some people with Hashimoto’s have elevated anti-Tg but normal TPO antibodies, so testing both increases the likelihood of catching it [1].

Timing — thyroid labs should be drawn in the morning, ideally fasting, and before taking thyroid medication if you’re already on it. Afternoon draws and post-medication draws can produce misleading results.

Part 4: What Actually Moves the Needle

The Hashimoto’s Approach Is Different

Treating Hashimoto’s as if it’s simple hypothyroidism, replacing hormone and monitoring TSH, addresses the downstream consequence while the upstream cause continues. The autoimmune process doesn’t pause because TSH has normalized. Left unaddressed, it drives progressive destruction of thyroid tissue and ongoing inflammatory symptoms even when hormone levels look stable.

Selenium is the most evidence-supported nutritional intervention in Hashimoto’s. Multiple randomized controlled trials have shown that selenium supplementation (typically 200 mcg daily of selenomethionine) significantly reduces TPO antibody levels and improves thyroid tissue appearance on ultrasound over a period of months [1]. The thyroid contains the highest concentration of selenium of any organ in the body, and selenoproteins are critical for both thyroid hormone synthesis and the antioxidant defense that protects thyroid cells from immune-mediated damage. When selenium is depleted, Hashimoto’s tends to progress faster. This is one of the most robust supplement recommendations in integrative medicine not because it sounds good, but because the trial data is consistent.

Vitamin D is consistently low in people with autoimmune thyroid disease. Multiple studies show that Hashimoto’s patients have lower levels than matched controls, and that correcting those levels is associated with reduced antibody burden [1]. I’m not looking for vitamin D to be “sufficient” in the lab’s terms, I want levels above 60 ng/mL. There is a meaningful clinical difference between a level of 25 ng/mL (which most labs call normal) and 65 ng/mL when it comes to immune regulation in autoimmune disease.

Gluten and Hashimoto’s — this is a nuanced area and I want to be honest about it. There is a real association between Hashimoto’s and celiac disease: rates of celiac disease are meaningfully higher in people with Hashimoto’s than in the general population, and untreated celiac can worsen thyroid autoimmunity [1]. For people who test positive for celiac or gluten sensitivity, a strict gluten-free diet is a clinical priority, not a wellness preference. For Hashimoto’s patients without confirmed celiac disease, the evidence for gluten elimination is less definitive but some patients notice real symptom improvement on a trial. My recommendation: test properly first (anti-tissue transglutaminase antibodies, anti-endomysial antibodies) before assuming, because the testing becomes unreliable once someone has already eliminated gluten.

Iodine — this is the area where wellness content tends to go wrong. Iodine is necessary for thyroid hormone synthesis, and deficiency causes hypothyroidism. But in people with established Hashimoto’s, high-dose iodine supplementation can trigger or worsen autoimmune flares. I ensure adequate dietary iodine through food sources. I don’t recommend iodine supplementation in Hashimoto’s patients.

Zinc and iron — both are needed for T4-to-T3 conversion. Iron deficiency impairs thyroid function at multiple levels and is common in women with Hashimoto’s — often because heavy menstrual periods, which can themselves be a consequence of hypothyroidism, deplete iron over time. A full iron panel,not just hemoglobin, is part of every thyroid workup in my practice.

The Medication Conversation

The standard treatment for hypothyroidism is levothyroxine, synthetic T4. For the majority of patients this works well: TSH normalizes, symptoms resolve, and no further adjustment is needed.

But a meaningful subset of patients on levothyroxine continue to feel unwell despite a normal TSH. The 2014 ATA guidelines (which remain the primary reference document for hypothyroidism treatment) concluded that levothyroxine monotherapy should remain the standard of care, finding no consistent evidence that combination T4/T3 therapy produces superior outcomes [2]. What they also acknowledged, and what the subsequent decade of research has reinforced, is that persistent symptoms in treated patients are real and require further evaluation of T3 conversion, of nutritional status, of other contributing conditions [2, 3].

The European Thyroid Association has taken a more open position: in patients with persistent symptoms despite optimized levothyroxine therapy, a supervised trial of combination T4/T3 therapy may be considered after other causes have been excluded. This is not a recommendation to move everyone to combination therapy. It is an acknowledgment that TSH-controlled does not always mean symptom-controlled, and that some patients have a T3 need that T4-only therapy cannot fully meet.

Desiccated thyroid extract (DTE), which contains both T4 and T3 from animal thyroid glands, is another option some patients prefer, particularly those who report feeling better on it despite adequate-looking labs on levothyroxine. The evidence base is more limited, but patient response, symptom experience, and individual conversion differences are all legitimate factors in this conversation.

My clinical approach: optimize the full panel, not just TSH. Address selenium, vitamin D, zinc, and iron before drawing conclusions about medication adequacy. If someone is on levothyroxine with a controlled TSH and a low-normal free T3 and still feels poorly, that’s a conversation worth having, not a reason to be reassured.

Part 5: Retesting and What to Watch

The 6-Week and 6-Month Framework

After starting or adjusting thyroid medication, TSH and free hormone levels should be rechecked at 6–8 weeks. Thyroid hormone changes move slowly. The pituitary takes weeks to register a new dose, so earlier retesting produces misleading results and unnecessary adjustments [2].

For Hashimoto’s specifically, I recheck TPO antibodies at 6 months when we’ve introduced selenium or made meaningful dietary changes. Antibody levels respond more slowly than symptoms do. A 3-month recheck often shows no movement even when the patient genuinely feels better, and that’s still progress.

Once stable, I review the full panel annually, not just TSH. A TSH that slowly drifts upward over years while symptoms quietly return is a signal worth catching early. Either the medication needs adjustment or the autoimmune process is advancing.

Track at home: energy levels, sleep quality, morning body temperature (consistently below 97.8°F on waking can suggest undertreated hypothyroidism in some patients), hair loss, bowel regularity, and cold tolerance. These are the signals that tell you whether treatment is working in practice, not just on paper.

Return sooner if: symptoms significantly worsen after a period of stability, heart palpitations or unusual warmth develop (which can indicate over-treatment or a Hashimoto’s flare), or you become pregnant. Thyroid hormone requirements increase substantially in pregnancy, often within the first few weeks, and doses typically need adjustment quickly [2].

What to Ask For

If you’ve been told your thyroid is fine based only on TSH, ask specifically for: free T3, free T4, TPO antibodies, and thyroglobulin antibodies. If you’re already on levothyroxine with a normal TSH and still feel unwell, ask whether your free T3 has been measured, and what it actually is. If it’s sitting in the lowest quarter of the reference range while your symptoms persist, that’s a conversation worth pursuing… not a reason to accept that this is just how you feel now.

Where to Go From Here

The thyroid is not a simple gland with a simple dial. It is part of a hormonal cascade involving the brain, the pituitary, the liver, the immune system, and every cell in your body. Evaluating it through a single number and declaring everything fine is not thyroid medicine. It is TSH management, and those are not the same thing.

You deserve a workup that asks the right questions. A clinician who takes your symptoms seriously even when your labs look acceptable. A treatment plan that addresses what’s actually driving the problem, not just what the number on a report reflects.

If you’ve recognized yourself in any of this and want to understand what your full picture looks like, that’s exactly where we start.

Book a Consultation with Heal Integrative Wellness

Sources

1. Klubo-Gwiezdzinska J, Wartofsky L. Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment. Polish Archives of Internal Medicine. 2022;132(3):16222. doi:10.20452/pamw.16222

2. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670–1751. doi:10.1089/thy.2014.0028

3. Idrees T, Palmer S, Braunstein GD, Swerdloff RS. Subclinical hypothyroidism, outcomes and management guidelines: a narrative review and update of recent literature. Current Medical Research and Opinion. 2023;39(3):351–365. doi:10.1080/03007995.2023.2165811

This masterclass is written and reviewed by the clinical team at Heal Integrative Wellness. It is for educational purposes and does not replace individualized medical advice. Please consult your healthcare provider before making changes to your treatment plan.

© Heal Integrative Wellness — Series 3: The First Diagnosis

How long do you think this has been developing?

Because here’s what the research tells us: by the time someone receives a type 2 diabetes diagnosis, they’ve typically had significant insulin resistance for seven to ten years. Their pancreatic beta cells — the ones that produce insulin — have likely already lost close to half their functional capacity. The disease that got named that day didn’t start that day. It built slowly, over years, sending signals along the way that were either missed, minimized, or never connected into a pattern.

I say this not to assign blame to anyone, healthcare workers are working within real constraints, and this is a systemic failure, not an individual one. I say it because I want you to understand the full picture of what you’re dealing with. And because the answer to that question “how long this has been developing?” is also the answer to how much time you have to change the trajectory.

For the majority of people with type 2 diabetes who are still in the earlier stages, with insulin resistance as the primary driver and without significant complications, the biology is still responsive. The window is still open.

This masterclass is for both groups: those who just received a diagnosis and want to understand what it actually means, and those who were told their blood sugar is “a little high” or their A1c is “borderline.” If you’re in the second group, I want to say this directly: you are not fine, you are not pre-anything in the way that word implies safety. You are on a continuum. And the continuum is still reversible where you’re standing.

Part 1: Recognizing the Pattern

The Continuum Nobody Explains

We covered insulin resistance in depth in the third masterclass of this series. The short version: insulin resistance is the state in which your cells stop responding normally to insulin, your pancreas compensates by producing more, and the downstream consequences: elevated blood sugar, inflammation, fat accumulation, and hormonal disruption build over years before any diagnostic threshold gets crossed.

Type 2 diabetes is what happens at the end of that process, when the pancreas can no longer compensate adequately and blood glucose rises past the official cutoff.

Those cutoffs are: fasting glucose at or above 7.0 mmol/L (126 mg/dL) on two occasions, an A1c at or above 6.5%, or a 2-hour glucose at or above 11.1 mmol/L during a glucose tolerance test [1]. What those numbers don’t convey is the decade of biology that preceded them.

An A1c of 6.4% is called prediabetes. An A1c of 6.5% is called diabetes. The biological difference between those two numbers is almost nothing. The clinical management they typically receive is entirely different. That gap is one of the most consequential in primary care.

Here’s what the pattern looks like, well before those numbers are reached:

The slow creep that gets normalized — blood sugar readings of 5.4, then 5.6, then 5.9, then 6.2 across successive years. Each individual result looks only marginally worse than the last. The trajectory gets missed because each appointment addresses the current number, not the direction of travel.

Weight gain concentrated in the abdomen — visceral fat is the most metabolically active fat depot, and it drives insulin resistance directly through inflammatory signals and interference with insulin receptor function. This isn’t a cosmetic concern. It’s a metabolic marker worth tracking.

Fatigue that peaks in the afternoon, especially after eating — post-meal blood sugar spikes cause an exaggerated insulin response, which can then push blood sugar lower than it should be. The mid-afternoon crash that so many people manage with coffee or another snack often has a blood sugar story underneath it.

Recurrent skin infections, slow wound healing, or unusual thirst — these are the classic presentation most people associate with diabetes, but they typically appear when glucose has been elevated for some time. If you have any of these, you are not in early-stage disease.

The cluster that travels together — type 2 diabetes rarely arrives alone. The 2023 AHA/ACC cardiovascular-kidney-metabolic syndrome framework formally recognizes what clinicians have long observed: blood sugar dysregulation, hypertension, dyslipidemia, kidney changes, and cardiovascular risk are not separate problems. They are one system at different stages of dysfunction [2]. If you have more than one, they belong in the same conversation.

The People Most Likely to Be Missed

People with normal weight — type 2 diabetes occurs at normal BMI, particularly in people with high visceral fat relative to lean mass. BMI-based screening misses this group.

Women in perimenopause — the estrogen decline that accompanies the perimenopause transition substantially increases insulin resistance. Women who were metabolically well-regulated in their 30s can shift into prediabetic ranges in their 40s without any other obvious trigger. I see this regularly, and I see how often it gets attributed to stress or aging rather than investigated properly. If your blood sugar shifted in your 40s without obvious explanation, this is worth looking at specifically.

People of South Asian, East Asian, Middle Eastern, and Hispanic heritage — these populations develop insulin resistance and type 2 diabetes at lower BMI thresholds than European-heritage populations. Standard screening criteria calibrated for European populations systematically underscreen these groups [1].

People with PCOS — insulin resistance is present in up to 80% of women with PCOS regardless of body weight, as covered in the hormones masterclass. Without glucose metabolism screening, the metabolic burden of PCOS goes untracked for years.

Part 2: The Conversation That Didn’t Happen

What You Deserved to Hear

There’s a version of the diabetes diagnosis conversation that goes something like this: your A1c is 6.8, you have type 2 diabetes, try to watch what you eat, here’s a metformin prescription, come back in three months.

I understand why it goes that way. The appointment is fifteen minutes. There is a lot to cover. And clinicians are genuinely doing their best within a system that doesn’t give them the time this conversation requires.

But what doesn’t get covered is everything that would actually help you understand and act on what you’ve just been told. What type 2 diabetes actually is at the cellular level. What your specific metabolic drivers are. Why standard dietary advice doesn’t work equally for everyone. What the research says about reversibility. And — most importantly — what that word, reversibility, actually means for you.

The DIRECT trial, published in the Lancet and followed with two-year durability data, showed that intensive dietary intervention produced complete diabetes remission — defined as A1c below 6.5% without medication — in 46% of participants at one year and 36% at two years [3]. These were people who already had type 2 diabetes, not prediabetes. Remission. Not just better management. Remission.

This is not fringe integrative thinking. This is a landmark randomized controlled trial in one of the world’s most respected medical journals. And most people walking out of a diabetes diagnosis appointment never hear about it. That matters.

I also want to acknowledge something that often goes unspoken. Type 2 diabetes carries significant social stigma — the sense that this happened because of personal failure, that the diagnosis reflects something about character or choices. It doesn’t. And beyond being inaccurate, that framing is clinically counterproductive. The 2025 ADA Standards of Care now include psychosocial screening as a formal component of diabetes management specifically because shame, diabetes distress, and depression directly worsen glycemic control and reduce the ability to engage with treatment [1]. Your emotional experience of this diagnosis is not separate from the clinical picture. It is part of it.

✦ Subscribe to Continue Reading

The rest of this masterclass — including what a complete diabetes workup should look like beyond A1c, the dietary framework with the best evidence for reversal, the role of continuous glucose monitoring, the medications worth understanding (and why the SGLT2 inhibitors are more than blood sugar drugs), and the full monitoring framework for protecting your kidneys, eyes, heart, and nerves — is available to paid subscribers.

Every piece in this series is written by our clinical team, grounded in peer-reviewed evidence, and built around the questions we hear most often from patients who felt they left their appointment with a label but not a plan.

Already a subscriber? Continue below.

Book A Consultation

Subscribe now

Part 3: What Good Testing Actually Looks Like

Beyond A1c

A1c is an average. It reflects mean blood glucose over approximately three months, weighted toward recent weeks. It’s a useful population screening tool, but as a window into your individual metabolic reality, it has real limits.

A1c can be falsely low in people with certain hemoglobin variants, iron deficiency anemia, or conditions that affect red blood cell turnover. It can be falsely elevated in iron deficiency. Two people with the same A1c can have completely different glucose variability patterns: one relatively flat, one spiking dramatically throughout the day, and the health implications differ. A1c is where we start. It is not where we stop.

A thorough assessment should include:

Fasting glucose and A1c together — for baseline and ongoing monitoring. They don’t always move in parallel and each tells a slightly different part of the story.

Fasting insulin and HOMA-IR — this is still the assessment most people with a diabetes diagnosis have never had. You can have a rising A1c and have no understanding of whether it’s primarily driven by insulin resistance (the cells aren’t responding), beta cell fatigue (the pancreas is struggling to keep up), or both. That distinction changes the treatment approach in meaningful ways.

C-peptide — a marker of insulin production from the pancreas itself. This helps distinguish type 2 diabetes, where insulin production is present but insufficient from conditions that can be misdiagnosed as type 2, particularly LADA.

GAD65 and islet cell antibodies — specifically to screen for Latent Autoimmune Diabetes in Adults (LADA). LADA is significantly underdiagnosed in adults and is often initially mistaken for type 2. If you were diagnosed with type 2 as an adult, particularly if you’re relatively lean or the standard medications aren’t working as expected, these antibody tests belong in your workup. LADA requires a different management approach and progresses to insulin dependence faster when mismanaged.

Continuous glucose monitoring (CGM) — not just for insulin-dependent diabetes anymore. The 2025 ADA Standards of Care support CGM use in type 2 diabetes managed with non-insulin therapies [1], and I recommend it to most of my patients as an early investigative tool. Two weeks of CGM data shows you how specific foods, activities, sleep quality, and stress levels affect your glucose in real time. It makes the abstract concrete. And it changes behavior in ways that a quarterly A1c reading simply cannot.

Urine albumin-to-creatinine ratio (UACR) and eGFR — kidney screening should begin at diagnosis and be repeated annually. Diabetic kidney disease starts as small amounts of protein in the urine — long before kidney function declines — and this is the window where the right interventions can halt or reverse progression [1]. Most patients are not told this has been checked. Ask specifically.

Dilated eye exam — diabetic retinopathy also begins before it causes symptoms. Baseline at diagnosis, then annually. This is in the guidelines. It is also frequently not arranged.

Comprehensive lipid panel — including triglycerides, HDL, and LDL particle size if available. The lipid pattern that accompanies diabetes (high triglycerides, low HDL, small dense LDL particles) carries higher cardiovascular risk than a standard LDL reading conveys [2].

Part 4: What Actually Moves the Needle

The Possibility of Remission

I want to use the word remission deliberately, because I want you to have it as part of how you think about what’s possible.

Remission, defined as A1c below 6.5% for at least three months without medication, is not a fringe outcome. It is a documented, achievable state for a meaningful proportion of people with type 2 diabetes, particularly those in earlier stages [3]. It is not cure, the underlying metabolic vulnerability persists and requires continued attention. But it is a state in which the disease is not active, medications are not required, and the risk of complications is substantially reduced.

The interventions most consistently associated with remission:

Significant weight loss (specifically in the range of 10–15% of body weight) achieved through whatever method is sustainable and appropriate for that individual. The DIRECT trial used intensive dietary intervention. GLP-1 medications and bariatric surgery achieve this most reliably at the higher end [3].

Low-carbohydrate dietary patterns — for people who cannot or prefer not to pursue very low-calorie approaches, well-structured low-carbohydrate eating has produced significant A1c reductions and medication reduction in multiple trials. The mechanism is direct: reducing dietary carbohydrate reduces the glucose burden that the impaired insulin system has to manage. This is not the right approach for everyone, but for insulin-resistant presentations it is mechanistically the most logical starting point.

The Dietary Framework

Rather than a single prescription, here’s what the evidence supports as principles:

Refined carbohydrates and added sugar are the universal first priority. Ultra-processed carbohydrates, sweetened beverages, and refined starches drive post-meal glucose spikes and chronic hyperinsulinemia. Removing these from the daily baseline is relevant regardless of which overall pattern someone follows.

Protein and non-starchy vegetables are the foundation of a meal. Protein has minimal glucose impact and supports satiety and lean mass. Non-starchy vegetables provide fiber that slows glucose absorption and supports gut health. Building meals around these two categories first, before adding carbohydrates, changes the metabolic math substantially.

Whole food carbohydrates are not the same as refined ones. Legumes, intact whole grains, and most whole fruits produce meaningfully lower glucose responses than their refined counterparts, and come with fiber, protein, and micronutrients that modify how they’re metabolized. They are not interchangeable with white bread.

Meal timing is underused. Glucose tolerance is highest in the morning and declines through the day, this is a real circadian metabolic pattern. Eating the largest carbohydrate intake earlier in the day produces lower glucose excursions than the same food eaten at night. Time-restricted eating aligned with earlier hours has shown specific metabolic benefit in insulin resistance and type 2 diabetes.

Food order within a meal changes glucose outcomes. Eating vegetables and protein before carbohydrates produces meaningfully lower post-meal glucose peaks. This is practical, free, and requires no dietary restriction — only sequence. I tell patients this and watch something shift. A tool that costs nothing tends to land differently than another thing to restrict.

Movement as Medicine

Resistance training specifically preserves insulin sensitivity in skeletal muscle. Muscle is the primary site of glucose uptake. More functional muscle mass means more glucose clearance capacity, and this is why resistance training has a direct glucose-lowering effect independent of weight loss. Losing lean mass during rapid weight loss is a specific concern in diabetes management, which is why protein and resistance training go together.

A 10–15 minute walk after meals produces meaningful reductions in post-meal glucose — in some studies comparable to a pharmacological intervention. It’s free, safe, requires no equipment, and is one of the most underutilized tools in diabetes management. I encourage patients to treat it as part of the meal, not optional movement afterward.

The Medications Worth Understanding

Metformin remains the most studied, safest, and most affordable first-line option. Its primary mechanism is reducing glucose production in the liver. It does not cause hypoglycemia. It has emerging evidence for benefits beyond glucose control, including cardiovascular protection and potential effects on longevity pathways. It is genuinely underappreciated and often discontinued too quickly.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) cause the kidneys to excrete glucose directly into the urine. But their most clinically significant effects in diabetes management are not about blood sugar, they are about organ protection. These medications have demonstrated substantial reductions in hospitalization for heart failure and meaningful slowing of diabetic kidney disease progression, independently of their glucose-lowering effects [2]. The 2025 ADA guidelines strongly support their use in people with type 2 diabetes who have cardiovascular disease or chronic kidney disease, specifically for these protective effects [1]. This is a medication class I think every patient with type 2 diabetes deserves to understand.

GLP-1 receptor agonists (semaglutide, tirzepatide) reduce blood sugar through multiple mechanisms, produce substantial weight loss, and have cardiovascular outcome data showing significant reductions in heart attack and stroke in high-risk patients [1]. In the diabetes context, they are not primarily weight loss medications, they are cardiovascular protection medications that also significantly improve glycemic control and support weight loss.

My clinical approach uses these medications not as a sign that lifestyle intervention has failed, but as tools that address specific mechanisms, often in parallel with lifestyle work, not instead of it. Someone with significant cardiovascular risk and type 2 diabetes does not benefit from delaying an SGLT2 inhibitor while “trying lifestyle first.” The organ protection begins with the medication. The lifestyle work builds the foundation underneath it.

Part 5: Retesting and What to Watch

The 90-Day, Annual, and Ongoing Framework

At 90 days, I want A1c, fasting glucose, and fasting insulin. Is the A1c moving? Is the fasting insulin, the upstream driver, also improving? If the A1c improves but insulin stays elevated, we haven’t addressed the root yet.

Annually: full metabolic panel, urine albumin-to-creatinine ratio, eGFR, liver enzymes, complete lipid panel, blood pressure. Dilated eye exam. Foot examination. These are not optional extras… they are the monitoring that prevents complications from developing undetected [1]. Ask specifically whether each of these has been done.

For anyone on an SGLT2 inhibitor: urinary tract and genital infections are more common with this class — worth knowing and watching for. Monitor kidney function at 3 months after starting, then annually.

For anyone on a GLP-1 agent: gastrointestinal symptoms typically peak in the first 4–8 weeks and improve with careful dose escalation. Protein intake needs active monitoring. Anyone with a personal or family history of medullary thyroid cancer or MEN2 should not be on this class.

Between labs, track energy (particularly post-meal energy), sleep quality, thirst, urinary frequency, exercise tolerance, and any sensory changes in the feet or hands. These are the signals that tell you whether glucose is well-controlled between draws.

Return sooner than scheduled if: symptoms of hypoglycemia develop on medication (shakiness, sweating, confusion), urinary symptoms worsen suddenly, any vision changes occur, or any new foot sores or wounds that are slow to heal. That last one doesn’t wait, diabetic foot wounds can progress quickly and warrant prompt attention.

Where to Go From Here

I opened this piece by asking how long you think this has been developing.

The answer to that question is also the answer to how much time and biological capacity remains for things to change. The disease built over years. So did the opportunity to redirect it. For the majority of people with type 2 diabetes who are reading this, particularly those who are early in the progression, where insulin resistance is still the primary driver, the biology is still listening.

What it responds to is not generic advice to eat better and exercise more. It responds to understanding the mechanisms, addressing the specific drivers that are operating in your particular body, monitoring the right markers, and using every available tool — dietary, pharmacological, and lifestyle — together rather than in sequence.

The appointment was fifteen minutes. This is the rest of the conversation.

And if you want to have that conversation with someone who will actually look at your full picture, we’re here for that.

Book a Consultation with Heal Integrative Wellness

Sources

1. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1):S1–S352. doi:10.2337/dc25-SINT

2. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606–1635. doi:10.1161/CIR.0000000000001184

3. Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7(5):344–355. doi:10.1016/S2213-8587(19)30068-3

This masterclass is written and reviewed by the clinical team at Heal Integrative Wellness. It is for educational purposes and does not replace individualized medical advice. Please consult your healthcare provider before making changes to your treatment plan.

© Heal Integrative Wellness — Series 3: The First Diagnosis

Obesity is a chronic disease. Not a lifestyle choice. Not a failure of discipline. Not a reflection of how much you care about yourself or your health. A chronic, complex, biologically-driven disease — with its own hormonal mechanisms, its own genetic contributors, its own feedback systems, and its own clinical guidelines for treatment.

The American Medical Association formally recognized this in 2013. But the culture of medicine — and the wider culture — has been slow to follow. Patients are still walking out of appointments having been told to try harder. Still being handed a printed pamphlet about portion sizes by someone who spent four minutes with them. Still having legitimate symptoms dismissed because the chart says their BMI is high and the assumption is that the number explains everything.

It doesn’t.

I’ve sat with patients who have spent decades doing everything they were told, eating less, moving more, tracking every meal…and still felt like their body was working against them. Not because they were doing it wrong. Because nobody had explained to them that the biology was doing exactly what it was designed to do, and that willpower was never the tool for the job.

That’s what this piece is about. Not to excuse anything, and not to say that what you eat and how you move don’t matter, they absolutely do and we’ll get there. But to give you a framework that replaces shame with understanding. Because shame has never healed a chronic disease. Understanding actually can.

Part 1: Recognizing the Pattern

The Biology Your Doctor Didn’t Have Time to Explain

Here’s what happens in the body when significant weight is gained and then lost.

Body fat — adipose tissue — is not passive storage. It is an active endocrine organ that produces hormones, releases inflammatory signals, and communicates constantly with your brain, your pancreas, your liver, and your cardiovascular system. When fat tissue becomes dysfunctional, which happens with excess accumulation, that communication system goes wrong in ways that make weight maintenance genuinely difficult, independent of behavior or intention.

The most important hormone in this story is leptin.

Leptin is produced by fat cells and tells your brain when you have enough energy — it’s the satiety signal, the metabolic regulator. In people with obesity, leptin levels are chronically high. That sounds like it should help. The problem is that the brain stops hearing the signal, it becomes leptin resistant. The hormone is there. The receptor stops responding. And the brain interprets the situation as starvation, even when it isn’t. So it responds the way it’s designed to respond to starvation: it raises appetite, lowers metabolic rate, and prioritizes fat storage.

This is why people who lose weight often experience intense hunger, a slower metabolism, and a powerful biological pull back toward where they started. These are not signs of weakness. They are documented physiological adaptations and they persist for years after weight loss, sometimes longer [1].

There’s a second mechanism worth knowing: the body appears to defend a particular weight range with remarkable determination. When weight drops below that range, multiple systems activate simultaneously to restore it metabolism slows, hunger hormones rise, satiety hormones fall, energy expenditure drops. And the more diet cycles someone has been through, the more times this has happened, the more entrenched the defense becomes.

This is the biology behind what people call yo-yo dieting. It isn’t a character flaw pattern. It’s a physiological one. And understanding it changes how we approach treatment entirely.

What’s Actually Driving the Weight

When a patient comes to me struggling with weight that hasn’t responded to genuine effort, my first job is to ask: what is driving this? Because body weight is not a simple equation. It is a result, and the result can be shaped by many different upstream causes.

Here’s what I look for:

Insulin resistance — chronically elevated insulin signals the body to store fat and makes it harder to access stored fat for energy. If you’ve ever noticed that your hunger surges in the afternoon, that you feel worse after eating certain things, or that your weight tends to accumulate in your midsection specifically, insulin resistance may be part of your picture. We covered this in depth earlier in this series.

Thyroid dysfunction — hypothyroidism slows metabolic rate, increases fluid retention, and changes how the body handles fat. It is one of the most commonly missed contributors to weight that won’t shift, particularly in women. We’ll cover this in the next masterclass. If this resonates for you, don’t wait.

Hormonal shifts — the perimenopause transition in women and declining testosterone in men both change how the body distributes and stores fat. Elevated cortisol from chronic stress does the same thing, specifically driving fat toward the abdomen. These aren’t side effects of getting older — they are hormonal mechanisms that deserve clinical attention.

Sleep disruption — if you’ve ever woken up ravenous after a bad night of sleep and wondered why: this is why. Poor sleep raises ghrelin (the hunger hormone), lowers leptin (the satiety hormone), elevates cortisol, and impairs glucose metabolism. Someone sleeping five hours a night is navigating a hormonally distinct metabolic environment from someone sleeping eight. That difference is real and measurable.

Medication effects — certain antidepressants, antipsychotics, corticosteroids, and blood pressure medications carry significant weight gain as a documented effect. If your weight shifted after a medication change, that connection belongs in the conversation with your doctor.

A thorough assessment looks at all of these. An appointment that ends with “eat less, move more” has looked at none of them.

Part 2: This Is Not About Who You Are

The Harm That Happens When Medicine Gets This Wrong

I want to say something that I don’t think gets said enough in clinical settings.

The stigma around weight is one of the most persistent forms of medical bias that exists, and it causes real, measurable harm. Patients with obesity receive fewer diagnostic workups. They spend less time with their physicians. They report feeling judged and dismissed. And they are significantly less likely to seek medical care as a result of it [1]. That last point is the one that quietly costs lives.

When your symptoms get attributed to your weight without investigation, you don’t receive the investigation. The thyroid that needs treatment doesn’t get treated. The hormonal shift that explains the last three years doesn’t get identified. The insulin resistance that has been building for a decade doesn’t get caught. Instead, you get sent home, sometimes with a pamphlet, sometimes with just a number goal and a referral to a nutritionist…and sometimes with nothing at all.

A 2025 Lancet commission, a landmark document from an international group of over 75 expert clinicians , drew a distinction I think every patient deserves to understand. There is a meaningful difference between having a higher body weight and having clinical obesity, which is defined as functional impairment and organ-specific complications that result from excess adiposity [1]. BMI does not reliably tell you which one you’re dealing with. Two people with the same BMI can have completely different metabolic profiles, completely different risks, and completely different clinical needs.

At Heal Integrative Wellness, I never make a clinical decision based on BMI alone. I look at body composition, metabolic markers, inflammatory status, hormonal profile and critically, how you actually feel. The number on the scale is one data point. It is not a diagnosis.

✦ Subscribe to Continue Reading

The rest of this masterclass — including what a complete metabolic workup for weight actually looks like, the dietary approaches with the most evidence behind them and why they work differently for different people, the honest conversation about GLP-1 medications, and the monitoring framework that tracks what actually matters — is available to paid subscribers.

Every piece in this series is written by our clinical team, grounded in peer-reviewed evidence, and built around the questions we hear most often from patients who deserve a fuller answer than they’ve been given.

Already a subscriber? Continue below.

Book A Consultation

Subscribe now

Part 3: What Good Testing Actually Looks Like

What We Actually Look For

The 2025 Lancet commission on clinical obesity explicitly states that measures of central adiposity (not BMI alone) should guide clinical assessment and decision-making [1]. This reflects what clinicians who work in this space have known for a long time: where fat is stored matters as much as how much there is. Visceral fat — the fat that accumulates around abdominal organs — is metabolically active and inflammatory in a way that fat under the skin is not. Same BMI, very different biology.

A thorough assessment should include:

Waist circumference — the most practical proxy for visceral fat. Risk thresholds are generally greater than 94 cm (37 inches) for men and greater than 80 cm (31.5 inches) for women, with adjustments for different ethnic backgrounds [1]. Waist-to-hip ratio adds further context.

Body composition analysis — bioelectrical impedance or DEXA scanning to distinguish fat mass from lean mass. Two people at the same weight can look entirely different on a body composition scan — and the clinical picture is different in each case.

Fasting glucose, fasting insulin, and HOMA-IR — to assess insulin resistance specifically, because it is one of the most common drivers of weight that won’t shift and one of the most actionable. It also determines which dietary interventions will and won’t work for a particular person.

Full thyroid panel — TSH, free T3, free T4, and thyroid antibodies. Not just TSH. The reasons are covered in the next masterclass, but briefly: TSH alone misses subclinical hypothyroidism and Hashimoto’s, both of which affect weight and both of which are treatable.

Hormonal panel — sex hormones (testosterone total and free, estradiol, progesterone, LH, FSH, SHBG) and cortisol. Hormonal changes are among the most common and most under recognized contributors to weight that shifts without explanation.

Full metabolic panel including liver enzymes — as covered in the MASLD masterclass. Liver health and metabolic health are deeply intertwined. If enzymes are elevated, it belongs in the conversation.

CRP and inflammatory markers — elevated high-sensitivity CRP tells me the fat tissue is metabolically active and driving systemic inflammation. That’s a different clinical picture than the same weight without inflammation, and it changes what I prioritize.

Complete lipid panel with triglycerides — specifically looking for the pattern of high triglycerides, low HDL, and small dense LDL particles that accompanies insulin resistance and visceral fat. Standard LDL alone doesn’t tell this story.

Part 4: What Actually Moves the Needle

There Is No Single Answer… and That’s the Point!

There is no one dietary pattern that works for everyone. And this is not a diplomatic hedge — it reflects genuine biological differences between people. What works for someone whose weight is primarily driven by hyperinsulinemia looks different from what works for someone in perimenopause, which looks different again from someone whose weight shifted after years of poor sleep and elevated cortisol.

That said, here’s what the evidence actually supports:

Dietary quality matters more than any single macronutrient target. Mediterranean-style eating, DASH, and whole-food patterns consistently outperform macronutrient-defined diets in long-term outcomes [2, 3]. The common thread is food quality: minimally processed, nutrient-dense, not chronically spiking insulin, supporting the gut microbiome, and providing enough protein to protect lean mass.

For insulin-resistant patterns specifically, reducing refined carbohydrates is the most mechanistically logical step. This doesn’t mean zero carbohydrates, it means that whole food carbohydrates (legumes, vegetables, intact grains) metabolize differently from refined starches and added sugars, and the distinction matters more for insulin-resistant individuals than for anyone else.

Protein adequacy is not optional. During weight loss especially, adequate protein (generally 1.2–1.6g per kg of body weight) preserves lean mass, supports satiety, and maintains metabolic rate. Undereating protein while reducing calories is one of the most common and consequential errors I see.

Meal timing may matter as much as content. Glucose tolerance is highest earlier in the day. Time-restricted eating aligned with earlier hours (finishing eating earlier in the day and maintaining a meaningful overnight fast) has emerging evidence for metabolic benefit beyond calorie counting. The mechanisms involve circadian rhythm and insulin normalization.

Resistance training is the non-negotiable. Aerobic exercise is valuable. But preserving and building lean muscle mass is the single most important factor in preventing metabolic rate decline during weight loss. It also improves insulin sensitivity, supports bone density, and improves hormonal profiles in both sexes. I tell patients: cardiovascular exercise is medicine. Resistance training is essential medicine.

Sleep is not a lifestyle recommendation to slot in if you have time, it is a metabolic intervention. Insufficient sleep (under 7 hours for most adults) produces documented hormonal disruption that works directly against every other intervention in this list. If sleep isn’t addressed, everything else is working against a significant headwind.

Managing stress is not self-care in the abstract, it is clinical work. Chronic cortisol elevation drives visceral fat accumulation specifically, impairs insulin sensitivity, increases appetite and food cravings, and disrupts sleep. Meditation, breathwork, protecting rest, reducing overcommitment, these are not soft additions to a protocol. They address a documented hormonal driver of disease.

The Honest Conversation About GLP-1 Medications

This is the topic the last five years have transformed, and I want to address it with the nuance it deserves.

GLP-1 receptor agonists, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not diet pills. They act on receptors in the brain, gut, and pancreas to reduce appetite, slow gastric emptying, improve insulin secretion, and produce metabolic changes that lead to substantial, sustained weight loss in ways that weren’t previously achievable with medication [2].

The evidence is significant. Average weight loss with semaglutide 2.4 mg weekly is approximately 15% of body weight over 68 weeks, with meaningful improvements in blood pressure, triglycerides, blood sugar, liver fat, and inflammatory markers accompanying that loss [2]. Tirzepatide, targeting both GLP-1 and GIP receptors, produces even greater average weight loss in trials.

But I want to be clear about two things these medications are not:

They are not a permanent solution when used in isolation. In most patients, weight returns substantially when the medication is stopped — which means the underlying biology hasn’t changed, only been managed. My approach, and the one reflected in the 2025 Canadian guidelines, is that pharmacotherapy works best as part of a comprehensive program that identifies the drivers, builds genuine lifestyle infrastructure, and supports long-term metabolic health — not just short-term weight loss [2].

And they are not appropriate for everyone. GLP-1 medications are contraindicated in people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. They have a real side effect profile — primarily nausea and gastrointestinal symptoms — that requires careful dose escalation. And muscle loss during rapid weight loss is a genuine concern, which is exactly why protein adequacy and resistance training are not optional additions when someone is on a GLP-1.

At Heal Integrative Wellness, medication when indicated is part of a clinical protocol… not a prescription handed over with a three-month follow-up. The goal is a metabolic environment that supports health, with or without pharmacotherapy as part of the picture.

Part 5: Retesting and What to Watch

The 90-Day and 6-Month Check-In

At 90 days, I want the full metabolic panel — fasting glucose, insulin, HOMA-IR, triglycerides, HDL. Are the metabolic markers moving? Body weight matters less at this stage than metabolic direction. Someone who has lost 4% of body weight but whose fasting insulin has dropped substantially is on the right track, even if the scale feels disappointing.

At 6 months, I want to repeat body composition if available, reassess inflammatory markers, check liver enzymes if they were elevated at baseline, and revisit the hormonal panel if a hormonal driver was identified. This is when the pattern becomes clear.

For anyone on a GLP-1 medication: protein intake needs active monitoring, lean mass needs checking, and gastrointestinal tolerance needs honest assessment. Heart rate should also be tracked — GLP-1 agents can mildly elevate resting heart rate in some patients [2].

Between labs, track energy levels, sleep quality, hunger patterns, exercise tolerance, and mood. Weight is one signal. It is not the only one — and on some weeks, not even the most relevant one.

Come back sooner if severe nausea or vomiting isn’t resolving with dose adjustment, if weight is dropping faster than 1–1.5% of body weight per week sustained, if you notice significant muscle weakness, or if any new symptoms appeared after a medication change.

A Note on the Long Game

Obesity is a chronic disease. Like hypertension, like diabetes, like any other chronic condition, it requires long-term tending, not a 12-week intervention and a goal weight that serves as a finish line.

The patients I see who thrive over time are the ones who stop treating their body as a problem to solve and start treating their metabolic health as something to care for continuously. Who build real habits, address the actual drivers, use medication when it genuinely helps, and define success by how they feel, what their labs show, and what they’re able to do — not by a number. That shift, when it happens, is one of the most meaningful things I get to witness in practice.

If you’ve recognized yourself in any of this and want to understand what’s actually driving your picture, that’s the conversation we start with.

Book a Consultation with Heal Integrative Wellness

Sources

1. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221–262. doi:10.1016/S2213-8587(24)00316-4

2. Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M, et al. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ. 2025;197(27):E797–E809. doi:10.1503/cmaj.250502

3. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875–E891. doi:10.1503/cmaj.191707

This masterclass is written and reviewed by the clinical team at Heal Integrative Wellness. It is for educational purposes and does not replace individualized medical advice. Please consult your healthcare provider before making changes to your treatment plan.

© Heal Integrative Wellness — Series 3: The First Diagnosis

You can have significant liver disease with no symptoms. No pain. No yellowing skin. No dramatic sign that anything is wrong. Just a number on a lab report that gets flagged, mentioned in passing, and then filed away under “something to keep an eye on.”

I’ve had patients come to me who were told exactly that — years ago. One woman I’m thinking of had elevated liver enzymes flagged at 38, was told to cut back on alcohol even though she barely drank, and wasn’t offered any further investigation. She came to see me at 44 with fibrosis showing on imaging. Six years of watching. Six years that mattered.

That number on your lab report is not nothing. It’s your liver trying to tell you that the metabolic pressure you’ve been under has started to leave a mark.

The condition is called MASLD. You may have heard the older name: nonalcoholic fatty liver disease, or NAFLD. In 2023, a global consortium of medical societies formally renamed and redefined it — because the new name tells you exactly what this disease actually is. Metabolic dysfunction-associated steatotic liver disease. The liver problem that comes from metabolic dysfunction. Not from drinking. Not from bad luck. From the same interconnected system we’ve been talking about throughout this series.

This is not a rare diagnosis. It affects somewhere between 25 and 30 percent of the general population. Most of those people have no idea [1].

And before you decide this doesn’t apply to you because you eat reasonably well and don’t drink much — MASLD can and does develop in people with normal weight, normal cholesterol, and no obvious risk factors. If you have insulin resistance, if your blood pressure has been creeping up, if you’ve been told your triglycerides are high — your liver is in this conversation whether or not anyone has put it there [2].

Part 1: Recognizing the Pattern

Why This Gets Missed

The liver is a remarkably forgiving organ. For a long time, it absorbs the impact of metabolic stress without complaint. It doesn’t have pain receptors the way your joints or your gut do. It just quietly accumulates fat, and then — when fat accumulation triggers inflammation — it starts to scar.

The progression moves through stages: fat accumulation in liver cells, then inflammation and injury when that fat triggers an immune response, then early scarring called fibrosis, and eventually — in a smaller proportion of people — advanced irreversible scarring called cirrhosis. The first two stages are largely reversible with the right intervention. The last two are not, or only partially. This is why finding it early changes everything. And why a system that waits for symptoms before looking is failing people quietly, year after year.

Here’s what makes the pattern recognizable before it gets that far:

An elevated ALT or AST on routine bloodwork — this is often the only early signal. A lot of clinicians note it, ask about alcohol, and repeat the test in a year. That year matters more than the conversation suggests.

Fatigue that doesn’t resolve with sleep — a liver working under metabolic stress is a liver working harder than it should. The fatigue has a reason, even when the cause isn’t obvious.

A sense of fullness or mild pressure under your right ribs — the liver sits just there. When it’s enlarged from fat accumulation, some people notice it. Most don’t, which is part of the problem.

The metabolic cluster — if you have insulin resistance, type 2 diabetes, high triglycerides, low HDL, or blood pressure that keeps nudging upward, MASLD is part of the same picture. These conditions don’t travel alone because they don’t have separate causes — they share the same root. The 2024 joint guidelines from three major European medical associations now make this explicit: liver screening should happen proactively in anyone with cardiometabolic risk factors, not only once symptoms appear [2].

What’s Actually Happening

The liver is a metabolic hub. It processes fat, regulates blood sugar, filters what doesn’t belong, produces proteins your blood depends on, and manages cholesterol — among hundreds of other functions. When insulin resistance is present, the liver receives a constant, incorrect signal: keep producing glucose, keep storing fat. Over time, fat accumulates in liver cells. Not because you ate too much fat — because the signaling system is broken.

This is why MASLD connects so directly to the insulin resistance piece earlier in this series. If you read that article and recognized yourself in it, your liver is part of that story.

When fat accumulation triggers inflammation — which happens in a subset of people, and researchers are still working out exactly why some progress and others don’t — the condition becomes more serious. Inflammatory injury causes cell death, and the liver responds by laying down scar tissue. Once that scarring sets in, the window for full reversal begins to close. Which is exactly why catching this early isn’t just useful — it’s genuinely important.

Part 2: This Is Not in Your Head

What Should Have Happened at That Appointment

“Your enzymes are a bit elevated — we’ll keep an eye on it.”

I hear this from patients constantly. And what I want you to understand is that watching without investigating is not a neutral clinical act. Every year of unaddressed metabolic dysfunction is another year of potential fat accumulation, possible ongoing inflammation, and continued progression risk. The liver doesn’t repair itself while we wait.

What should have happened at that appointment, what I want to happen for every person who reads this, is a real conversation. Is there insulin resistance underneath this? What are the triglycerides doing? What’s the fasting glucose? Has anyone calculated a FIB-4 score, which can be done right now with labs you’ve probably already had, and costs nothing extra [2]?

A 2024 joint guideline from the European associations covering liver disease, diabetes, and obesity now explicitly states that non-invasive screening should be applied proactively in people with cardiometabolic risk, not reactively, after symptoms appear [2]. That is a meaningful shift in the standard of care. And it’s the kind of care that most fifteen-minute appointments haven’t caught up to yet. That gap is part of why this series exists.

I also want to address the weight piece directly, because I see the harm from the shortcut regularly. MASLD has a real association with obesity but it is not exclusively a disease of people with a high BMI. Lean MASLD is real, increasingly recognized, and in some studies carries a higher risk of progression. When a clinician attributes elevated liver enzymes to someone’s weight and stops there, a meaningful proportion of people who need further investigation get sent home instead. You’re allowed to ask for more.

✦ Subscribe to Continue Reading

The rest of this masterclass including exactly what a thorough liver workup should include, what a FIB-4 score actually tells you and what to do with it, the lifestyle interventions with the most evidence, where specific supplements genuinely fit in, and what the first FDA-approved MASH medication means for people who need it, is available to paid subscribers.

Every piece in this series is written by our clinical team, grounded in peer-reviewed evidence, and built around the questions we hear most often from patients who feel they haven’t been given the full picture. Because usually, they haven’t.

Already a subscriber? Continue below.

Book a Consultation

Subscribe now

Part 3: What Good Testing Actually Looks Like

The Tests That Tell the Real Story

A liver enzyme elevation is a starting point, not a conclusion. Here’s what actually getting to the bottom of it looks like:

Basic liver panel — ALT and AST are the primary markers of liver cell injury. GGT is often overlooked but deserves specific attention: it’s sensitive to metabolic stress and frequently rises before ALT does, making it an early signal worth tracking.

FIB-4 score — four numbers already on your labs (age, ALT, AST, platelet count) combined into a calculation that estimates how likely it is that significant fibrosis is present. Below 1.3 is reassuring. Above 2.67 warrants imaging. The space in between is where clinical judgment matters most [2]. This takes thirty seconds to calculate and is almost never done proactively. Ask for it by name.

Fasting insulin and HOMA-IR — because assessing the liver without looking at the metabolic driver underneath is an incomplete assessment. These numbers tell me what’s fueling the problem.

Fasting lipids including triglycerides — triglycerides above 150 mg/dL are a meaningful metabolic signal. In the context of elevated liver enzymes, they shift the picture substantially.

Liver ultrasound — widely available, non-invasive, and able to detect fat accumulation when it’s significant. It’s a useful first look, but it doesn’t measure fibrosis. Think of it as opening the door, not reading the whole room.

FibroScan (transient elastography) — this is where the picture sharpens. It uses sound waves to measure liver stiffness, which correlates directly with the degree of scarring. The 2024 guidelines identify it as the preferred non-invasive fibrosis assessment for anyone with an intermediate or high FIB-4 [2]. If you’ve never been offered this and your numbers are in the grey zone, it’s worth asking about specifically.

MRI-PDFF — when more precise fat quantification is needed, MRI-based proton density fat fraction is the most accurate non-invasive option. Typically used in specialist settings or when earlier imaging is ambiguous.

Liver biopsy remains the technical gold standard but the 2024 guidelines reflect where the field is moving: toward validating non-invasive tools precisely because biopsy is invasive, carries real risk, and is unnecessary for most people. Accurate staging without unnecessary procedures is now achievable for the majority of patients [2].

Part 4: What Actually Moves the Needle

Start With the Metabolic Foundation

MASLD is a metabolic disease. Treating it metabolically is not an integrative workaround — it is the explicit first-line recommendation across every major guideline.

Weight loss, when it’s part of the picture, is the most powerful single lever. A 5% reduction in body weight meaningfully reduces liver fat. A 7–10% reduction reduces inflammation and improves the cellular picture. Getting to 10% or more can actually reverse early fibrosis — the liver rebuilding itself in response to a changed metabolic environment [2]. I find that genuinely remarkable every time I explain it to a patient. The liver is trying to heal. We’re just giving it the conditions to do so.

But weight loss is the outcome, not the method. The method is what actually gets you there.

Dietary pattern matters more than any single food rule. The Mediterranean pattern has the most consistent evidence in MASLD — not because of any one ingredient, but because of the overall composition: abundant vegetables, legumes, whole grains, fish, and olive oil; limited ultra-processed foods, refined carbohydrates, and added sugar. That last one deserves its own moment.

Fructose is metabolized almost entirely in the liver. Unlike glucose, which distributes broadly, fructose goes straight to the liver and directly promotes fat accumulation there. This is not a reason to eliminate whole fruit — the fiber and micronutrients in whole fruit substantially change how it’s processed. It is a reason to look hard at sweetened beverages, fruit juices, and anything with added sugar. These aren’t abstract risks. They are a direct metabolic burden on the organ we’re trying to support [2].

And here’s something I genuinely enjoy telling patients: coffee is good for your liver. Multiple studies show that regular coffee consumption is associated with slower fibrosis progression in MASLD. Two to three cups of regular coffee daily appears to have a real hepatoprotective effect, likely through antioxidant and anti-inflammatory mechanisms. It’s consistent enough that it now appears in clinical guidance [2]. One of the more pleasant recommendations in my toolkit.

Movement helps even when the scale doesn’t move. Both aerobic exercise and resistance training reduce liver fat independently of weight loss. This matters — it means that getting active is doing something real at the cellular level even when bodyweight stays the same. 150 minutes of moderate activity per week is the guideline minimum; more appears to produce additional liver benefit.

Alcohol is not neutral here, even in moderate amounts. Current guidelines advise minimizing alcohol intake — not just avoiding heavy drinking. A liver under metabolic stress handles even moderate alcohol differently than a healthy liver. Most patients haven’t been told this.

Where Supplements Fit In

Before I recommend any supplement, I run a thorough micronutrient assessment. What I find shapes what I suggest. These are the ones with the clearest evidence specifically in the MASLD context:

Vitamin E (800 IU daily) has been shown in clinical trials to reduce liver inflammation and improve the cellular picture of MASH in non-diabetic adults — and it’s one of the few supplements that has earned its way into formal clinical guidelines [3]. High-dose vitamin E should always be used with clinical oversight, and it isn’t appropriate for everyone. But for the right patient, it’s a meaningful intervention.

Omega-3 fatty acids (EPA and DHA) reduce fat accumulation in the liver, which is a real effect in early-stage disease. They don’t address inflammation or fibrosis as consistently, but for someone with steatosis and elevated triglycerides, the case for them is solid [3].

Berberine is the one I’m probably most enthusiastic about in this context. It improves insulin sensitivity, reduces triglycerides, and has been shown in clinical trials to reduce liver fat and improve liver enzymes in MASLD. It works through the same cellular pathway as metformin — which is exactly why I take it seriously clinically, not just because it comes from a plant [3]. For patients where metformin isn’t the right fit, berberine is a genuinely defensible option.

Silymarin (milk thistle) — I’ll be honest: the evidence here is more mixed than the wellness world suggests. Standardized silymarin preparations have shown modest benefit in reducing liver enzymes and oxidative stress. It’s not a primary intervention. As part of a broader protocol, it has a supporting role [3].

When Medication Is the Right Answer

In March 2024, the FDA approved resmetirom (Rezdiffra) — the first medication ever specifically approved for the treatment of MASH with moderate to advanced fibrosis [4]. For patients who have been in the watching-and-waiting pattern with established disease, this is a genuine milestone.

Resmetirom works by activating a specific thyroid receptor in the liver that regulates fat metabolism — reducing liver fat and inflammation without affecting the thyroid system elsewhere in the body. It demonstrated meaningful fibrosis improvement in clinical trials and earned its approval on that basis [4].

It isn’t for everyone. It’s specifically indicated for non-cirrhotic MASH with fibrosis at stages F2 or F3. Most people with MASLD — those in earlier stages — are still best served by the metabolic and lifestyle interventions above. But knowing this option exists matters, especially for anyone who has been waiting.

GLP-1 medications (semaglutide, tirzepatide) also belong in this conversation. They weren’t designed as liver medications, but the metabolic improvements they produce — reduced weight, improved insulin sensitivity, lower triglycerides — translate directly into liver benefit. The 2024 guidelines explicitly recommend them for MASLD management in patients with comorbid diabetes or obesity [2].

Part 5: Retesting and What to Watch

The 6-Month and Annual Check-In

Liver healing moves more slowly than hormonal change. Meaningful reassessment takes time.

At six months, I want to see liver enzymes (ALT, AST, GGT), fasting insulin, and triglycerides. Are the numbers moving in the right direction? Even a 20–30% reduction in ALT tells me the intervention is working, even if the number is still elevated.

At twelve months, anyone who started with an intermediate or elevated FIB-4 should have it recalculated. If a FibroScan was done at baseline, a repeat at one year gives real data about whether the liver is responding.

If you’re on resmetirom, liver function testing at 4–8 weeks after starting, then every three months. The monitoring schedule here is specific and important [4].

Between labs, track your energy, any right-sided abdominal fullness, and how your metabolic symptoms feel overall. The liver doesn’t produce dramatic warning signs in early disease — which is exactly why we monitor the surrounding picture as a proxy.

Come back sooner than scheduled if your enzymes double from baseline, you develop new pain under your right ribs, your fatigue suddenly worsens without explanation, or you notice any yellowing of the skin or whites of your eyes. That last one doesn’t wait for a scheduled appointment.

What to Ask For

If you’ve been told your enzymes are elevated and nothing more was done — that’s the conversation worth revisiting. Ask specifically for a FIB-4 calculation, fasting insulin, and a liver ultrasound if one hasn’t been done. These aren’t specialist-only tests. They’re the starting point for actually understanding what’s happening.

If your FIB-4 comes back above 1.3, ask about FibroScan or a referral to a hepatologist. Not because you have cirrhosis. Because knowing your stage is what makes the rest of the plan make sense.

Where to Go From Here

MASLD is not a verdict. It’s a signal — and for most people reading this, it’s a signal that arrived early enough to change what happens next. The liver’s capacity for recovery, when the metabolic environment genuinely shifts in its favor, is one of the things I find most remarkable in this work. Given the right conditions, the liver heals. The science on this is not uncertain.

If you’ve had an enzyme elevation noted and nothing further was done, that’s worth revisiting — not with anxiety, but with the quiet confidence that comes from understanding what you’re actually dealing with. If you have insulin resistance, elevated triglycerides, or blood pressure that keeps creeping up, your liver is in this conversation even if no one has put it there yet.

That’s what we’re here to change.

If any of this resonated and you want to understand what your picture actually looks like, that’s exactly the kind of conversation we have.

Book a Consultation with Heal Integrative Wellness

Sources

1. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Annals of Hepatology. 2024;29(1):101133. doi:10.1016/j.aohep.2023.101133

2. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology. 2024;81(3):492–542. doi:10.1016/j.jhep.2024.04.031

3. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings. Endocrine Practice. 2022;28(5):528–562. doi:10.1016/j.eprac.2022.03.010

4. Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, Kim WR. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81(1):312–320. doi:10.1097/HEP.0000000000001112

This masterclass is written and reviewed by the clinical team at Heal Integrative Wellness. It is for educational purposes and does not replace individualized medical advice. Please consult your healthcare provider before making changes to your treatment plan.

© Heal Integrative Wellness — Series 3: The First Diagnosis

I want to start with something I say to patients in the clinic all the time.

You are not imagining it.

The exhaustion that sleep doesn’t fix. The mood that shifts without warning. The periods that changed. The body that feels like it belongs to someone else. These are not character flaws or anxiety spiraling into physical symptoms. They are signals. This is your body running a communication system that something in the network has shifted.

Women with premature ovarian insufficiency wait an average of two years to get a diagnosis, despite showing up to multiple appointments and describing exactly what they’re feeling. Two years of being sent home with reassurance. That’s not an anomaly in the data, it’s a pattern. And it has real consequences: bone loss, cardiovascular risk, and a slow erosion of the confidence that comes from trusting your own body.

So before we get into the biology, the testing, or the treatment — I want to be clear: pursuing an answer is not overreacting. It is exactly what you should be doing.

Part 1: Recognizing the Pattern

Why Hormonal Imbalance Gets Missed

Here’s the thing about hormones: they don’t work in isolation. They operate as an interconnected network, where each one affects the others. When one shifts, the rest compensate and those compensations show up as what looks like a dozen separate problems.

That’s why hormonal imbalance is so easy to miss. The fatigue gets blamed on work. The mood shifts get attributed to stress. The weight changes get attributed to diet. The sleep disruption gets treated with melatonin. None of the symptoms point clearly at the same root until you look at them together.

If you’re a woman, the pattern that fits your experience is worth identifying:

Irregular or absent periods + acne + excess body hair + stubborn weight — this is the PCOS pattern. Insulin resistance is almost always part of the picture, present in up to 80% of women with PCOS regardless of body weight. The good news: the lifestyle work from Masterclasses 1 and 2 applies here as directly as anywhere.

Cycles changing + sleep falling apart + mood that feels unfamiliar + weight shifting to the middle — this is the perimenopause pattern, and it can start years before your last period. If you’re in your 40s and everything shifted at once, this is likely the reason.

Periods that stopped — especially with high training volume, undereating, or significant stress, this is hypothalamic amenorrhea. Your brain, sensing scarcity or threat, has essentially paused your reproductive system to conserve energy. It’s a protective response. It’s also a signal that something important needs to change.

Fatigue that doesn’t budge + slow weight gain + cold all the time + dry skin + hair thinning, this is the thyroid pattern, and it is one of the most underdiagnosed contributors to hormonal symptoms in women. If this resonates, thyroid markers absolutely need to be part of your workup.

If you’re a man, the pattern tends to be quieter:

Low testosterone rarely announces itself with a dramatic symptom. It’s more of a slow fade less drive, lower libido, harder to build muscle, easier to gain weight around the middle, a tiredness that wasn’t there five years ago. Each change feels explainable on its own. Together, they’re pointing at something specific.

What Each Hormone Is Actually Doing

Lab results mean more when you know what you’re looking at. Here’s the plain-language version:

Estrogen (estradiol) is far more than a reproductive hormone. It protects your bones, your heart, your brain, and your mood. When it’s low, the effects show up everywhere — not just in your cycle. When it’s imbalanced relative to progesterone, it creates its own set of problems even when the number technically looks “in range.”

Progesterone is estrogen’s counterbalance, and it’s the one that most often goes low first — before periods even become irregular. Low progesterone tends to show up as anxiety, insomnia, and a dramatically worse week before your period.

Testosterone matters for women too. It affects energy, libido, muscle strength, and mood. It’s often not even tested in women’s standard panels, which is why it’s also commonly missed.

TSH, T3, T4 (thyroid) should be checked in anyone presenting with fatigue, weight changes, or mood disturbance. Thyroid dysfunction is common, treatable, and frequently the explanation for symptoms that have been chalked up to everything else.

Cortisol has a daily rhythm: high in the morning to get you going, tapering through the day. When that rhythm breaks down from chronic stress or poor sleep, the downstream effects on your sex hormones, your metabolism, and your sleep architecture are significant.

FSH and LH tell us where in the system the disruption is coming from. High FSH points to the ovaries; normal FSH with absent periods points to the brain-ovary communication pathway. That distinction changes everything about the treatment.

Part 2: This Is Not in Your Head

From “I’ve Been Told I’m Fine” to “I’m Finally Getting Answers”

I’ve sat with patients who have spent years feeling dismissed. Who learned to describe their symptoms in ways they thought would be taken seriously, then revised those descriptions when they weren’t, then eventually started doubting whether anything was actually wrong. That self-doubt is not weakness it’s a predictable response to having your signals ignored.

Research on social-emotional wellbeing documents this clearly: when physical symptoms go unaddressed or are attributed to psychological causes, people lose confidence in their own body’s signals over time [4]. They stop advocating for themselves. They normalize suffering that doesn’t need to be normalized.

Here is what I want you to understand: mood instability, anxiety, sleep disruption, and cognitive fog are not “emotional” symptoms that are less real or less biological than a lump you can feel. They have direct hormonal mechanisms. A woman with low estrogen or progesterone is not anxious because she’s struggling psychologically. She’s anxious because her brain chemistry has changed and treating that as a mental health problem while the hormonal root goes unaddressed is like treating a headache with painkillers while leaving the underlying hypertension untreated.

A 2025 research review made this point clearly in the context of diabetes: female-specific physiology across the reproductive cycle, pregnancy, and menopause is still routinely ignored in research design and clinical guidelines [3]. The care that gets delivered was often developed for a standard patient who doesn’t reflect most women’s reality. That’s not a personal failing of individual clinicians, it’s a systemic gap that patients increasingly need to advocate around.

At Heal Integrative Wellness, our starting point is this: your symptoms are information. The diagnostic process is not about confirming or ruling out a single condition it is about understanding the whole story your body is telling.

✦ Subscribe to Continue Reading

The rest of this masterclass — including exactly when to time your labs, what a full hormonal workup should include, the lifestyle and medication roadmap, and the retesting timeline — is available to paid subscribers.

Every masterclass in this series is written by our clinical team, grounded in peer-reviewed evidence, and built around the questions we hear most often in practice. The goal is to give you the kind of information your appointment didn’t have time for.

Subscribe now

Book a Consultation

Already a subscriber? Continue below.

Part 3: What Good Testing Actually Looks Like

For Women: Timing Is Everything

Here’s something that almost never gets explained at the time of testing: your hormones shift dramatically across your menstrual cycle. Testing at the wrong point doesn’t give a wrong result — it gives a meaningless one.

Days 2–5 of your cycle (early follicular phase) is when FSH, LH, and estradiol should be drawn if you’re investigating irregular cycles or ovarian reserve. An FSH above 25–30 IU/L in this window suggests ovarian insufficiency or a perimenopause transition.

Around day 21 (mid-luteal phase) is the right time to check progesterone. This confirms whether you actually ovulated and a progesterone below 16 nmol/L in this window suggests the cycle was anovulatory, which matters for fertility, bone health, and hormonal balance.

TSH and prolactin can be tested anytime, though prolactin is best drawn in the morning. If you don’t have regular periods, the cycle timing framework is less relevant, but interpretation requires more care.

Two thresholds worth knowing, from the Society for Endocrinology guidelines [2]: estradiol below 200 pmol/L in a woman without a recent period is consistent with hypogonadism, as is an endometrial lining of 4mm or less on ultrasound. These are the markers that distinguish hormonal deficiency from other causes of cycle disruption — and they are regularly not checked until years into the diagnostic delay.

On PCOS: the diagnosis requires irregular periods plus signs of excess androgens (acne, excess hair, elevated testosterone) and/or polycystic appearance on ultrasound, after other causes are excluded. Ultrasound alone is not sufficient — but the full clinical picture is usually clear enough that diagnosis shouldn’t take years.

On body-identical hormones: if HRT is appropriate for you, the current evidence supports 17β-estradiol — not equine estrogens, not synthetic ethinylestradiol — delivered transdermally where possible. Transdermal estradiol bypasses the liver, which meaningfully reduces cardiovascular and clotting risk. Paired with micronized progesterone for uterine protection. This isn’t a fringe integrative position — it’s what the Society for Endocrinology now recommends [2].

On hypothalamic amenorrhea: the first step is lifestyle — adequate food, reduced training load, active stress management. But if cycles don’t return within 6–12 months, or if bone density is already compromised, hormone support should not wait. The bone loss from untreated hypothalamic amenorrhea is real and only partially reversible.

For Men: Don’t Accept “Normal Aging” Without a Full Picture

The challenge for men isn’t detecting low testosterone — it’s that the symptoms feel so much like ordinary life stress that most men don’t connect them to a hormonal cause until years have passed.

A complete workup should include total testosterone, free testosterone (what’s actually available to your cells), and SHBG. Add LH and FSH to identify where the disruption originates, prolactin to rule out a pituitary issue, and iron studies to screen for hemochromatosis, which is an underappreciated cause of hypogonadism that is very treatable once found.

Test in the morning — before 10am, ideally fasting when testosterone is highest. A single low reading is worth repeating before acting on it.

One important reframe: addressing the root drivers — insulin resistance, sleep apnea, abdominal weight, chronic stress — substantially raises testosterone on its own. In men where these are present, lifestyle intervention is not a delay to treatment. It often is the treatment, and a more durable one.

Part 4: What Actually Moves the Needle

The Foundation Nobody Skips

Before any medication, before any targeted supplement, three things have to be in place, because no hormone therapy works well without them.

You have to eat enough. This is not about eating perfectly. It is about eating sufficiently. Hormones are made from food, literally. Cholesterol is the precursor for every steroid hormone your body produces: estrogen, progesterone, testosterone, cortisol. Very low-fat diets impair hormone synthesis at the most fundamental level. And chronic undereating, even without significant weight loss, suppresses reproductive hormones in both sexes. If you’re restricting and your hormones are dysregulated, that connection is direct.

Stress is part of the protocol, not separate from it. Cortisol and the reproductive hormones share the same biochemical building blocks. When the body is under chronic stress, it deprioritizes sex hormone production in favor of the survival response. This isn’t metaphorical, it’s enzymatic competition. Meditation, breathwork, nature time, protecting sleep, reducing overcommitment: these are clinical interventions, not lifestyle add-ons.

Exercise smarter, not just more. Resistance training is one of the best things you can do for hormonal health — it supports testosterone in men and improves insulin sensitivity in both sexes. But excessive cardio, especially in women who are underfueled or under stress, is a well-documented hormonal disruptor. The question isn’t whether you exercise it’s whether your training load is matched by recovery, nutrition, and sleep.

When Medication Is the Right Answer

Our philosophy at Heal Integrative Wellness is to give lifestyle the chance to work, but not at the expense of your health while waiting.

For women with confirmed estrogen deficiency, especially younger women and those with premature ovarian insufficiency, delaying hormone therapy while “trying lifestyle first” causes real harm. Bone loss, cardiovascular changes, and cognitive effects from untreated deficiency are not hypothetical risks. The evidence for HRT in these situations is not controversial, it’s standard of care.

For PCOS, my approach is different from what most patients have been offered. I don’t prescribe the pill as a first-line response. Birth control suppresses symptoms by overriding your cycle — it doesn’t touch the underlying hormonal and metabolic dysfunction. When you come off it, everything comes back. We go after the root.

Before any prescription, I run a full micronutrient panel. Two things I check specifically: Zinc and Vitamin D — and I’m not looking for “normal range.” I want them above normal. Both are foundational to ovarian function, insulin sensitivity, and androgen regulation. A Vitamin D sitting at 32 ng/mL when the lab says “sufficient” is not where we want it for a woman managing PCOS.

Then we build a targeted supplement protocol:

Myo-inositol to D-chiro-inositol at a 40:1 ratio is the most evidence-backed supplement intervention for PCOS. This is the ratio that mirrors the body’s own physiological balance. It improves insulin signaling at the ovarian level directly — reducing excess androgen production, restoring cycle regularity, and supporting egg quality. For many patients, this alone creates meaningful change within 3 months.

L-Carnitine improves how cells use fat for energy, reduces circulating androgens, and has been shown in clinical trials to improve ovarian response and menstrual regularity in women with PCOS. It also supports the metabolic piece, most PCOS is inseparable from how the body handles energy and fat metabolism.

CoQ10 supports mitochondrial function and cellular energy — which matters for egg quality, ovarian response, and overall metabolic efficiency. For women with PCOS who are also thinking about fertility, CoQ10 is one of the most important additions to the protocol.

This combination, inositol at the correct ratio, L-carnitine, and CoQ10, alongside optimized Zinc and Vitamin D, gives us a comprehensive first line that addresses the mechanisms rather than masking the symptoms. We retest at 90 days, review labs and how you’re feeling, and adjust from there.

For men with confirmed low testosterone after addressing modifiable causes, testosterone replacement therapy is appropriate. Monitoring at 3 months after initiation, then every 6–12 months, with checks on red blood cell levels, PSA, and lipids.

Part 5: Retesting and What to Watch

The 90-Day Check-In

Hormones take time to respond to intervention whether that’s lifestyle change or hormone therapy. Three months is the first meaningful window to reassess.

If you started lifestyle changes: retest your panel at 3 months. Symptom tracking matters as much as numbers here, sometimes labs normalize before you feel better, and sometimes symptoms resolve before labs do. Both directions tell you something important.

If you started hormone therapy: retest at 3 months to confirm you’re in the therapeutic range. For women, the target estradiol for replacement is approximately 300–600 pmol/L [2]. For men on TRT, the goal is mid-normal range, not the high end.

Once stable: annual review is appropriate unless symptoms change, you make dose adjustments, or bone density is a concern.

Track at home between labs: energy patterns, sleep quality, mood consistency, cycle regularity (for women), and libido. A hormone level that looks good on paper while you feel worse than before therapy started is a clinical signal that needs attention — not a reason to be reassured.

Go back sooner if you notice: return of prior symptoms after stabilization, breakthrough bleeding on HRT, significant mood deterioration, or anything that feels out of keeping with your baseline.

Ask for More Than the Standard Panel

A basic hormone panel typically checks TSH, estradiol, and LH. It often leaves out free testosterone, SHBG, progesterone timed to the luteal phase, fasting insulin, and morning cortisol, all of which matter.

If your panel came back “in range” but you still feel the same, that result is not a conclusion. It is an incomplete picture. Asking your clinician for a more thorough assessment or seeking one from someone with an integrative lens is not overreacting. It is exactly the right next step.

Where to Go From Here

Hormonal imbalance is not a life sentence. These systems are responsive — to how you eat, how you sleep, how you manage stress, and when it’s needed, to the hormones your body is no longer making adequately on its own.

What I hope you take from this masterclass is not just information, but permission. Permission to take your symptoms seriously. Permission to ask for more than a cursory reassurance. Permission to keep looking until you have answers that actually explain what you’re experiencing.

You know your body. I’m here to help you understand what it’s trying to say.

[Book a Consultation with Heal Integrative Wellness]

Sources

1. Apollo 24|7. Hormonal Imbalance Tests Every Woman Must Know. Apollo Diagnostic Health Topics. 2025. apollo247.com/diagnostic-health-topics/apollo-womens-health-basic/hormonal-imbalance-tests-symptoms

2. Jayasena CN, Devine K, Barber K, et al. Society for Endocrinology guideline for understanding, diagnosing and treating female hypogonadism. Clinical Endocrinology. 2024;101(5):409–442. doi:10.1111/cen.15097

3. Hossmann S, Tan S, Mader JK, Klonoff DC, et al. One size does not fit all: The need for sex-specific precision medicine in diabetes technology. Journal of Diabetes Science and Technology. 2025. doi:10.1177/19322968251340673

4. Queensland Health. Mental Health and Wellbeing Strategy 2024–2029. Queensland Government. 2024.

This masterclass is written and reviewed by the clinical team at Heal Integrative Wellness. It is for educational purposes and does not replace individualized medical advice. Please consult your healthcare provider before making changes to your treatment plan.

© Heal Integrative Wellness — Series 3: The First Diagnosis

Here’s the strange thing about a high cholesterol diagnosis: nothing feels different afterward.

You walked into that appointment feeling fine. You walked out with a number on a piece of paper that apparently means something is wrong. No pain, no fatigue, no symptoms pointing you toward the problem. Just a lab result and a lot of unanswered questions.

That absence of symptoms is exactly what makes high cholesterol dangerous and exactly why catching it early matters as much as it does. Plaque buildup in your arteries is a decades long process. It doesn’t announce itself. It just accumulates, quietly, until one day it does.

Your diagnosis caught it in the quiet phase. That’s the whole point.

Part 1: The Pattern Behind the Diagnosis

What Your Numbers Actually Mean

A standard lipid panel gives you four numbers. Here’s what they’re actually telling you:

LDL-C is the primary driver of plaque formation in artery walls. Below 100 mg/dL is the general target for most adults; below 70 mg/dL if you have established heart disease or are at high risk. This is the number to focus on.

HDL-C helps clear cholesterol from your arteries. Above 40 mg/dL for men, above 50 mg/dL for women — and higher is genuinely better.

Triglycerides reflect circulating fats and are closely tied to refined carbohydrate intake, sugar, and alcohol. Below 150 mg/dL is desirable.

Non-HDL-C is total cholesterol minus HDL. It captures a broader range of artery-clogging particles than LDL alone, and is increasingly recognized as a better cardiovascular predictor. (Ask your clinician for this number if it wasn’t included in your report. The target is below 130 mg/dL.)

Patterns Worth Recognizing

High LDL-C with elevated total cholesterol usually points toward saturated fat intake: fatty meats, full-fat dairy, processed foods. High triglycerides with low HDL is a different pattern entirely, and more often reflects excess refined carbohydrates, sugar, and underlying insulin resistance, even in people who appear to be a healthy weight!

The “normal weight but high triglycerides and low HDL” pattern is one of the most commonly missed. If that’s you, insulin resistance should be part of the conversation.

If a parent or sibling had high cholesterol or a heart attack before age 60 (men) or 65 (women), it’s worth raising the possibility of Familial Hypercholesterolemia with your provider. It’s significantly more common than most people realize, it doesn’t respond to lifestyle changes alone, and most people who have it are never diagnosed.

One Thing to Rule Out First

Before attributing elevated cholesterol to diet and lifestyle, a handful of medical conditions can raise cholesterol on their own, hypothyroidism being the most common, along with kidney disease, liver disease, and poorly controlled diabetes. Some medications do it too, including certain acne treatments and blood pressure medications.

A simple thyroid test alongside your lipid panel can rule this out quickly. If an underlying condition is the driver, treating it often normalizes your numbers without anything else needing to change.

Part 2: The Mental Shift

From “I Feel Fine” to “I’m Protecting My Future”

Think of your arteries like pipes. Plaque builds up gradually. You don’t feel a thing until flow is severely restricted or the pipe bursts. The reason so many heart attacks come “out of nowhere” is that the warning signs were silent for years beforehand.

The reframe that matters: you are not sick. You caught a signal early enough to do something about it. The next 90 days have the potential to do more for your long-term cardiovascular health than almost anything else you’ll do this decade.

Research consistently shows that a 10–20% reduction in LDL-C meaningfully lowers cardiovascular risk. The Cholesterol Treatment Trialists’ Collaboration, a meta-analysis of 26 randomized controlled trials involving 170,000 participants, established that each 1 mmol/L reduction in LDL-C is associated with approximately a 22% reduction in major vascular events, including heart attacks and strokes [1]. That holds consistently across age groups, both sexes, and different baseline risk levels. The biology is straightforward: lower LDL, less plaque, fewer events.

The goal here is a clear 3-month framework: a diagnostic period with a measurable endpoint so that by the end of it, you know whether lifestyle has done its job, or whether additional support is needed. Either outcome is useful information.

✦ Subscribe to Continue Reading

The rest of this masterclass — including gender-specific guidance, your full intervention roadmap, supplement protocols, and the retesting timeline — is available to paid subscribers.

At Heal Integrative Wellness, we believe that the quality of health information you receive should not depend on your ability to pay a specialist’s hourly rate. Every masterclass in this series is written and reviewed by clinicians, backed by peer-reviewed evidence, and built around the questions we hear most in our own practice.

Subscribe now

Book a Consultation

Already a subscriber? Continue below.

Part 3: Gender-Specific Considerations

For Women: A Gap in Care That Needs Naming

High cholesterol in women is not simply the same condition presenting in a different body. The hormonal landscape is different, the risk timeline is different, and the likelihood of receiving appropriate treatment is — unfortunately — also different.

A large 2025 analysis found that women have higher average LDL-C levels than men, yet are significantly less likely to reach their LDL targets. Among women with established heart disease, only 31% achieve the recommended LDL-C goal of below 70 mg/dL, compared to 47% of men. Women are prescribed statins less often, and high-intensity statins even less frequently. What makes this particularly striking is that the gap persists regardless of whether the treating physician is male or female which suggests it’s systemic, not individual [2].

Women benefit from statins just as much as men when it comes to preventing heart attacks and cardiovascular death. The evidence on this is unambiguous. If you’re a woman with elevated LDL-C, particularly with other risk factors, and the response you’ve received is “let’s just watch it” that warrants a more detailed conversation.

Estrogen and the menopausal transition matter here in a concrete way. During your reproductive years, estrogen keeps LDL-C lower, HDL-C higher, and arteries more flexible. That protection doesn’t disappear overnight at menopause it erodes gradually through perimenopause, but the lipid shift that follows is real. Cholesterol that looked acceptable at 42 may genuinely require attention at 52. Annual lipid testing through perimenopause and into menopause is worth requesting, not waiting to be offered.

Women who experienced gestational hypertension, preeclampsia, or gestational diabetes carry a measurably higher lifetime cardiovascular risk. If that applies to you, it’s worth flagging in the context of this conversation, it changes the risk picture.

For Men: Earlier, Higher Risk, and the Tendency to Wait

Elevated cholesterol tends to develop earlier in men, often through the 30s and 40s, and the risk of a cardiac event at a younger age is higher. The clinical challenge is rarely access to treatment. It’s the tendency to deprioritize a condition that produces no symptoms whatsoever.

The sobering reality: the first sign of coronary artery disease in men is, too often, a heart attack. A lab result telling you your LDL is elevated is an opportunity most people don’t get in advance of a crisis.

Waist circumference is the home metric that matters most beyond the scale. Above 40 inches signals visceral fat, the kind that wraps around your organs, drives inflammation, worsens insulin resistance, and pushes lipid numbers in the wrong direction. The scale measures total mass; the tape measure tells you about the metabolically active fat that specifically affects vascular health.

Testosterone and lipids have a bidirectional relationship that often goes undiscussed. Low testosterone is associated with higher LDL-C, lower HDL-C, and higher triglycerides. The lifestyle interventions that most improve testosterone: progressive resistance training, consistent sleep, stress management, reducing central adiposity, are also the ones that most improve lipid profiles. These aren’t separate agendas.

Part 4: The Intervention Roadmap

Three Months. Then a Decision.

For most adults with LDL-C below 190 mg/dL, no established heart disease, and no diabetes with high-risk features — three months of consistent lifestyle intervention is the right first move before starting medication. Not because medication is bad (it isn’t), but because this period tells you something important: whether your cardiovascular system responds to lifestyle change, and to what degree.

The threshold that changes this equation: If your LDL-C is 190 mg/dL or above, or if you’ve already had a heart attack, stent, stroke, or coronary artery disease diagnosis, lifestyle is still foundational, but medication belongs in the picture from day one, not after a waiting period.

What to Eat: The Portfolio Approach

The most evidence backed dietary strategy for lowering LDL-C isn’t a named diet most people have heard of. It’s called the Portfolio diet, developed at the University of Toronto, and it works by stacking four cholesterol lowering foods together. The effects are additive each component contributes independently, and together they produce reductions of 17–35% in LDL-C, comparable to a low-dose statin in the strongest trials [3].

Soluble fiber (10–25g/day) binds cholesterol in the gut before it’s absorbed. Sources: oats, barley, beans, lentils, psyllium husk, apples, citrus. The simplest starting point is oatmeal for breakfast and legumes at one meal daily.

Plant protein (1–2 servings/day) — lentils, chickpeas, black beans, edamame, tofu — lowers LDL directly and simultaneously displaces saturated fat from your diet, which compounds the effect.

Nuts (a small handful daily) — roughly 30g, or what fits in your palm. Almonds and walnuts are the most studied. Walnuts specifically add omega-3 fatty acids on top of the LDL-lowering benefit.

Plant sterols/stanols (2g/day) block cholesterol absorption in the gut. Available as fortified foods or supplements; at 2g/day, they independently lower LDL-C by 5–10%.

Alongside these: the saturated fat swap matters. Replace butter with olive oil, fatty red meat and processed meats with leaner alternatives, and default to low-fat dairy or unsweetened plant milks. You don’t need to do this perfectly, consistently is what counts.

Exercise, Alcohol, and Sleep

Aerobic exercise (150 minutes per week of moderate activity — brisk walking, cycling, swimming) is the most reliable lifestyle lever for raising HDL-C, and also modestly reduces LDL-C and triglycerides. Even a 5–10% reduction in body weight through combined diet and exercise improves every lipid marker simultaneously.

Alcohol has a direct dose-dependent effect on triglycerides: ethanol converts to triglycerides in the liver. If your triglycerides are elevated, reducing alcohol is one of the highest-yield changes you can make — and the results show up relatively quickly.

Sleep is the one most people miss in a cholesterol conversation. Chronic sleep restriction raises inflammatory markers, worsens insulin resistance, and disrupts lipid metabolism. Seven to eight hours of quality sleep is a clinical target here, not just a lifestyle preference.

When Medication Is the Right Call

Statins have decades of high-quality evidence behind them. The mechanism is clear, the benefit is consistent, and the risk reduction is meaningful: roughly 22% fewer major vascular events per 1 mmol/L reduction in LDL-C, across more than 170,000 trial participants [1].

If three months of consistent lifestyle effort hasn’t moved your LDL-C meaningfully toward goal, adding medication is the correct clinical response. A significant number of people have genetic or structural factors that lifestyle simply cannot fully overcome. Medication and lifestyle work better together than either does alone; patients who maintain strong habits alongside statin therapy often achieve better control at lower doses.

Supplements: Where They Actually Fit

Think of supplements as supportive working alongside dietary change, not substituting for it. Start your lifestyle changes at week one; introduce supplements at weeks 4–6 once the foundation is in place.

CoQ10 is produced naturally in your body and essential for cellular energy. There are two reasons it belongs in this conversation. First, if you’re on a statin: statins block the same biochemical pathway that produces CoQ10, which is why muscle aches are a common side effect. Supplementing helps replenish what statins deplete — a 2024 meta-analysis of 7 RCTs found CoQ10 significantly reduced muscle pain in people with statin-induced myopathy [4]. Second, independently: a 2023 meta-analysis of 50 RCTs involving 2,794 people found CoQ10 reduced LDL-C by approximately 3 mg/dL and triglycerides by approximately 9 mg/dL, with modest HDL improvement [5]. A separate 2025 meta-analysis of 45 RCTs also found a 3.4 mmHg reduction in systolic blood pressure [6] — making it doubly useful for cardiovascular risk overall. Take: 100–200 mg/day as ubiquinol (the better-absorbed form), with a fat-containing meal. Allow 8–12 weeks. CoQ10 production declines with age, so it’s particularly worth considering over 50 and for all statin users.

L-Carnitine shuttles fatty acids into the mitochondria to be burned for energy, which means when carnitine levels are adequate, your body clears circulating fats more efficiently. A 2023 dose-response meta-analysis of 60 RCTs involving 3,933 people found L-carnitine significantly reduced triglycerides (−10 mg/dL), LDL-C (−7.5 mg/dL), and total cholesterol (−7 mg/dL), while raising HDL-C [7]. Effects were strongest at doses of 2g/day or more, and in people with elevated triglycerides, high LDL-C, or carrying extra weight, which matches the most common lipid patterns. Carnitine comes almost entirely from animal foods, so those eating mostly plant-based tend to have lower baseline levels and may see stronger effects from supplementation. Take: 1,500–2,000 mg/day of L-carnitine tartrate or acetyl-L-carnitine with a meal. Give it 12 weeks.

Red Yeast Rice deserves its own honest conversation, because it is one of the most misunderstood supplements in this space.

It works. Studies consistently show it can lower LDL-C by 15–25%, comparable to a low-dose statin. The reason is straightforward: its active ingredient, monacolin K, is chemically identical to lovastatin — a prescription statin drug [8]. This is the part that tends to get glossed over in wellness contexts.

The problems are real. There is no mandatory standardization of monacolin K content in RYR supplements, and a 2024 analytical study found many products contain significantly more or less than their labels claim [9]. Some products contain citrinin, a mycotoxin produced during fermentation that can damage the kidneys. And because it works pharmacologically like a statin, the side effect profile is equivalent: muscle damage and liver dysfunction have been reported at monacolin K doses as low as 3 mg/day. The European Commission now restricts RYR supplements to less than 3 mg/day of monacolins; the FDA has issued consumer warnings citing safety and standardization concerns [10].

The one clinical nuance worth knowing: some people who couldn’t tolerate pharmaceutical statins report tolerating RYR better, particularly at lower doses. This has been observed in meaningful patient cohorts and nobody fully understands why yet. It’s a real phenomenon — but it doesn’t remove the need for monitoring.

The bottom line: don’t take red yeast rice independently. If you’re interested in it, bring it up with your clinician. That conversation should include a liver function baseline, a plan for regular monitoring, third-party certified products that are verified citrinin-free, and an honest comparison to whether a low-dose pharmaceutical statin might be a better-supervised option. Calling a statin a supplement doesn’t make it safer.

Part 5: The Retesting Timeline

90 Days, Then You’ll Know

Repeat your fasting lipid panel at 90 days. What you’re looking for:

LDL-C at target — below 100 mg/dL for most people, below 70 mg/dL if you’re higher risk. If you’re there, the lifestyle intervention worked. Continue and retest in 6 months, then annually.

Moving in the right direction, but not at goal — this is a judgment call made in context. How much did it move? How closely did you follow the protocol? A 90-day extension with tighter adherence is reasonable; so is starting a conversation with your clinician about whether medication makes sense now.

Minimal movement despite genuine effort — genetics are likely playing a meaningful role. Starting medication is the correct clinical response to that data, not a defeat. A significant subset of people with elevated LDL-C have Familial Hypercholesterolemia or lipid metabolism variations that lifestyle cannot fully overcome on its own.

What to Track at Home in Between

A weekly check-in on dietary patterns not calorie counting, but noting saturated fat in (red meat, butter, processed food) and Portfolio foods in (legumes, nuts, fiber) builds pattern recognition that makes the 90-day result interpretable.

Waist circumference measured monthly is one of the most underused tools for tracking visceral fat trends. A decreasing waist circumference is a reliable proxy for improving insulin sensitivity and lipid metabolism, even when the scale stays flat.

Return to your provider sooner if you notice: unexplained muscle pain or weakness, especially if you’re on statins or taking red yeast rice — contact your clinician promptly; any chest pain or shortness of breath; sudden vision changes; or a severe unexplained headache.

A Note on What to Ask for at Your Next Test

If your lipid panel only reported LDL-C, consider asking your clinician to also include Non-HDL-C and ApoB next time. Both give a more complete picture of cardiovascular risk particularly if your triglycerides are elevated or you have signs of insulin resistance, and are increasingly referenced in clinical guidelines as better predictors than LDL-C alone.

Where to Go From Here

A high cholesterol diagnosis is not a sentence. For the majority of people who receive it and respond with consistent, informed action, it’s a warning that leads to a trajectory that never ends badly.

You now have the framework. The pattern that got you here. The reframe that makes the work feel worthwhile rather than punitive. The biological differences that affect how this shows up in your body. The evidence behind the dietary strategy, the supplements that are genuinely useful, the supplement that needs a clinical conversation, and the timeline for knowing whether any of it is working.

If you want to do this with clinical support — not just a masterclass — our team is here for consultations that build a personalized roadmap from your actual labs, history, and goals.

[Book a Consultation with Heal Integrative Wellness]

The next masterclass in Series 3 covers Hormonal Imbalance – Restoring the Body’s Communication Network.

Subscribe now

Sources

1. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi:10.1016/S0140-6736(10)61350-5

2. Handelsman Y et al. Gender disparities in LDL-C achievement and statin prescribing. Lipid analysis, 2025.

3. Jenkins DJA, Chiavaroli L et al. Portfolio Dietary Pattern and Cardiovascular Disease: a Systematic Review and Meta-analysis of Controlled Trials. Progress in Cardiovascular Diseases. 2018;61(1):54–69. doi:10.1016/j.pcad.2018.05.004

4. Grüneberg M et al. Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis. 2024. PMC12554813.

5. Liu Z, Tian Z, Zhao D et al. Effects of Coenzyme Q10 Supplementation on Lipid Profiles in Adults: A Meta-analysis of Randomized Controlled Trials. Journal of Clinical Endocrinology & Metabolism. 2023;108(1):232–249. doi:10.1210/clinem/dgac585

6. Roshanzamir S et al. Effects of coenzyme Q10 administration on blood pressure and heart rate in adults: a systematic review and meta-analysis of 45 randomized controlled trials. 2025.

7. Askarpour M et al. The effects of L-carnitine supplementation on lipid profiles in adults: A systematic review and dose-response meta-analysis of 60 randomized controlled trials. ScienceDirect. 2023.

8. Pirro M, Vetrani C, Bianchi C et al. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. Journal of the American College of Cardiology. 2021;77(5):620–628. doi:10.1016/j.jacc.2020.11.056

9. Righetti AA et al. Red Yeast Rice or Lovastatin? A Comparative Evaluation of Safety and Efficacy. Phytotherapy Research. 2024. PMC11745150.

10. Norata GD, Banach M. The Impact of Red Yeast Rice Extract Use on the Occurrence of Muscle Symptoms and Liver Dysfunction: An Update from the Adverse Event Reporting Systems and Available Meta-Analyses. Nutrients. 2024;16(3):444. doi:10.3390/nu16030444

11. Karampetsou N et al. Safety and Efficacy of the Consumption of Red Yeast Rice Extract for the Reduction of Hypercholesterolemia: A Systematic Review and Meta-Analysis of 14 clinical trials. Nutrients. 2024;16(10):1453. doi:10.3390/nu16101453

12. Glenn AJ et al. Portfolio Diet Score and Risk of Cardiovascular Disease: Findings From 3 Prospective Cohort Studies. Circulation. 2023. doi:10.1161/CIRCULATIONAHA.123.065551

This masterclass is written and reviewed by the clinical team at Heal Integrative Wellness. It is intended for educational purposes and does not constitute individualized medical advice. Please consult your healthcare provider before making changes to your treatment plan.

© Heal Integrative Wellness — Series 3: The First Diagnosis

“130/85. Your doctor said you need to watch it. You nodded, drove home, and searched ‘blood pressure 130’ on your phone. Four tabs later, you weren’t sure if you needed immediate hospitalization or just less salt.”

That’s the moment this article is for.

Hypertension is the most common chronic condition in American adults. Nearly half of all U.S. adults now meet diagnostic criteria yet most feel nothing. No headache. No chest pain. No signal at all that anything is wrong. Which is exactly what makes it dangerous, and exactly why catching it in the early window matters so much.

This masterclass covers everything your clinician doesn’t have time to explain in a 15-minute appointment: what’s actually happening inside your arteries, how biology plays out differently for men and women, and what three months of focused lifestyle work can realistically accomplish before we talk about a prescription.

Part 1: The Pattern Behind the Diagnosis

What the Numbers Mean

Blood pressure is measured in two numbers: systolic (the top) and diastolic (the bottom). Systolic reflects the pressure in your arteries when your heart contracts and pushes blood forward. Diastolic reflects the pressure when your heart is at rest between beats.

If your reading was in the 120–139/80–89 range, you are in the window where lifestyle intervention has its greatest leverage. That is not a consolation, it is a clinical fact.

What’s Happening to Your Arteries

Think of your arteries as flexible, responsive tubes. Healthy arteries dilate when blood flow increases and constrict when it decreases. Blood pressure stays within a normal range because the vessel walls have elastic give.

With sustained hypertension, three things happen in sequence. First, the vessel walls are under chronic mechanical stress. Second, the inner lining, the endothelium, becomes dysfunctional, losing its ability to produce nitric oxide, the molecule responsible for smooth, flexible dilation. Third, the vessel walls thicken and stiffen through a process called vascular remodeling, as the body tries to reinforce itself against the pressure.

The result is a self-perpetuating cycle: stiff vessels create higher pressure, higher pressure accelerates stiffening. The heart, meanwhile, works harder to push blood through resistant arteries, and over years, that strain shows up as left ventricular hypertrophy( the cardiac muscle thickening as a stress response)

What’s important to understand is that this progression is slow, reversible in its early stages, and measurable. Elevated blood pressure in the 120s or early 130s systolic does not represent the same biological state as long standing Stage 2 hypertension. You are not yet at the downstream end of this process.

Why the Root Causes Matter More Than the Numbers

The number on the cuff is the symptom. These are the drivers:

Sodium and the fluid volume connection. The average American consumes roughly 3,400 mg of sodium per day, that’s more than double the 1,500 mg recommended for people with elevated blood pressure. Excess sodium draws water into circulation, increasing blood volume. Greater volume means higher pressure. The sodium-pressure relationship is well-established and particularly pronounced in certain populations (more on that in Part 3).

Arterial stiffness from inactivity. Regular aerobic exercise causes arteries to remodel favorably by become more elastic, better at dilating, and their endothelial cells produce more nitric oxide. Without that stimulus, arteries stiffen progressively, independent of body weight. Physical inactivity is not just a weight management issue; it is a direct vascular biology issue.

The chronic stress-cortisol-pressure axis. Cortisol and adrenaline cause immediate blood pressure increases through vasoconstriction (narrowing of vessels) and increased heart rate. When this stress response is chronic rather than occasional, blood pressure never fully returns to baseline between activations. Sympathetic nervous system overactivation is a documented contributor to essential hypertension.

Sleep quantity and quality. During deep sleep, blood pressure normally drops 10–20% in a pattern called “dipping.” Sleep apnea, which disrupts this dipping pattern through repeated nighttime oxygen drops and sympathetic activations, is now recognized as a direct cause of hypertension in susceptible individuals.

Part 2: The Mental Shift

The first thing most people feel when they’re diagnosed with hypertension is some version of failure. You eat too much salt. You don’t exercise enough. You’re too stressed and do nothing about it. The diagnosis arrives as an indictment.

Here’s what actually happened: your cardiovascular system responded predictably to an environment it wasn’t designed for. The modern food supply is built around sodium. Most jobs require sitting for eight hours. The average American screens consume 7 hours per day of stimulation that activates the stress response without allowing physical discharge. Your arteries did exactly what arteries do under these conditions.

That reframe matters not as comfort but as clinical clarity. If the cause is environmental mismatch, the intervention is environmental redesign, not willpower or self-punishment.

There’s also something important about the arc of this diagnosis. Elevated or Stage 1 hypertension is not a failed state. It is the body’s signal that the vascular system is under load and that signal, caught early, is genuinely useful information. The window between “first elevated reading” and “sustained Stage 2 requiring immediate medication” is where lifestyle interventions produce their most dramatic effects. That is the window you are in.

The goal of the next three months is not to “try to be healthier.” It is to execute a specific, evidence-informed intervention and measure its results at 90 days. That’s a clinical project, not a lifestyle aspiration.

Subscribe now

Book a Consultation

Subscribers continue below…

Part 3: Gender-Specific Considerations

For Women

The menopause threshold. Premenopausal women have a meaningful cardiovascular advantage. Before menopause, women have lower average blood pressures than age-matched men, a protection mediated primarily by estrogen. Estrogen promotes nitric oxide production, supports vascular flexibility, and modulates the renin-angiotensin-aldosterone system in a blood pressure lowering direction.

At menopause, that protection is removed. In the decade following menopause, the prevalence of hypertension among women rises sharply, eventually exceeding rates in men of the same age. The mechanisms involve loss of estrogen mediated vascular protection, increased sympathetic nervous system activation, salt sensitivity, and altered renal sodium handling.

Clinically, this means a woman in her late 40s or early 50s who has always had normal blood pressure may begin seeing readings edge upward without any obvious lifestyle change. This is not a failure of compliance it is the biology and it needs to be anticipated rather than discovered reactively.

Hormone therapy and blood pressure. The route of estrogen administration matters. A large observational study in Hypertension (2023, n > 100,000) found that oral estrogen was associated with a 14% higher risk of developing hypertension compared with transdermal estrogen. Non oral forms (patches, gels, and vaginal preparations) at the lowest effective dose appear to carry lower blood pressure risk. For women navigating both menopausal symptoms and early hypertension, this is a relevant clinical conversation.

Salt sensitivity is more pronounced post-menopause. Estrogen normally modulates the kidney’s response to sodium. After menopause, women frequently become more salt-sensitive, meaning the same sodium load produces a larger blood pressure increase than it would have in their 30s or 40s. Dietary sodium reduction tends to produce greater blood pressure benefit in postmenopausal women than in age-matched men, a point worth noting when prioritizing interventions.

Oral contraceptives. In younger women, combined oral contraceptives containing synthetic progestins can modestly raise blood pressure through mineralocorticoid effects. If you are on hormonal contraception and receiving a hypertension diagnosis, this interaction is worth discussing with your prescriber.

For Men

Earlier onset, visceral adiposity, and the risk invisibility problem. Men develop hypertension at higher rates and younger ages than premenopausal women. In men, excess body weight tends to deposit around the abdominal organs rather than subcutaneously. Visceral fat is metabolically far more active, producing more inflammatory signals and driving more RAAS activation per unit than subcutaneous fat. A man with a waist circumference above 40 inches carries substantially elevated vascular risk.

This is why waist measurement is the most informative home monitoring tool for men tracking cardiovascular health. The scale measures total mass; the tape measure tells you about the fat that’s doing the cardiovascular damage.

The testosterone-blood pressure bidirectional relationship. Hypertension and low testosterone interact through overlapping mechanisms. Testosterone has complex vascular effects, but low testosterone is associated with increased visceral adiposity which, as noted above, independently drives blood pressure. The relationship is bidirectional: visceral fat promotes changes of testosterone to estradiol, lowering testosterone further, while also activating RAAS and worsening insulin resistance, both of which raise blood pressure.

Men with uncontrolled hypertension presenting with fatigue, low libido, or body composition changes warrant testosterone evaluation as part of a complete metabolic workup, not as a treatment for hypertension itself, but because untreated low testosterone can undermine the lifestyle interventions that lower blood pressure.

Sleep apnea is the hidden driver you must rule out. Obstructive sleep apnea (OSA) affects approximately 30% of men aged 30–49, rising to 40% of men aged 50–70. Its relationship to hypertension is direct and well-established: each episode triggers a sympathetic surge that acutely raises blood pressure, and repeated overnight cycles maintain elevated 24-hour blood pressure loads. Men with OSA who are hypertensive frequently respond incompletely to lifestyle and even pharmacological intervention because the blood pressure signal is being regenerated 200–300 times per night while they sleep.

If you are male, hypertensive, and have any of the following: loud snoring, witnessed breathing pauses, non-restorative sleep, morning headaches, excessive daytime sleepiness, or a neck circumference above 17 inches, a sleep study is clinically indicated before committing to a 3-month lifestyle-only trial. Treating the OSA can produce blood pressure reductions equivalent to a moderate antihypertensive drug.

Part 4: The Intervention Roadmap

Our Clinical Philosophy: Lifestyle First, Measured at 90 Days

This practice’s position on hypertension management begins with a principle: three months of consistent, protocol-based lifestyle intervention should precede pharmacological treatment in patients with Stage 1 hypertension and no high-risk features (no diabetes, no established cardiovascular disease, no evidence of end-organ damage, and no readings in the Stage 2 range or above).

The reason is not that medication is bad. The reason is that medication added too early makes it impossible to determine whether lifestyle changes are working. It also sets the patient on a trajectory toward permanent pharmacological management of a problem that may have a behavioral solution. The 3-month window is not a delay — it is a diagnostic period with a clear endpoint: we retest, compare against baseline, and make a data-informed decision.

Exceptions are made for Stage 2 hypertension (≥140/90), hypertension with concurrent diabetes or kidney disease, or any reading suggesting end-organ involvement. These situations require immediate clinical attention and are beyond the scope of this article.

Lifestyle Foundation

Dietary Strategy: The DASH Framework

The Dietary Approaches to Stop Hypertension (DASH) diet is the most rigorously studied dietary intervention for blood pressure. A meta-analysis of 17 RCTs (n = 2,561) found that DASH reduced systolic blood pressure by 6.74 mmHg and diastolic by 3.54 mmHg, a reduction comparable to low-dose antihypertensive medication in many cases. Effects are larger in participants with higher baseline blood pressure.

The DASH principles are straightforward: emphasize vegetables, fruits, whole grains, low-fat dairy, lean proteins, nuts, and legumes. Limit red meat, added sugars, and sodium. It’s not an elimination diet, it’s a macronutrient rebalancing.

Practical anchor points:

• Fill half your plate with non-starchy vegetables and fruit at each meal

• Include a calcium-rich food at most meals (low-fat dairy, fortified plant milk, leafy greens)

• Choose whole grains over refined grains as your default

• Use herbs and citrus as flavoring; push salt off the table

• Limit processed meats and cured foods, which are the primary sodium contributors in the American diet

Aerobic Exercise

This is arguably the most powerful single lifestyle lever for blood pressure. A 2022 meta-analysis of aerobic training in hypertensive patients found a systolic blood pressure reduction of approximately 8.9 mmHg with regular aerobic exercise, Thats just as effective or exceeds first-line antihypertensive medications in Stage 1 hypertension. A dose-response analysis confirmed that each additional 30 minutes per week of aerobic activity produced further reductions of approximately 1.78 mmHg in systolic blood pressure.

The mechanism is direct: aerobic exercise stimulates endothelial shear stress, promoting nitric oxide release and sustained vascular remodeling toward greater elasticity. It also reduces sympathetic nervous system tone at rest.

Target prescription: 150 minutes per week of moderate-intensity aerobic activity (brisk walking, cycling, swimming, dancing), distributed across at least 4–5 sessions. Combined aerobic and resistance training programs produce systolic reductions of 6.4 mmHg on average, with additional benefit from increasing exercise intensity.

Stress and the Autonomic Nervous System

Sustained psychological stress maintains elevated sympathetic tone, keeping baseline blood pressure elevated between stressors. Evidence supports several interventions that lower sympathetic activity and resting blood pressure: diaphragmatic breathing practices, regular moderate-intensity exercise (which serves double duty), adequate sleep, and structured relaxation practices. Device-guided slow breathing (targeting 6 breaths per minute) has RCT support for blood pressure reduction.

This is not soft advice. Sympathetic overactivation is a well-characterized physiological driver of essential hypertension. Addressing it belongs in any serious intervention protocol.

Sleep

Chronic short sleep (below 6 hours) is associated with blood pressure dysregulation through multiple mechanisms: elevated evening cortisol, impaired vascular recovery during sleep, and disruption of the normal nocturnal blood pressure dip. For patients with hypertension, 7–8 hours of quality sleep is a clinical target, not a lifestyle preference.

If sleep quality is poor despite adequate time in bed 9 insomnia, early awakening, or non-restorative sleep) this warrants clinical evaluation. Sleep disruption from insomnia and sleep disruption from OSA require different interventions.

When Supplements Enter the Picture

After 4–6 weeks of lifestyle implementation, or concurrent with lifestyle changes in patients with Stage 1 hypertension who want to maximize their 90-day window, two supplements have meaningful evidence for blood pressure support.

Magnesium

Magnesium is critical to vascular smooth muscle relaxation, endothelial function, and regulation of the calcium channel signaling that governs vasoconstriction. Magnesium deficiency is associated with increased vascular reactivity and elevated blood pressure.

A 2024 umbrella meta-analysis of 10 prior meta-analyses (n = 8,610 total participants) found that magnesium supplementation significantly reduced systolic blood pressure by 1.25 mmHg and diastolic blood pressure by 1.40 mmHg. A separate comprehensive 2024 meta-analysis of 38 RCTs (n = 2,709) using a dose-response model found reductions of −2.81 mmHg systolic and −2.05 mmHg diastolic. Effects appear largest in individuals with confirmed magnesium deficiency or insulin resistance, and are greater with longer supplementation durations.

Clinical note: effects are modest in isolation but additive with dietary changes and exercise. Think of magnesium not as a blood pressure drug but as restoring a nutritional substrate that is genuinely required for normal vascular function.

Typical clinical dosing: magnesium glycinate at 200–400 mg per day, taken in the evening to support sleep as a secondary benefit. Avoid magnesium oxide (poor bioavailability) and dose slowly upward to avoid GI symptoms.

CoQ10 (Coenzyme Q10)

CoQ10 is a fat-soluble compound essential for mitochondrial ATP production and a powerful endogenous antioxidant. Its relevance to hypertension centers on oxidative stress: elevated reactive oxygen species impair nitric oxide bioavailability in the vascular endothelium, reducing the endothelium’s capacity to dilate and regulate pressure. CoQ10 partially restores this system.

A 2025 systematic review and meta-analysis of 45 RCTs found that CoQ10 supplementation significantly reduced systolic blood pressure by 3.44 mmHg, with subgroup analysis showing greater effects at doses below 200 mg/day and with interventions lasting more than 8 weeks. Effects on diastolic blood pressure were modest and non-significant in this analysis.

CoQ10 is particularly relevant for two populations in our patient base: patients who have recently started statins (which reduce endogenous CoQ10 synthesis and can precipitate or worsen hypertension), and patients over 50 whose natural synthesis has declined with age.

Clinical dosing: 100–200 mg daily with a fat-containing meal for absorption. Allow 8–12 weeks for full effect — CoQ10’s antioxidant action requires time to reduce accumulated endothelial oxidative stress.

When Medication Enters — After 3 Months

If three months of consistent lifestyle intervention has not brought systolic blood pressure below 130 mmHg and diastolic below 80 mmHg, pharmacological intervention is appropriate.

Several classes of antihypertensive medications have well-established safety and efficacy profiles. The right choice depends on individual factors including age, sex, race, comorbidities, and specific blood pressure pattern. This is a conversation for your clinician.

What we want to be clear about: beginning medication does not mean lifestyle changes stop. The evidence is consistent that medicated patients who continue with DASH, exercise, and sodium reduction often achieve better control at lower doses and some ultimately reduce or discontinue medication after sustained lifestyle change. Medication and lifestyle work synergistically, not as alternatives.

Part 5: The Retesting Timeline

At 90 Days: The Decision Point

After 3 months of lifestyle intervention, you should have a formal blood pressure reassessment. Ideally an average of multiple readings taken on different days, not a single clinical measurement. We recommend home blood pressure monitoring throughout the intervention period for two reasons: first, clinic readings often overestimate true blood pressure due to white coat effect; second, patterns over time are more informative than single data points.

Bring your home log to the 90-day appointment.

If readings are consistently below 130/80: Continue the lifestyle protocol. Retest in 6 months. Annual monitoring thereafter if stable.

If readings are in the 130–139/80–89 range with progress: Continue lifestyle work; evaluate whether specific components (sodium, exercise volume, sleep, supplements) can be intensified. Consider 90-day extension before initiating medication.

If readings remain above 140/90, or have not moved despite adherent lifestyle changes: Pharmacological intervention is appropriate. This is not a failure, it is the expected outcome for a subset of patients whose hypertension has significant genetic or structural components that lifestyle alone cannot fully address.

Home Monitoring Protocol

Weekly: Resting blood pressure check in the morning before coffee or medication. Sit quietly for 5 minutes first.

Monthly: Waist circumference measurement (for men specifically, as a proxy for visceral fat trend).

Continuous: Track sleep quality, sodium intake patterns, and exercise volume. Blood pressure moves in response to these inputs, and noting correlations, “readings were higher this week when sleep was under 6 hours,” is clinically useful data.

Red Flags for Earlier Evaluation

Return for evaluation sooner than the 90-day mark if you experience:

• Any reading at or above 180 systolic or 110 diastolic

• Sudden severe headache, particularly at the back of the head

• Vision changes (blurring, spots, loss of peripheral vision)

• Chest pain or shortness of breath

• Morning headaches or non-restorative sleep pattern (possible OSA signal)

• Significant swelling in the legs

These symptoms alongside elevated blood pressure may indicate end-organ involvement that requires immediate clinical evaluation.

Book a consultation →

If this article raised questions specific to your numbers — your blood pressure readings, your home monitoring data, or where you are three months into a lifestyle protocol — our clinical team is available for one-on-one consultations.

What’s Coming Next in Series 3

Masterclass 3: High Cholesterol — Beyond the Numbers to Vascular Protection

Masterclass 3 covers the complete cholesterol story: what the different markers mean, why the standard panel often misses the real risk, and the evidence-based intervention roadmap for meaningful vascular protection.

References

1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127–e248.

2. Saneei P, Salehi-Abargouei A, Esmaillzadeh A, Azadbakht L. Influence of dietary approaches to stop hypertension (DASH) diet on blood pressure: a systematic review and meta-analysis on randomized controlled trials. Nutr Metab Cardiovasc Dis. 2014;24(12):1253–1261.

3. Filippou CD, Tsioufis CP, Thomopoulos CG, et al. Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure Reduction in Adults with and without Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2020;11(5):1150–1160.

4. Fu L, et al. Meta-Analysis of the Effect of Aerobic Training on Blood Pressure in Hypertensive Patients. Computational and Mathematical Methods in Medicine. 2022.

5. de Barcelos GT, Heberle I, Coneglian JC, et al. Effects of Aerobic Training Progression on Blood Pressure in Individuals With Hypertension. Front Sports Act Living. 2022;4:719063.

6. Jabbarzadeh Ganjeh B, Zeraattalab-Motlagh S, Jayedi A, et al. Effects of aerobic exercise on blood pressure in patients with hypertension: a systematic review and dose-response meta-analysis of randomized trials. Hypertens Res. 2024;47(2):385–398.

7. Rezende VF, et al. Exercise characteristics and blood pressure reduction after combined aerobic and resistance training: a systematic review with meta-analysis and meta-regression. PubMed. 2023.

8. Alharran AM, Alzayed MM, Jamilian P, et al. Impact of Magnesium Supplementation on Blood Pressure: An Umbrella Meta-Analysis of Randomized Controlled Trials. Curr Ther Res Clin Exp. 2024;101:100755.

9. Alharran AM, et al. Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 2025.

10. Behers BJ, Behers BM, Stephenson-Moe CA, et al. Magnesium and Potassium Supplementation for Systolic Blood Pressure Reduction in the General Normotensive Population. Nutrients. 2024;16(21):3617.

11. Roshanzamir F, et al. Effects of coenzyme Q10 administration on blood pressure and heart rate in adults: A systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2025.

12. Zhang DL, et al. Dose-Response Effect of Coenzyme Q10 Supplementation on Blood Pressure among Patients with Cardiometabolic Disorders. J Nutr. 2022.

13. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37(5):1199–1208.

14. Kalenga CZ, et al. Women taking oral estrogen hormones may have increased risk of high blood pressure. Hypertension. 2023.

15. Pérez-López FR, Chedraui P, Cuadros JL, et al. Postmenopausal Hypertension. Hypertension. 2008.

16. Pérez-López FR, et al. Menopause and Hypertension. Hypertension. 2008.

17. American Urological Association. Obstructive Sleep Apnea and Its Impact on Men’s Health. AUA News. 2024.

18. Su M, et al. Association between obstructive sleep apnea and male serum testosterone: A systematic review and meta-analysis. Andrology. 2022;10(3):452–461.

There’s a specific kind of disorientation that comes with being told your numbers are “borderline.”

Not diabetic. Not fine. Somewhere in between and staring at a lab result that raises more questions than your doctor had time to answer.

Insulin resistance and prediabetes occupy exactly that territory. They’re common enough that clinicians sometimes deliver the news quickly, assuming patients know what it means. Most don’t. And that gap between the diagnosis and a real plan is exactly where people get stuck or where the condition quietly progresses.

This masterclass is our attempt to close that gap. We’re going to walk you through why this happened, what it actually means for your body, and what the evidence says you can do about it starting today!

Part 1: The Pattern Behind the Diagnosis

How Your Body Gets Here

Insulin resistance doesn’t announce itself. It builds over years, through a gradual process that many people never notice until a number on a lab report flags it.

Here’s the core mechanism: insulin is the hormone that signals your cells to absorb glucose from the bloodstream. In insulin resistance, that signal starts to lose its potency. Your cells stop responding as efficiently, and your pancreas compensates by producing more insulin and sometimes dramatically more. For a while, this works. Your glucose stays normal because your pancreas is working overtime to keep it there. But that compensation has a biological cost, and it is not sustainable indefinitely.

The clinical thresholds matter here. Fasting glucose between 100–125 mg/dL, or an HbA1c between 5.7–6.4%, places you in the prediabetic range (a physiological state that carries real risk) but is also the most actionable window in the progression toward type 2 diabetes. Randomized controlled trials have consistently shown that 32–52% of individuals in this range return to normal glucose regulation through intensified lifestyle intervention, and the evidence for lifestyle modification is classified as strong in the most recent systematic reviews and meta-analyses [1, 2].

What to Look for in Yourself

Several patterns tend to appear before a diagnosis is made, and recognizing them helps contextualize your situation.

Central weight gain is one of the most consistent early signs. Excess insulin preferentially directs fat storage to the abdominal area. A waist circumference above 40 inches in men or 35 inches in women is a visible marker worth taking seriously.

Post-meal energy crashes — specifically the fatigue or mental fog that sets in 1–3 hours after eating, suggest reactive hypoglycemia: your body is overshooting insulin production in response to a meal, then bottoming out. If you feel better before you eat than after, this is a pattern worth discussing with your provider.

Skin changes can be the most overlooked indicator. “Acanthosis nigricans” a darkening and thickening of the skin at the neck, underarms, or groin is a direct dermatologic marker of high insulin. Skin tags in these same locations have also been associated with elevated insulin.

Laboratory ratios can reveal insulin resistance even when fasting glucose looks normal. A triglyceride-to-HDL ratio greater than 3.5 is a clinically useful indicator, with research showing it reflects underlying insulin resistance with meaningful accuracy.

Root Causes Worth Examining

Understanding why this happens isn’t about assigning blame. It’s about identifying which levers are yours to pull.

Dietary patterns high in refined carbohydrates and added sugars are the most established contributor. The average American consumes approximately 17 teaspoons of added sugar daily well above the American Heart Association’s recommended limits( 6 teaspoons for women and 9 for men). Repeated cycles of high post-meal glucose demand chronically elevated insulin production.

Physical inactivity accelerates the process. Skeletal muscle is the body’s primary site for glucose disposal this accounts for approximately 80% of insulin-stimulated glucose uptake in healthy adults [3]. When muscle mass is low or undertrained, the capacity to clear glucose from the bloodstream is proportionally reduced.

Sleep is one of the most underappreciated variables in metabolic health. Sleep restriction to 4–5 hours per night has been shown in controlled trials to decrease insulin sensitivity by 16–30% [4, 5]. A systematic review and meta-analysis of 35 randomized controlled trials confirmed that reductions in sleep duration, sleep quality, and circadian misalignment all independently impair insulin sensitivity [6]. Treating insulin resistance without addressing sleep is like bailing water without plugging the hole.

Chronic psychological stress drives cortisol elevation, and cortisol directly antagonizes insulin signaling. This creates a real physiological mechanism — not just a lifestyle concern — that makes stress management a clinical priority, not a luxury.

Part 2: The Mental Shift

From “I Failed” to “I Now Know”

The most common emotional response to a prediabetes or insulin resistance diagnosis is shame. Patients interpret it as evidence of personal failure as though their body is grading them on a test they should have studied harder for.

The research tells a different story. A substantial proportion of people with chronic conditions develop comorbid depression or anxiety, and the emotional weight of a new diagnosis is well-documented to directly impair the motivation and cognitive resources needed to respond to it. Shame, in particular, is associated with avoidance, which is the opposite of what the situation calls for.

We want to offer a reframe, and we mean it clinically.

Your body is not broken. It is doing exactly what it evolved to do: storing energy efficiently in an environment where food was scarce and unpredictable. The problem is that the modern food environment: hyperpalatable, calorically dense, endlessly available, has outpaced a system that was never designed for it. This is not a personal failure. It is a systems mismatch.

What the diagnosis does give you is information. Prediabetes is not a disease. It is a risk state and critically, it is the stage at which lifestyle intervention has its most powerful impact [7]. The HbA1c window of 5.7–6.4% exists in medical guidelines precisely because this is where the evidence for reversal is strongest. Many people who receive this diagnosis and act on it never progress to type 2 diabetes.

✦ Subscribe to Continue Reading

The rest of this masterclass, including gender-specific guidance, your full intervention roadmap, and the retesting timeline is available to paid subscribers.

At Heal Integrative Wellness, we believe that the quality of health information you receive should not depend on your ability to pay a specialist’s hourly rate. Every masterclass in this series is written and reviewed by licensed clinicians, backed by peer-reviewed evidence, and built around the questions we hear most in our own practice.

Subscribe now

Book a Consultation

Already a subscriber? Continue below.

Part 3: Gender-Specific Considerations

For Women

Insulin resistance in women is not simply a quieter version of what men experience. It is a fundamentally different hormonal landscape, and those differences have real clinical implications for how you should understand, track, and treat this condition.

Your insulin sensitivity moves with your menstrual cycle. Research comparing insulin sensitivity across cycle phases has shown that it decreases significantly during the luteal phase — the week or two before your period — when progesterone rises and estrogen declines relative to the follicular phase [8]. This means that the same meal or lifestyle pattern can produce meaningfully different glucose responses depending on where you are in your cycle. Standard 14-day continuous glucose monitoring windows often miss this variation entirely; a full 28–30 day monitoring period is more informative.

The PCOS connection is foundational. Polycystic ovary syndrome — the most common endocrine disorder in women of reproductive age, affecting an estimated 5–18% of this population and has insulin resistance as a core pathophysiological feature, present in 35–80% of affected women regardless of body weight [9, 10]. If you have irregular periods, acne, excess facial or body hair, or fertility challenges alongside elevated insulin markers, PCOS may be the driving diagnosis rather than a secondary finding. Addressing insulin resistance in this context changes both the treatment approach and the monitoring targets significantly.

Gestational diabetes history is a red flag. A history of gestational diabetes substantially increases the risk of future insulin resistance and type 2 diabetes. If this applies to you, it should prompt earlier and more frequent metabolic screening than standard guidelines might suggest.

For Men

Men tend to develop insulin resistance earlier, often with fewer obvious external signals, but with a more pronounced cardiovascular risk profile.

Visceral fat is the central mechanism. Men preferentially deposit excess calories as visceral fat, the metabolically active fat stored deep in the abdominal cavity around the organs. Unlike subcutaneous fat, visceral fat releases pro-inflammatory cytokines and free fatty acids directly into the portal circulation, driving both insulin resistance and systemic inflammation. Waist circumference remains one of the most clinically useful home metrics for tracking metabolic improvement in men; if it is decreasing, insulin sensitivity is likely improving regardless of what the scale shows.

The testosterone feedback loop deserves attention. Insulin resistance suppresses testosterone production, and low testosterone independently worsens insulin resistance — creating a bidirectional relationship that can quietly perpetuate itself. Addressing insulin resistance through lifestyle intervention is one of the most evidence-supported strategies for improving testosterone levels naturally in men with this pattern.

Sleep apnea screening matters. Men with insulin resistance have significantly elevated rates of obstructive sleep apnea, and sleep apnea further worsens glucose control — closing a loop that keeps both conditions entrenched. If you snore heavily, wake unrefreshed, or have been told you stop breathing in your sleep, this warrants investigation alongside your metabolic workup.

Part 4: The Intervention Roadmap

Lifestyle First — This Is the Foundation

The evidence for lifestyle modification in reversing insulin resistance and prediabetes is not modest. It is strong, replicated across multiple systematic reviews and meta-analyses, and graded as the first-line recommendation by every major endocrine and metabolic medicine society [1, 7]. Lifestyle intervention produces normoglycemia reversal at rates that exceed most medications in the short term, and the benefits are durable when habits are maintained.

Here is what the evidence actually supports:

Nutrition

There is no single prescribed diet for insulin resistance, but the research converges consistently on a few core principles.

Protein at breakfast meaningfully reduces mid-morning glucose variability and cravings. Eggs, Greek yogurt, cottage cheese, fish, tofu, or legumes at the first meal of the day provides a stable metabolic foundation. Fiber at every meal, from vegetables, legumes, and intact whole grains — slows glucose absorption and reduces insulin demand. The simplest structural framework is this: fill half your plate with non-starchy vegetables, a quarter with quality protein, and a quarter with fiber-rich carbohydrates. Add a modest amount of quality fat (olive oil, avocado, nuts, fatty fish) for satiety and to support fat-soluble nutrient absorption.

The single highest-impact dietary change for most people is eliminating sugar-sweetened beverages. Liquid sugar raises blood glucose faster than nearly any food source and provides no nutritional value to offset the insulin cost. This one change, made consistently, can meaningfully shift glucose patterns within weeks.

Meal timing matters more than many patients expect. Eating two to three structured meals daily — rather than grazing constantly — allows insulin levels to decline between meals, which is physiologically important for both insulin sensitivity and metabolic flexibility. Late-evening high-carbohydrate meals are particularly problematic.

Exercise

Skeletal muscle is your primary glucose disposal site, and building it is one of the most direct interventions available.

Resistance training two to three times per week has been shown across multiple meta-analyses to significantly reduce fasting insulin and HOMA-IR (a validated measure of insulin resistance), independent of weight loss [11, 12]. The mechanism is direct: each pound of muscle increases your metabolic capacity to absorb glucose without additional insulin demand. This is the “sink” for glucose that makes everything else work better.

Post-meal walking is one of the most accessible and evidence-backed tools available. A randomized crossover study published in Scientific Reports found that a 10-minute walk immediately after a meal produced significantly lower blood glucose peaks compared to both rest and a delayed 30-minute walk [13]. Research published in Diabetes Care confirmed that three 15-minute post-meal walks per day improved 24-hour glycemic control as effectively as a single 45-minute session [14]. If you do nothing else after reading this, try a short walk after dinner.

Breaking up prolonged sitting with 2-minute movement breaks every hour has also been shown to significantly improve glycemic control, independent of structured exercise [15]. Movement frequency matters, not just movement volume.

Sleep

Restricting sleep to 4–5 hours per night reduces insulin sensitivity by 16–30% in controlled trials — a magnitude comparable to poor dietary habits [4, 5]. Prioritizing 7–8 hours is not a wellness recommendation. It is a clinical one, as evidence-based as any nutritional intervention in this space.

When Medication Enters the Picture

Let us be direct about our clinical philosophy here: at Heal Integrative Wellness, our preference is to allow a full 4 months of consistent, committed lifestyle change before introducing any pharmacological intervention. This is not a soft guideline, it is a principled position rooted in the evidence that lifestyle modification produces durable, whole-body benefits that no medication can fully replicate. Medication added too early can also obscure whether your lifestyle changes are working, making it harder to know which lever is actually moving your numbers.

If HbA1c remains in the prediabetic range after four months of genuine effort, structured nutrition, regular resistance training, sleep prioritization, and stress management, then the conversation about pharmaceutical support becomes appropriate and warranted. Additional triggers include significant cardiovascular risk factors or PCOS with active fertility goals, where the clinical calculus shifts.

When that threshold is reached, here is what the evidence supports:

Berberine deserves to be named first in this context, because it is frequently overlooked in conventional practice despite a meaningful body of clinical research. It is a plant-derived compound — found in barberry, goldenseal, and Oregon grape. It works primarily by activating the AMPK pathway, the same cellular energy-sensing mechanism that metformin targets.

The evidence for its metabolic effects is substantive. A 2025 randomized clinical trial comparing berberine hydrochloride directly to metformin in newly diagnosed prediabetic patients found comparable reductions in fasting glucose, postprandial glucose, and HbA1c across 12 weeks, with fewer gastrointestinal side effects in the berberine group [17]. A broad meta-analysis of randomized controlled trials confirmed that berberine significantly reduces fasting glucose, HbA1c, and HOMA-IR and importantly, found that its therapeutic effect becomes most apparent after more than 3 months of consistent use [18]. This is a clinically critical point: patients who try berberine for 4–6 weeks and see little change are not giving it adequate time.

Typical doses studied in trials range from 500 mg two to three times daily, taken with meals. For patients who prefer to start with a non-prescription option, or who have mild-to-moderate insulin resistance without urgent cardiovascular risk, berberine is a clinically reasonable first step and one we frequently discuss before moving to prescription medications.

Metformin remains the most extensively studied prescription insulin-sensitizing medication. It reduces hepatic glucose production and improves peripheral glucose uptake, and its use in prediabetes is well-supported — particularly in individuals under 60, with BMI ≥35, or with a history of gestational diabetes. The Diabetes Prevention Program, a landmark RCT, demonstrated that metformin reduced the incidence of type 2 diabetes by 31% compared to placebo over a 2.8-year follow-up [16].

GLP-1 receptor agonists (such as semaglutide) are most appropriate for patients with significant obesity or those who have not responded to the approaches above. They improve insulin secretion, slow gastric emptying, reduce appetite, and promote weight loss, with strong evidence for glucose normalization. A meta-analysis found that GLP-1 receptor agonists produced normoglycemia reversal in 68% of prediabetic participants compared to 21% in control groups [2].

The decision about whether any of these options is appropriate for your situation is one to make with your prescribing provider, who can account for your full clinical picture, other medications, and individual risk factors. This section is designed to give you the vocabulary and context to have that conversation productively — not to replace it.

Part 5: The Retesting Timeline

Knowing When to Measure Progress

One of the most common sources of frustration in managing insulin resistance is testing too early — or not knowing what to watch for at home while waiting for lab work.

If you are starting lifestyle interventions only: Retest HbA1c and fasting glucose at 3–6 months. This timeframe allows sufficient dietary and exercise adaptation to produce measurable change in HbA1c, which reflects the prior 2–3 months of average glucose.

If medication is initiated: Most providers will order follow-up labs at approximately 3 months to assess response and tolerability.

Once stabilized (HbA1c below 5.7%, fasting glucose below 100 mg/dL): Annual retesting is appropriate when risk factors are well-controlled. More frequent testing every 6 months is reasonable if you have a family history of type 2 diabetes, have experienced weight regain, or have additional cardiovascular risk factors.

Home monitoring in between labs:

If you have access to a glucometer, weekly fasting spot checks can provide useful trend data. You don’t need to check daily, consistency over weeks tells you more than individual readings.

Waist circumference measured monthly is one of the most underused home tools. A decreasing waist circumference is a reliable proxy for improving insulin sensitivity, even when the scale stays the same.

Journaling your energy patterns after meals gives you qualitative data about how your interventions are working. The reduction in post-meal crashes is often one of the first noticeable signs of improving insulin sensitivity before any number on a lab report changes.

Return to your provider sooner if you experience:

Increased thirst or urination (potential sign of progression), significant weight regain, worsening post-meal fatigue despite lifestyle changes, or new cardiovascular symptoms of any kind.

Where to Go From Here

A diagnosis of insulin resistance or prediabetes is not a sentence. For the majority of patients who receive it and respond with consistent, informed action, it is the last warning before a condition that never arrives.

You now have the framework. The pattern that got you here. The mental reframe that makes action possible. The biological differences that affect how this condition presents in your body. The evidence-based tools to change your trajectory. And the timeline for measuring whether they’re working.

If you want to do this with clinical support — not just a masterclass — our team is available for one-on-one consultations that build a personalized roadmap based on your specific labs, history, and goals.

[Book a Consultation with Heal Integrative Wellness]

The next masterclass in Series 3 covers hypertension — the first diagnosis that millions of people receive without understanding why it happened or what the evidence actually supports for reversing it.

Sources

1. Galaviz KI, Weber MB, Suvada K, et al. Interventions for reversing prediabetes: A systematic review and meta-analysis. American Journal of Preventive Medicine. 2022;62(4):614–625. doi:10.1016/j.amepre.2021.10.020

2. Galaviz KI, et al. PMC10420389 — full network meta-analysis of pharmacological and non-pharmacological prediabetes reversal interventions. American Journal of Preventive Medicine. 2022. PMC full text available at pmc.ncbi.nlm.nih.gov/articles/PMC10420389

3. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S157–S163. doi:10.2337/dc09-S302

4. Nedeltcheva AV, Kessler L, Imperial J, Penev PD. Exposure to recurrent sleep restriction in the setting of high caloric intake and physical inactivity results in increased insulin resistance and reduced glucose tolerance. Journal of Clinical Endocrinology & Metabolism. 2009;94(9):3242–3250.

5. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and type 2 diabetes. Journal of Applied Physiology. 2005;99(5):2008–2019. doi:10.1152/japplphysiol.00660.2005

6. Olvera Lopez E, Rook JM, Tsakiridis E. Effects of sleep manipulation on markers of insulin sensitivity: A systematic review and meta-analysis of randomized controlled trials. Sleep Medicine Reviews. 2022;63:101610. doi:10.1016/j.smrv.2022.101610

7. American College of Lifestyle Medicine. Clinical Practice Guideline for the Use of Therapeutic Lifestyle Change as the Primary Intervention for Prediabetes and Type 2 Diabetes. American Journal of Lifestyle Medicine. 2023.

8. Valdes CT, Elkind-Hirsch KE. Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. Journal of Clinical Endocrinology & Metabolism. 1991;72(3):642–646. doi:10.1210/jcem-72-3-642

9. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical Epidemiology. 2014;6:1–13. doi:10.2147/CLEP.S37559

10. Vrbíková J, Cibula D, Dvořáková K, et al. Markers of insulin resistance in polycystic ovary syndrome women: An update. World Journal of Diabetes. 2022;13(3):266–279. PMC8984569. doi:10.4239/wjd.v13.i3.266

11. Boyer W, Toth L, Brenton M, et al. The role of resistance training in influencing insulin resistance among adults living with obesity/overweight without diabetes: A systematic review and meta-analysis. Obesity Research & Clinical Practice. 2023;17(4):279–287. doi:10.1016/j.orcp.2023.06.002

12. Wang J, Fan S, Wang J. Resistance training enhances metabolic and muscular health and reduces systemic inflammation in middle-aged and older adults with type 2 diabetes: a meta-analysis. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70024

13. Hashimoto K, Dora K, Murakami Y, et al. Positive impact of a 10-min walk immediately after glucose intake on postprandial glucose levels. Scientific Reports. 2025;15(1):22662. doi:10.1038/s41598-025-07312-y

14. Colberg SR, Zarrabi L, Bennington L, et al. Postprandial walking is better for lowering the glycemic effect of dinner than pre-dinner exercise in type 2 diabetic individuals. Journal of the American Medical Directors Association. 2009;10(6):394–397.

15. Dempsey PC, Howard BJ, Lynch BM, et al. Interrupting prolonged sitting with brief bouts of light walking or simple resistance activities reduces resting blood pressure and plasma noradrenaline in type 2 diabetes. Journal of Science and Medicine in Sport. 2016;19(10):769–775.

16. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346(6):393–403. doi:10.1056/NEJMoa012512

17. Chaudhary PS, Deshmukh SV, Jaybhaye D, Kaur S. Comparative study of efficacy and safety of berberine hydrochloride versus metformin in newly diagnosed prediabetic patients: a randomized clinical trial. International Journal of Basic & Clinical Pharmacology. 2025;14(5):694–699. doi:10.18203/2319-2003.ijbcp20252563

18. Ye Y, Liu X, Wu N, et al. Efficacy and safety of berberine alone for several metabolic disorders: A systematic review and meta-analysis of randomized clinical trials. Frontiers in Pharmacology. 2021;12:653887. doi:10.3389/fphar.2021.653887

This masterclass is written and reviewed by the clinical team at Heal Integrative Wellness. It is intended for educational purposes and does not constitute individualized medical advice. Please consult your healthcare provider before making changes to your treatment plan.

© Heal Integrative Wellness — Series 3: The First Diagnosis

Maybe you’re sitting in your car in a parking lot. Maybe you’re at your kitchen table, lab results open on your laptop, staring at numbers that don’t quite feel real yet. You understood some of what was said. You’re Googling the rest. And underneath all of it is a question that no search engine can answer cleanly:

How did I get here — and what do I actually do now?

This series is for you.

Why We’re Building This

At Heal Integrative Wellness, we’ve spent years sitting across from patients in exactly that moment — the first diagnosis. Pre-diabetes. Hypertension. Thyroid dysfunction. Elevated inflammatory markers. PCOS. Early metabolic syndrome. The list changes. The feeling doesn’t.

What we’ve learned is that the first diagnosis is not an ending. It’s a warning light and warning lights exist for one reason: to give you time to act before something becomes harder to fix.

In our last series, we explored longevity hacks and the proactive steps you can take before illness appears. Now we’re going deeper, into the territory most people actually need help navigating: the moment after the diagnosis lands, and the real, evidence-based path forward.

No influencer protocols. No miracle supplements. No shame.

Just medicine, delivered with the kind of honesty and care you deserve from an actual clinical team.

What Makes This Series Different

The internet is not short on health content. What it is short on is health content that treats you like an intelligent adult who just received difficult news and needs real answers, not fear-based headlines or oversimplified “wellness” fixes.

Every masterclass in this series is built around five sections that we believe every patient deserves to understand when they receive a new diagnosis:

1. The Pattern Behind the Diagnosis Chronic disease doesn’t appear overnight. We’ll trace the biological and lifestyle threads that build over years — not to assign blame, but because understanding how something happened is the first step to changing it.

2. The Mental Shift A diagnosis changes the way you see yourself, your body, and your future. That psychological weight is real, and it matters clinically. We’ll address the emotional landscape honestly, because your mindset is part of your treatment plan.

3. Gender-Specific Considerations Medicine has historically studied men and applied the findings to everyone. That’s changing — and it should! Each masterclass will examine how the same condition can present differently, progress differently, and respond differently depending on whether you’re a man or a woman. You deserve a roadmap built for your biology.

4. The Intervention Roadmap This is the section patients often want to skip to and we understand why. We’ll cover the evidence-based landscape of both lifestyle interventions and medication options, with enough detail to have an informed conversation with your own provider. We’re not here to replace your doctor. We’re here to make you a more empowered patient in that room.

5. The Retesting Timeline Knowing what to do is only half the work. Knowing when and how to measure whether it’s working is what separates people who reverse their trajectory from those who don’t. We’ll give you concrete, clinically grounded timelines for monitoring your progress.

Who This Is For

This series is for the person who just got the call.

It’s also for the person who got the call two years ago and still isn’t sure they fully understand what happened or what they’re doing about it. It’s for the caregiver who sits with a loved one at appointments and leaves with more questions than answers. It’s for anyone who feels like they’ve been handed a diagnosis but not a direction.

You don’t need to be a medical professional to follow this series. You don’t need to already have a functional medicine team or an integrative health background. You just need to care about understanding your own health at a deeper level and be willing to take it seriously.

A Word on Our Approach

We practice integrative medicine because we believe the best outcomes come from combining the rigor of conventional medicine with the whole-person perspective that lifestyle, nutrition, stress, sleep, and meaning all contribute to your biology. We don’t dismiss pharmaceuticals. We don’t dismiss food as medicine either. We live in the evidence, and we’ll bring you there with us.

We’ll cite the research. We’ll explain the mechanisms. We’ll also talk about what it actually feels like to receive this kind of news and try to change course because we’ve had those conversations thousands of times, and we know it isn’t just biochemistry.

What’s Coming

Our first masterclass launches March 18th, and we’re starting with one of the most common first diagnoses we see: Pre-Diabetes and Insulin Resistance, a condition that is almost entirely reversible when caught early, and yet almost universally misunderstood by the people who receive it.

After that, we’ll move through the diagnoses that show up most often in our clinic: hypertension, hypothyroidism, elevated cholesterol, PCOS, anxiety and HPA axis dysregulation, fatty liver, and more.

Subscribe so you don’t miss it. Share this with someone who needs it. And if you’ve been sitting with a diagnosis of your own, wondering what to actually do —

You’re in the right place.

Heal Integrative Wellness Evidence-based. Patient-centered. Built for the real world.

Book a Consultation

Subscribe now

Share

Heal Integrative Wellness content is written by medical professionals and is intended for educational purposes. It does not replace individualized medical advice. Always consult your healthcare provider before making changes to your treatment plan.

As a longevity doctor, I view Environmental Medicine as a cornerstone of healthspan. We are currently living in an unprecedented chemical and electromagnetic landscape. To ignore the invisible drivers of aging—air particulates, endocrine disruptors, and light pollution—is to leave a massive hole in your longevity strategy. This isn’t about fear-mongering; it’s about Environmental Resilience.

The Invisible Accelerants of Aging

1. Endocrine Disrupting Chemicals (EDCs): The Metabolic Imposters

Modern life is saturated with compounds like phthalates, parabens, and bisphenols (found in plastics and many household goods). Unlike traditional toxins, EDCs are “hormone mimics.” They interfere with cellular signaling at incredibly low concentrations.

Research in Metabolism Disrupting Chemicals (2017) shows that EDCs can “reprogram” metabolic set-points, contributing to insulin resistance. They occupy hormone receptors—particularly estrogen and thyroid receptors—leading to “hormonal noise” that accelerates cellular aging.

2. PM2.5 and the Neuroinflammation Bridge

Fine particulate matter (PM2.5) is small enough to bypass the lungs and enter the bloodstream, where it triggers systemic oxidative stress. Perhaps more concerning is the “Nose-to-Brain” pathway. Particulates can travel via the olfactory nerve directly into the brain, triggering neuroinflammation.

Studies in Environmental Health Perspectives (2021) link chronic air pollution exposure to accelerated biological aging, specifically measured by shortened telomeres. If the air around you is “heavy,” your brain and heart are paying an oxidative tax.

3. Circadian Light Pollution: The Melatonin Theft

Blue light at night ($460-480$ nm) suppresses melatonin. Beyond sleep, melatonin is one of the body’s most potent endogenous antioxidants. By disrupting the circadian light-dark cycle, we are effectively stripping our cells of their nightly “antioxidant wash,” which is a primary driver of long-term cellular decay.

Case Study: Neda – The Environmental Pivot

Neda, 34, was struggling to manage her PCOS symptoms despite a low-glycemic diet and strength training. Her androgen levels remained elevated, and she felt “stuck.”

• The Clinical Insight: We conducted an environmental audit. Neda was heating her meal-prepped food in plastic containers (BPA/BPS exposure) and lived near a busy intersection without adequate ventilation.

• The Biological Toll: The EDCs in her plastics were acting as “obesogens,” interfering with her insulin signaling. The PM2.5 from local traffic was keeping her in a state of chronic, low-grade inflammation.

• The Shift: We focused on accessible swaps. We moved her food to glass jars (repurposed from the grocery store) and used “Source-Control”—simply keeping windows closed during peak traffic hours and using a DIY air filtration method.

Within three cycles, Neda’s androgen levels stabilized. The environmental “interference” was gone, allowing her diet and exercise to finally work.

🔒 DIRECTORS’ CIRCLE & PATIENT CONTENT

The following section includes our clinical-grade Environmental Shield Protocol. To unlock our full evidence-based library and learn how to secure your personal ecosystem, consider a paid subscription or join us as a patient.

Read more

In the medical community, we are beginning to recognize that loneliness is not just a feeling—it is a chronic, systemic stressor with a mortality risk comparable to smoking 15 cigarettes a day.¹ It is time we stop viewing social health as a “soft” science and start treating it as a critical component of our Social Biosphere.

The Biochemistry of Connection: Beyond the Surface

Superficial advice often tells us to “just get out more.” However, the neuroendocrinology of connection is far more complex. It involves a sophisticated interplay between the brain, the heart, and our very genes.

1. The Oxytocin Buffer & The Amygdala

Positive social interactions trigger the release of oxytocin. Often called the “bonding hormone,” its clinical value lies in its ability to downregulate the amygdala—the brain’s fear center.² By dampening amygdala activity, oxytocin lowers cortisol levels and blood pressure. It acts as a natural brake on the “fight or flight” response, allowing the body to redirect energy from “survival” to “repair.”³

2. HRV and Vagal Co-regulation

When we are in the presence of someone we trust, our nervous systems begin to co-regulate. This phenomenon improves Heart Rate Variability (HRV), the gold standard marker for autonomic resilience. High-quality relationships “train” your Vagus nerve to be more responsive, effectively increasing your ability to bounce back from all forms of stress.

3. The CTRA: How Loneliness Changes Your DNA

Perhaps most startling is the research by Steve Cole on the Conserved Transcriptional Response to Adversity (CTRA). Molecular studies show that perceived social isolation actually shifts the expression of your genes.⁴ Loneliness triggers a “pro-inflammatory” genetic profile, upregulating genes that promote systemic inflammation and downregulating those involved in antiviral responses.⁵

Perceived isolation literally instructs your white blood cells to prepare for an injury that never comes, leaving you in a state of chronic, low-grade inflammation.⁶

Case Study: Layal – The “Isolated Achiever”

Layal, a 38-year-old high-performing attorney, came to the clinic with persistent fatigue, digestive issues, and elevated inflammatory markers (hs-CRP) that didn’t respond to an anti-inflammatory diet.

• The Clinical Insight: Layal had recently moved to a new city for a promotion. While she was “connected” via Zoom and Slack all day, she had zero “in-person” co-regulation. She was living in a state of perceived social isolation.

• The Biological Toll: Her body was stuck in the CTRA profile. Her elevated CRP wasn’t caused by her food; it was caused by the lack of a “social buffer.” Her nervous system felt unsafe, keeping her in a pro-inflammatory “survival mode.”

• The Shift: We didn’t just change her supplements; we prescribed social immersion. We identified two specific “anchor” activities where she could engage in face-to-face interaction without the pressure of performance.

How we re-wired Layal’s inflammatory profile through social architecture—and the specific “Biological Connection Protocol” we use for our patients—continues below.

🔒 DIRECTORS’ CIRCLE & PATIENT CONTENT

The following section includes our clinical-grade Social Connection Protocol, including actionable steps for improving Vagal tone through social cues. To unlock our full evidence-based library, consider a paid subscription or join us as a patient.

Read more

Hormesis is the biological phenomenon where a mild, acute stressor triggers an adaptive overcompensation. By “challenging” your cells with controlled amounts of stress, you force them to become more efficient at repair. The goal is to apply Strategic Stress followed by Radical Recovery.

The Science of Resilience: Thermal and Metabolic Stress

1. Heat Shock Proteins (HSPs) & Cardiovascular Defense

Sauna use is more than a spa treatment; it is a vascular workout. High temperatures trigger Heat Shock Proteins (HSPs), which act as “molecular chaperones.” They identify misfolded proteins—the precursors to neurodegenerative diseases—and either refold them or mark them for clearance. Research in JAMA Internal Medicine correlates frequent sauna use with a 40% reduction in all-cause mortality, primarily through improved endothelial function and reduced systemic inflammation.

2. Cold Shock Proteins (CSPs) & Synaptic Repair

Cold exposure (plunges or showers) upregulates RBM3, a cold shock protein. RBM3 is neuroprotective; in animal models, it has been shown to assist in the regeneration of synapses. Furthermore, acute cold triggers “brown fat” thermogenesis, which improves glucose disposal and metabolic rate.

3. Autophagy: The Cellular “Janitor”

When we withhold nutrients through Intermittent Fasting, we activate autophagy (self-eating). This is a survival mechanism where cells degrade and recycle their own damaged components (mitochondria, misfolded proteins). Activating this pathway is a primary lever in slowing the biological aging clock.

The Relaxation Response: Calming the NF-κB Storm

Before we look at how our patients apply these stressors, we must address the “Brakes.” Strategic stress only works if the nervous system can return to a state of Homeostasis.

Chronic stress keeps the body in a pro-inflammatory state by upregulating NF-κB, a protein complex that controls DNA transcription and cytokine production. When NF-κB is chronically active, it accelerates telomere shortening—effectively aging your DNA.

The “Relaxation Response” is the physiological opposite of the “Fight or Flight” response. It is mediated by the Vagus Nerve, the longest cranial nerve in the body and the primary driver of the parasympathetic nervous system. A “toned” Vagus nerve allows for a higher Heart Rate Variability (HRV), which is one of our most important clinical markers for resilience. By performing specific Vagus nerve exercises, we can manually flip the switch from cellular “alarm” to cellular “repair,” upregulating telomerase—the enzyme that maintains the protective caps on your chromosomes.

Case Studies: Finding the Hormetic Edge

Case 1: Mika – The Thermal Hybrid

Mika, 42, wanted to maximize his recovery after adding heavy lifting to his routine.

• The Clinical Insight: Given Mika’s family history of high cholesterol, we used the “vascular gymnastics” of thermal stress to support his arteries.

• The Shift: We implemented a “Contrast Protocol.” Mika began using the sauna 4 times a week for 20 minutes, followed by a 3-minute cold plunge. This widened his “hormetic window,” significantly improving his HRV.

Case 2: Neda – The Fasting Nuance

Neda, 34, wanted to try aggressive 24-hour fasts to manage her PCOS and weight.

• The Clinical Insight: Fasting for women is distinct. Excessive nutrient scarcity can spike cortisol and disrupt the HPA axis, particularly for women managing the demands of motherhood.

• The Shift: We utilized “Crescendo Fasting”—12-14 hour windows only on non-training days. This triggered autophagy without signaling “starvation” to her hormonal system. We paired this with Vagus toning to lower her NF-κB levels.

🔒 DIRECTORS’ CIRCLE & PATIENT CONTENT

The following section includes our clinical-grade Hormesis Protocol and the specific Vagus Nerve exercises we use to bolster the Relaxation Response. To unlock this blueprint, consider a paid subscription or join us as a patient.

Read more

As a longevity physician, I view exercise as the single most powerful “drug” in our pharmacopeia. It is the only intervention that simultaneously improves metabolic health, neuroplasticity, and cardiovascular resilience. However, we need to move beyond the idea of exercise as a tool for weight loss and start seeing it as a longevity shield.

To build a body that lasts, we must optimize for three critical metrics: VO2 Max, Skeletal Muscle Mass, and Metabolic Flexibility.

The Three Metrics of a Long Life

1. VO2 Max: Your Aerobic Ceiling

VO2 Max is the maximum amount of oxygen your body can utilize during intense exercise. Think of it as the size of your “engine.” Research published in JAMA demonstrates that moving from the “low” to “below average” fitness category reduces your risk of all-cause mortality by nearly 50%. It is perhaps the strongest statistical predictor of how many decades you have left.

2. Skeletal Muscle Mass: Your Metabolic Insurance

Muscle is much more than just a tool for movement; we now categorize it as an endocrine organ. When you lift weights, your muscles release myokines, signaling molecules that travel to your brain to improve mood and to your liver to improve insulin sensitivity. Muscle acts as a “glucose sink”—the more you have, the more sugar your body can safely dispose of, protecting you from diabetes and systemic inflammation.

3. Metabolic Flexibility: The Hybrid Engine

Metabolic flexibility is your body’s ability to seamlessly switch between burning carbohydrates and burning fat. A sedentary lifestyle “locks” you into burning glucose, leading to energy crashes and stubborn fat storage. High-quality movement trains your mitochondria to be “hybrid,” allowing you to tap into fat stores for steady, all-day energy.

Case Studies: Precision Movement

Case 1: Mika – Outrunning the Genetic Script

Mika, 42, came to us with a strong family history of early-onset cardiovascular disease. He was a “cardio junkie” with very little muscle mass.

• The Clinical Insight: Mika’s lack of muscle meant he had a poor “glucose sink,” leading to sub-clinical insulin resistance that was driving his high cholesterol.

• The Shift: We swapped two of his runs for heavy resistance training. By tracking his Body Composition, he saw that while his weight stayed steady, he was replacing inflammatory visceral fat with metabolic muscle. His lipids improved dramatically within months.

Case 2: Neda – The PCOS Power-Up

Neda, 34, is a busy mom managing PCOS. She felt she didn’t have the “perfect hour” to work out, so she remained sedentary.

• The Clinical Insight: Perfection was the enemy of Neda’s progress. PCOS thrives in sedentary environments, but “fad” high-intensity workouts were spiking her cortisol too high.

• The Shift: We started with “Movement Snacks”—3 minutes of air squats or lunges during her child’s playtime. These short bursts improved her metabolic flexibility without overtaxing her stress hormones.

🔒 DIRECTORS’ CIRCLE & PATIENT CONTENT

The following section includes our clinical-grade Exercise Protocol and instructions for testing your fitness without a lab. To unlock our full evidence-based library and reclaim your energy, consider a paid subscription or join us as a patient.

Read more

If you’ve ever felt like you’re “running on fumes” despite a clean diet and the right supplements, the culprit is likely not your fuel—it’s your timing. In lifestyle medicine, we view sleep not as a luxury or a period of inactivity, but as a sophisticated, high-energy state of metabolic and neurological restoration.

The Deep Science: Beyond “Avoiding Blue Light”

We’ve all heard the standard advice: “Turn off your phone before bed.” But to truly optimize your biology, you need to understand why.

Your body is governed by the Suprachiasmatic Nucleus (SCN)—a master clock in your brain that orchestrates billions of peripheral clocks in your liver, gut, and muscles. This system doesn’t just respond to “light” in a general sense; it is specifically sensitive to short-wavelength blue light ($460-480$ nm).

When this specific frequency hits the melanopsin receptors in your eyes, it sends a high-priority signal to the pineal gland to hard-stop the production of melatonin. Melatonin isn’t just a “sleep hormone”; it is a potent mitochondrial antioxidant. Without it, your mitochondria are left defenseless against the oxidative stress accumulated during the day.

Furthermore, we must discuss the Glymphatic System. Think of this as the brain’s plumbing. During deep NREM (Non-Rapid Eye Movement) sleep, the brain’s interstitial space expands by up to 60%, allowing cerebrospinal fluid to “power wash” the brain.

This process flushes out beta-amyloid and tau proteins—the metabolic “exhaust” linked to Alzheimer’s and cognitive decline. If you truncate your sleep, you are essentially leaving the “trash” from yesterday to rot in your neural pathways today.

Case Study: Nader – The “Midnight Oil” Stalemate

When we last checked in with Nader, 48, we had optimized his mitochondrial capacity. However, his progress hit a wall. He was experiencing “3:00 AM wiredness”—waking up with a racing mind and a cold sweat, unable to return to sleep until dawn.

Nader believed he was doing everything right. He worked in a dimly lit room and took melatonin. But a deeper dive into his lifestyle medicine assessment revealed two critical “mismatches”:

1. The Thermal Trap: Nader liked a hot bedroom. He didn’t realize that for sleep to initiate, the core body temperature must drop by approximately 2-3°F. His body was fighting to cool down all night, keeping his heart rate elevated.

2. The Digestive Delay: He was eating a “healthy” late-night protein snack. This forced blood flow to the gut and spiked his internal temperature, effectively “pausing” the glymphatic wash.

How we re-synchronized Nader’s master clock—and the specific “advanced” protocols we use for our clinical patients—continues below.

🔒 DIRECTORS’ CIRCLE & PATIENT CONTENT

The following section includes our clinical-grade Sleep Protocol and the “Sleep Sanctuary” Checklist. To unlock our full evidence-based library and reclaim your energy, consider a paid subscription or join us as a patient.

Read more

These organelles are far more than the “power plants” you learned about in high school biology. They are sophisticated command centers—sensing the environment, regulating metabolism, and acting as signaling hubs for inflammation and apoptosis (programmed cell death). As we age, these engines can become “leaky,” inefficient, and fewer in number—a process that is a primary hallmark of aging.

However, through the lens of lifestyle medicine, we have the power to intervene. By leveraging mitochondrial biogenesis (the birth of new mitochondria) and mitophagy (the recycling of damaged ones), we can literally upgrade your cellular hardware.

The Science of Restoration

Our protocol focuses on three biological levers to ensure your “engines” are running at peak efficiency:

1. The Master Switch (PGC-1α): This protein is the “general contractor” of the cell. Activating it triggers the creation of brand-new, high-functioning mitochondria.

2. The Cleanup Crew (Mitophagy): To make room for the new, we must clear the old. Mediated by proteins like PINK1 and Parkin, this process identifies and removes dysfunctional mitochondria that are leaking reactive oxygen species (ROS).

3. Mitohormesis: This is the principle of “beneficial stress.” By introducing controlled, mild stressors, we induce a protective response that makes your mitochondria more resilient to future challenges.

Case Studies: Precision in Practice

Case 1: Nader – The High-Performance Recovery

Nader, 48, came to me feeling “flat.” It wasn’t just a lack of focus; it was a profound lack of physical stamina that made his evening workouts feel like a mountain-climbing expedition. His biomarkers showed high levels of oxidative stress and low metabolic flexibility.

• The Approach: Nader was already “over-clocked” by his career. Adding more high-intensity stress would have backfired. We focused on mitohormesis through nutrient-dense fasting windows and targeted antioxidant support. By emphasizing the quality of his cellular engines over the quantity of his efforts, his evening stamina returned within weeks.

Case 2: Elena – The Hormonal Crossroads

Read more